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Abstract 
 
Introduction 
Human CD36 is a class B scavenger receptor expressed in a variety of cell types 
including macrophages and endothelial cells. This heavily glycosylated membrane 
protein has a large ectodomain (ED) responsible for binding a variety of ligands. 
These include oxidised LDL and long chain fatty acids, which link CD36 to the 
development of atherosclerosis and insulin resistance, respectively. CD36 has also 
been implicated in the phagocyte-uptake of apoptotic cells, anti-angiogenic effects in 
endothelial cells and development of a variety of fibrotic diseases, through 
interaction with thrombospondin-1. The main objective of this study was to express, 
purify and characterise the ligand binding ectodomain of CD36 with a view to better 
understanding how CD36 binds multiple ligands. 
 
Methods 
A baculovirus expression system was used to express and secrete CD36 ED with a 
12-His tag from insect cells using an N-terminal secretion sequence. Subsequent 
purification was performed using nickel affinity chromatography with functionality 
of the ED assessed through the ability to bind modified LDL in a solid phase binding 
assay. The N-glycosylation status of the purified ED was explored through use of the 
N-glycosidase PNGase F and mass spectrometric analysis. Initial studies to measure 
binding kinetics involved use of surface plasmon resonance (SPR) and binding of 
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commercially available antibodies, mAb1955, mAb1258 and mAbFA6-152, to 
purified CD36 ED immobilised on an NTA SPR sensor chip. 
 
Results 
The N-glycosylation status of CD36 ED produced in Sf21 and Hi5 insect cells was 
different with heterogeneous N-glycosylation being identified at individual 
glycosylation sites. Solid-phase ligand binding revealed that both glycosylated and 
deglycosylated ED retain affinity for modified LDL. The purified CD36 ED was 
found to homo-oligomerise particularly at higher concentrations. MAb1955 and 
mAb1258 were found to bind to the nickel on the sensor chip precluding 
microkinetic analysis of binding to CD36. However, mAbFA6-152 was found to 
bind to the immobilised CD36 ED with high avidity and two-step binding kinetics. 
 
Conclusions and future direction 
This study shows for the first time that N-glycosylation is not important for the 
binding of modified LDL to CD36. Furthermore it was demonstrated that native 
CD36 ED produced in Sf21 insect cells can be deglycosylated without denaturation, 
which may be critical for the success of future crystallisation trials. The 
characterisation of mAbFA6-152 binding by SPR is proof-of-principle that CD36 
ED can be studied using this technique paving the way for future biophysical 
analysis of ligand binding. 
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1. Introduction 
 
1.1. Scavenger Receptors 
 
Scavenger receptors, first identified by Brown and Goldstein in 1979, are membrane 
proteins originally recognised by their ability to bind and to mediate the endocytosis 
of chemically modified low density lipoproteins (LDL), such as the natural and 
clinically important oxidised LDL (oxLDL) and the synthetic acetylated LDL 
(acLDL) (Brown and Goldstein, 1979, Brown et al., 1979, Itabe et al., 2011). The 
ability to scavenge was attributed to particular membrane receptors being able to 
differentiate between normal self-molecules and altered self-molecules, with 
preferential binding of oxidised LDL over native LDL (Greaves and Gordon, 2009, 
Henriksen et al., 1981).  With the discovery of many more scavenger receptors in 
recent years it has become apparent that the range of ligands recognised by 
individual members of this family are diverse including unmodified endogenous 
proteins, and a number of exogenous microbial structures (Areschoug and Gordon, 
2009, Pluddemann et al., 2006). To account for this ligand polyspecificity it was 
proposed by Hartvigsen et al., that epitopes generated by oxidation of endogenous 
proteins are similar to those found on exogenous microbial structures (Hartvigsen et 
al., 2009).    
Scavenger receptors are a family of structurally heterogeneous membrane proteins 
that are subdivided into classes (A-H) depending on common structural features. 
Despite having the same general function, there is very little similarity between 
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classes (Canton et al., 2013).  The first scavenger receptors to be isolated and cloned 
were designated type I and type II scavenger receptors (Kodama et al., 1990, Rohrer 
et al., 1990). These two proteins generated by alternative splicing of the same gene 
were later designated as class A scavenger receptors (Emi et al., 1993, Freeman et 
al., 1990). Composed of 6 domains, 5 of which are identical (the C-terminal being 
different), these receptors bind poly-anionic ligands through a collagenous 
extracellular domain (Acton et al., 1993, Doi et al., 1993). 
 
1.2. Class B Scavenger Receptors 
 
The class B scavenger receptor CD36 was originally identified in 1983 on the 
surface of monocytes using the monoclonal antibody (mAb) OKM5 (Talle et al., 
1983). However, it was not recognised as a scavenger receptor until 1991 when it 
was shown that CD36 expressed on the surface of macrophages could recognise and 
facilitate the uptake of apoptotic cells (Savill et al., 1991). CD36 was further 
demonstrated as a scavenger receptor by binding oxLDL when expressed on the 
surface of transiently transfected human embryonic kidney (HEK) 293 cells 
(Endemann et al., 1993). Initially known as glycoprotein IV, CD36 was also shown 
at the time to be expressed on the surface of platelets (Asch et al., 1987) and 
endothelial cells (Swerlick et al., 1992). CD36 was also able to bind 
thrombospondin-1 (TSP-1) (Asch et al., 1987), collagen  (Tandon et al., 1989a) and 
to be responsible for the cytoadherance of erythrocytes infected with Plasmodium 
falciparum (Oquendo et al., 1989). Despite this, CD36 was not classified as a class B 
scavenger receptor until hamster SR-BI was cloned and identified as a new member 
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of the CD36 family (Acton et al., 1994). Through use of direct binding and 
competition assays it was found that CD36 and SR-BI bound modified LDL with a 
similar high affinity but lacked the ability to bind the same range of poly-anionic 
ligands that class A scavenger receptors could bind. Following this observation, 
CD36 and SR-BI were designated as the new class B scavenger receptors (Acton et 
al., 1994). 
Since the inception of the new term, other class B scavenger receptors have been 
identified including the human membrane glycoproteins, lysosomal integral 
membrane protein II (LIMP-2) (Vega et al., 1991) and the CD36 and LIMP-2 
Analogous-1 (CLA-1). Other additions include the Drosophila proteins epithelial 
membrane protein (emp) (Hart and Wilcox, 1993), Croquemort (Franc et al., 1996) 
and sensory neuron membrane protein (SNMP) which was originally identified in 
Lepidoptera  (Nichols and Vogt, 2008).  
LIMP-2 is a lysosomal protein that is important for activity and correct localisation 
of the enzyme β-glucocerebrosidase. LIMP-2 shares 34% primary amino acid 
identity with human CD36 (Reczek et al., 2007). CLA-1 shares 32% primary amino 
acid identity with human CD36. CLA-1 is mainly located at the plasma membrane, 
acting as a high affinity receptor for HDL, VLDL and LDL as well as modified LDL 
(Calvo et al., 1997). CLA-1 is the human homologue of SR-BI, the main difference 
being that SR-BI is not expressed in the hamster placenta (Acton et al., 1994, Cao et 
al., 1997). Hamster SR-BI and CLA-1 (hSR-BI) share 85% primary amino acid 
sequence identity (Murao et al., 1997). 
In insects, croquemort is expressed on the surface of macrophages and haemocytes 
and is required for phagocytosis of apoptotic corpses. It has a 23% amino acid 
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identity to CD36 (Franc et al., 1996). Emp is expressed in precursor cells and is 
thought to be required for proper development and function of epithelial cells. It has 
32% amino acid identity to CD36 (Hart and Wilcox, 1993). SNMPs are membrane 
bound proteins involved in odour detection, for example pheromones (Benton et al., 
2007). Numerous homologues have been identified across many insect orders 
(Nichols and Vogt, 2008). A CD36 ortholog in C. elegans, C03F11.3, has been 
shown to mediate binding and engulfment of fungal pathogens (Means, 2010). 
 
1.3. The Scavenger Receptor CD36 
1.3.1. Structure of CD36 
 
A defining feature that is thought to distinguish class B scavenger receptors from 
other scavenger receptors is the presence of two hydrophobic transmembrane 
domains and a large hydrophilic ectodomain (ED). This was first demonstrated in the 
study of LIMP-2 where it was found that both hydrophobic domains serve to anchor 
LIMP-2 within the lysosomal membrane with the ‘ED’ in the lumen (Vega et al., 
1991). Since the primary amino acid sequence of CD36 (472 amino acids) contains 
two hydrophobic regions next to amino- and carboxy-termini, a ditopic topology 
model was proposed with short cytoplasmic tails at the amino-terminus (GCDRNC-) 
and carboxy-terminus (-CACRSKTIK). This model was further supported by Tao et 
al., who showed that cysteines on both of the short amino-terminal and carboxy-
terminal tails were palmitoylated (Tao et al., 1996). Despite this ditopic model now 
being generally agreed upon, other models have been proposed in the past including 
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one with a single transmembrane domain. Pearce et al., reported that deletion of the 
carboxy-terminal putative transmembrane domain resulted in secretion of CD36 as 
opposed to membrane anchorage. This led to the hypothesis that only the carboxy-
terminus spans the membrane and the amino-terminus was suggested to be an 
uncleaved signal peptide that translocates to the extracellular space (Pearce et al., 
1994). A later study by Gruarin et al., disproved this theory. It was shown that 
truncation of the carboxy-terminal domain was not sufficient to result in CD36 
secretion. Only when both amino-terminal and carboxy-terminal domains were 
deleted was CD36 secretion observed. Additionally, a FLAG epitope attached to the 
amino-terminal domain of wild type CD36 expressed in transiently transfected COS-
7 cells, could only be detected when the cells were first permeabilised (Gruarin et 
al., 1997). This further reinforced the idea of two transmembrane domains with two 
short cytoplasmic tails. 
The majority of CD36 can be found in the large ED, predicted to have a molecular 
weight of 46kDa (the full-length protein is predicted to have a molecular weight of 
53kDa) (Figure 1.1). The transmembrane domains and cytoplasmic tails therefore 
make up only a small portion of the total protein. The extracellular domain is heavily 
modified post-translationally by glycosylation, phosphorylation and disulphide 
bridging. It is this ED that is also responsible for the binding a wide range of ligands.  
In 2013, Neculai et al., crystallised the ectodomain of human LIMP-2 and solved the 
structure to a medium resolution of 3Å (Figure 1.2). The structure includes a 
previously unidentified fold with an anti-parallel β-barrel core with many short α-
helical segments (Neculai et al., 2013). The β-barrel is imperfect, with one of the 13 
slats being replaced with a short loop that partly occupies the centre of the barrel. It 
was reported by Neculai et al., that the β-barrel is also asymmetric with four β-
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strands extending the full length of the LIMP-2 ectodomain structure, creating a 
prolate spheroid (Neculai et al., 2013). Furthest from the membrane at the end of the 
β-barrel is a three α-helix bundle that was proposed to be a binding site for β-
glucocerebrosidase and also thought to be responsible for the observed homo-
oligomerisation of the purified protein (Neculai et al., 2013).  
Due to the primary amino acid similarity shared by the ectodomains of all class B 
scavenger receptors, the crystal structure of LIMP-2 has been used as a template to 
homology model both CD36 and SR-BI. Electrostatic mapping of both of the 
homology models suggested the accumulation of cationic residues at the apex distal 
from the membrane (Neculai et al., 2013), which fits well with the theory that this 
helical bundle is also responsible for ligand binding in CD36 and SR-BI which are 
known to bind anionic ligands. 
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Figure 1.1. Cartoon representation of the predicted topology of human CD36.  
CD36 is a ditopic protein with short cytoplasmic amino-terminal and carboxy-terminal tails. Two 
cysteines on each tail are palmitoylated.  The majority of the protein can be found in a large 
ectodomain that is heavily modified post-translationally, and which is known to be responsible for 
ligand binding. The ectodomain is N-linked glycosylated at nine out of ten putative sites. The site 
shown to lack a glycan is highlighted by ‘*’. Three pairs of cysteines in the ectodomain form 
disulphide bridges, drawn based on pattern observed in bovine CD36. Two cysteines located within 
both the amino-terminal and carboxy-terminal tails are palmitoylated. A phosphorylation site at Thr92 
is known to regulate TSP-1 binding. The numbers shown indicate which amino acid residues within 
human CD36 are modified.  
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Figure 1.2. Structure of the human LIMP-2 ectodomain.  
The α-helices and β-strands are shown in ribbon format coloured red and yellow, respectively. The 
asparagines of N-linked glycosylation sites are shown in stick format coloured slate blue. The two 
disulphide bridges are coloured black. The apex of the protein is made up of an α-helix bundle, devoid 
of glycosylation sites, thought to be a primary ligand binding site and additionally through 
interactions between α5 and α7 helices of different LIMP-2 molecules, a site for homo-
oligomerisation (Neculai et al., 2013). 
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1.3.2. Ligands of CD36 and localisation of binding sites 
 
CD36 is capable of binding a diverse group of ligands. Through the use of 
glutathione S-transferase (GST)/CD36 fusion proteins, the binding domain for TSP-
1 was investigated (Frieda et al., 1995). It had previously been proposed, using small 
synthetic peptides to represent putative CD36 domains, that TSP-1 bound to CD36 
via a complex two-step process requiring low affinity binding to one region (amino 
acids from 139-155) which then allowed high affinity binding to a second region 
(amino acids 93-110) (Leung et al., 1992). Through use of a battery of GST/CD36 
fusion proteins which covered CD36 entirely, and radiolabelled TSP-1, it was shown 
by Freida et al., that amino-acid residues 93-120 was likely to be the main CD36 
binding site for TSP-1. It may be that binding to amino acid residues 93-120 can be 
modulated by the downstream amino acid sequence 139-155 (Frieda et al., 1995). By 
mapping the regions of CD36 implicated in ligand binding onto the LIMP-2 
structure (Figure 1.3 (a)), assuming CD36 has a similar fold, the TSP-1 binding site 
(amino acids 93-120) can be found along one of the β-strands which makes up part 
of the anti-parallel β-barrel core. The downstream sequence containing amino acid 
residues 139-155 is located within the α-helix bundle at the apex of the protein. 
Interestingly, antibodies that bind the sequence containing amino acid residues 155-
183 can block TSP-1 binding (Dawson et al., 1997), further highlighting the 
possibility of modulating TSP-1 binding to CD36 either through steric hindrance or 
an allosteric effect. 
 The further revelation that LIMP-2 also bound TSP-1 led to the identification of a 
conserved TSP-1 binding sequence found in the CD36 family which was called 
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CD36 LIMP-2 emp SR-BI homology or CLESH. It is composed of three conserved 
motifs, a protein kinase C (PKC) phosphorylation recognition site and two TSP-1 
motif binding blocks (Crombie and Silverstein, 1998). Following on from this many 
other non-CD36 related proteins have been discovered with CLESH domains and 
subsequently shown to bind TSP-1 (Crombie et al., 1998, Simantov et al., 2001).  
The identification of the oxLDL binding domain was achieved by Puente Navazo et 
al., who showed how monoclonal antibodies against the CD36 region containing 
amino acids 155-183 could inhibit oxLDL binding to human CD36 on the surface of 
transiently transfected COS cells, whereas an antibody against the CD36 region 
containing amino acids 30-76 could not (Puente Navazo et al., 1996). In contrast, 
Pearce et al., reported a different oxLDL binding region, mapped to amino acids 
120-155, with a second lower affinity region around amino acids 28-93 (Pearce et 
al., 1998). This study was performed using a similar method to Frieda et al., except 
in this study radiolabelled oxLDL was used (Frieda et al., 1995, Pearce et al., 1998). 
Later studies, by Kar et al., using GST/CD36 fusion proteins and site-directed 
mutagenesis, proposed that amino acids 160-168 contained the binding site of 
oxLDL and that Lys164 and Lys166 were crucial for the interaction (Kar et al., 
2008). By mapping the regions of CD36 implicated in modified LDL binding onto 
the LIMP-2 structure (Figure 1.3 (b)), these proposed binding sites fit from the α-
helical bundle at the apex of the protein down through the β-barrel to the N-terminus 
of the ectodomain which would be attached to a transmembrane region. Neculai et 
al., reported that the centre of the LIMP-2 ectodomain consists of a large cavity that 
transverses the entire length of the protein. It was proposed, having used mutagenesis 
and an inhibitor of SR-BI-dependent lipid transport from HDL, that a similar cavity 
within SR-BI is responsible for delivering cholesterol(esters) from lipoproteins to the 
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outer leaflet of the plasma membrane (Neculai et al., 2013). A similar process may 
exist for lipophilic ligands of CD36, however, without a true structure for CD36, the 
presence of a cavity in CD36 cannot be confirmed. Interestingly, a similar structure 
has been reported for fatty acid binding proteins (FABPs). These small highly 
conserved proteins are responsible for binding hydrophobic ligands and trafficking 
them around cellular compartments. They consist of a water-filled, binding pocket 
surrounded by ten anti-parallel beta sheets, forming a beta barrel, capped by two 
alpha helices which are thought to regulate ligand binding (Smathers and Petersen, 
2011). CD36 has also been reported to be capable of binding native lipoproteins 
HDL, VLDL and LDL (Calvo et al., 1998).  
Plasmodium falciparum is one of four species of Plasmodium that naturally infects 
humans, being responsible for most malarial disease and resultant mortality (Gardner 
et al., 2002). P. falciparum is thought to have a survival mechanism which involves 
the adherence of infected erythrocytes to the microvasculature of vital organs, 
limiting exposure to the immune system (Baruch et al., 1999). A number of 
receptors have been implicated in the cytoadherence of P. falciparum-infected 
erythrocytes to endothelial cells including CD36. The binding of these erythrocytes 
to CD36 can be inhibited by CD36 antibodies that recognise amino acids 155-183, 
the same antibodies that can block TSP-1 binding (Daviet et al., 1995, Daviet et al., 
1997). Using CD36 peptides to block the binding of infected erythrocytes, Baruch et 
al., identified amino acids 139-184 as the likely binding site (Baruch et al., 1999). P. 
falciparum erythrocyte membrane protein 1 (Pfemp1) has since been identified on 
the surface of the infected erythrocytes as a ligand for CD36 (Yipp et al., 2003). This 
binding region when mapped on to the LIMP-2 structure overlaps the modified LDL 
binding site as well as the region thought to possibly modulate TSP-1 binding 
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(Figure 1.3 (c)). This overlap would suggest the possibility of one ligand being able 
to modulate or prevent the binding of another ligand to CD36. 
Other ligands that bind CD36 include anionic phospholipids and long chain fatty 
acids (LCFA). The binding of anionic phospholipids (which also bind to SR-BI) was 
determined by incubating radiolabelled liposomes containing different phospholipids 
with COS cells transiently expressing CD36 or SR-BI. Both phosphatidylserine and 
phosphatidylinositol, phospholipids normally restricted to the inner leaflet of the 
plasma membrane, were identified as ligands of CD36 (Rigotti et al., 1995). It was 
proposed by Greenberg et al., that when cell membranes undergo lipid peroxidation, 
during senescence or apoptosis, the  hydrophobic component of fatty acids from 
within the lipid bilayer move to the aqueous exterior, becoming available for 
recognition by pattern recognition receptors, such as CD36 (Greenberg et al., 2008). 
In 1993, Harmon and Abumrad, identified an 88kDa membrane protein on the 
surface of rat adipocytes that when labelled with a derivative of LCFA led to 
inhibition of LCFA transport . This protein was designated as a fatty acid translocase 
(FAT), however it was later discovered to be the rat CD36 (Abumrad et al., 1993, 
Harmon and Abumrad, 1993). Further studies showed that the membrane 
impermeable sulfo-N-hydroxy-succinimidyl (NHS) ester of oleate (SSO), which 
binds to CD36 irreversibly, was able to prevent binding of not just LCFA but also 
oxLDL to the surface of macrophages. It was proposed that oxLDL and LCFA share 
the same binding site on CD36. Subsequently it was demonstrated that mutation 
K164A on CD36 resulted in poor LCFA uptake (Kuda et al., 2013a). This is 
agreement with Kar et al., who suggested that Lys164 was critical for oxLDL 
binding (Kar et al., 2008). Neculai et al., showed using Chinese hamster ovary 
(CHO) cells transiently transfected with CD36 with particular point mutations, that 
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L158, L161, K164 and K166 were required for binding DiI-labelled oxLDL (Neculai 
et al., 2013).  
CD36 has been shown to bind to microbial cell wall constituents, such as lipotechoic 
acid (LTA). This forms part of an innate immune response involving the association 
of CD36 with toll like receptors (TLR) 2 and 6 (Hoebe et al., 2005, Jimenez-
Dalmaroni et al., 2009). Fibrillar β-amyloid, which is a marker of Alzheimer’s 
disease, has also been shown to bind CD36, also with a possible association with toll 
like receptors, in this case, TLR4 and TLR6 (Bamberger et al., 2003, Stewart et al., 
2010). 
The interaction between advanced glycation end products (AGE) and CD36 has been 
linked to the progression of chronic inflammation and diabetes (Ohgami et al., 2002, 
Basta et al., 2004, Zhu et al., 2012). AGEs which form in hyperglycemic 
environments are lipids or proteins that have been excessively non-enzymatically 
glycated or oxidised after contact with aldose sugars (Schmidt et al., 1994). The 
accumulation of AGE in many different cell types can affect the structure and 
function of both the extracellular and intracellular environments by binding cell 
surface receptors, producing reactive oxygen species (ROS) and cross-linking 
proteins (Schmidt et al., 1994, Brownlee et al., 1985). It was shown that CHO cells 
overexpressing CD36 could recognise radiolabelled AGE which was then taken up 
by endocytosis (Ohgami et al., 2002). However, later studies showed that uptake of 
AGE by liver endothelial cells was not via CD36 and furthermore that CD36 was not 
involved with clearance of AGE from the circulation (Nakajou et al., 2005). Instead, 
AGE binding to mouse adipocytes via Cd36 was shown to induce oxidative stress 
and inhibition of leptin expression (Horiuchi et al., 2005). The hyper-reactivity of 
platelets from patients suffering from type 2 diabetes has been linked to the 
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accumulation of AGE (Hasegawa et al., 2002). In 2012, Zhu et al., showed that 
platelets from Cd36-null mice under hyperglycemic conditions did not form blood 
clots as readily as wild-type mice under the same conditions, leading to the 
conclusion that vascular dysfunction in type 2 diabetes is linked to AGE-CD36-
mediated platelet signalling pathways and subsequent platelet hyper-reactivity (Zhu 
et al., 2012).   
CD36 is also a receptor for growth hormone protein hexarelin and its derivative EP 
80317 (Bodart et al., 2002). EP 80317, which has no growth hormone properties, has 
been shown to interfere with the binding of oxLDL to CD36 (Marleau et al., 2005). 
Another ligand capable of blocking oxLDL binding to CD36 is salvianolic acid B 
(SAB), which is an abundant water-soluble compound extracted from the Danshen 
plant. SAB was shown to bind CD36 and furthermore inhibit uptake of modified 
LDL into macrophages in a CD36-dependent manner (Bao et al., 2012). Ursolic 
acid, a pentacyclic triterpenoid, has been shown to inhibit binding of β-amyloid 
protein to the surface of CD36-transfected CHO cells (Wilkinson et al., 2011). 
Together these ligands show promise as pharmaceutical agents for the treatment of a 
number of CD36-dependent disease states such as atherosclerosis, type 2 diabetes 
and Alzheimer’s disease.  
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Regions highlighted have been implicated in CD36 binding to (a) TSP-1, (b) modified LDL and (c) P. 
falciparum infected erythrocytes. Equivalent regions on LIMP-2 are highlighted based on a 
CD36/LIMP-2 primary sequence alignment. Coloured segments indicate possible ligand binding sites 
that have been identified based on different studies (see 1.3.2).  
  
 
 
 
 
Figure 1.3. Mapping regions of CD36 implicated in ligand binding onto the LIMP-2 crystal 
structure. 
(b) (a)
) 
(c) 
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1.4. Expression and Regulation of CD36 
1.4.1. Regulation of CD36  
 
The human CD36 gene is more than 35kb long and is located on chromosome 7, 
band q11.2 (Fernandez-Ruiz et al., 1993, Armesilla and Vega, 1994). The gene has 
15 exons, and the coding sequence begins in exon 3 and finishes in exon 14 (Figure 
1.4) (Armesilla and Vega, 1994). Alternative splicing of the mRNA transcript, 
however, is known to occur, and exons 4 and 5 can be skipped resulting in a protein 
lacking amino acids 43-143 which includes the TSP-1 binding domain and three 
putative N-linked glycosylation sites in the ectodomain. Transient expression of this 
variant in COS-1 and HEL cells was found to reach the cell surface, however it is 
unknown whether it adopts the wild-type fold. A similar exon skipping event can be 
seen with CLA-1 (Tang et al., 1994). Alternative splicing in exon 1 that lacks TATA 
boxes and CpG islands leads to the generation of different transcripts, regulated 
specifically by the tissue (Andersen et al., 2006, Sato et al., 2002, Zingg et al., 
2002). CD36 gene regulation is therefore complex, reflecting the broad expression 
pattern of the protein in many different cells types. This is in addition to multiple 
forms of post-translational modification which are likely to also be tissue specific 
and affect ligand interaction. It has been documented that CD36 is upregulated in 
response to different CD36 ligands. For example, CD36 is upregulated by oxLDL 
via a signalling pathway involving PKC and peroxisome proliferator-activated 
receptor gamma (PPAR-γ) (Feng et al., 2000) with the CD36 gene containing a 
PPAR-γ responsive element (Nagy et al., 1998). CCAAT/enhancer-binding  proteins 
(C/EBP) α and β, whose transcriptional activity is upregulated in type 2 diabetes by 
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p38-mediated serine phosphorylation has been shown to increase CD36 expression 
in different cells types. A C/EBP-responsive element has been identified within the 
CD36 promoter, suggesting another mechanism for regulating expression (Qiao et 
al., 2008, Qiao et al., 2006). 
 
 
Figure 1.4. Schematic representation of the human CD36 gene.  
The human CD36 gene consists of 15 exons. The 5’-untranslated region (5’-UTR) consists of exons 1, 
2 and part of 3. The remainder of exon 3, 4-13 and part of 14 encode human CD36. The 3’-UTR 
consists of part of exon 14 and exon 15. Alternative splicing of exon 1 allows tissue specific 
regulation. Modified from Collot-Teixeira, S., Martin, J., McDermontt-Roe, C., Poston, R. & 
McGregor, J. L. 2007. CD36 and macrophages in atherosclerosis. Cardiovasc Res, 75, 468-77 by 
permission of Oxford University Press. 
 
 
1.4.2. CD36 mutants and variants 
 
Many mutations have been identified within the coding sequence of the human 
CD36 gene including small and gross deletions, insertions, rearrangements, variant 
repeats and duplications (Rac et al., 2007). Two types of CD36 deficiency have been 
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identified from mutations, designated type I and type II. Type I is characterised by 
absence of CD36 expression in both monocytes and platelets, whereas type II is 
characterised by the absence of CD36 expression only in platelets. There are over 
twenty types of mutation which, as homozygous or compound heterozygous 
mutations, lead to type I CD36 deficiency (Rac et al., 2007). One of the most 
common of these mutations is C478T which results in an 81kDa protein (as opposed 
to the wild-type 88kDa protein), possibly with glycosylation defects, which leads to 
protein degradation (Kashiwagi et al., 1993, Kashiwagi et al., 1995, Kashiwagi et 
al., 2001). Related observable phenotypes of type I CD36 deficiency include 
abnormal glucose and lipid metabolism. 
The mechanism behind type II CD36 deficiency is unclear, however, it has been 
observed in individuals who have a heterozygous mutation in the CD36 gene, in 
particular C478T. Studies performed by Kashiwagi et al., found that both C478 and 
T478 forms of CD36 were present in monocytes from two patients with type II 
deficiency, but only T478 was present in the platelets of the same individuals, 
suggesting a platelet-specific regulation contributing to the phenotype (Kashiwagi et 
al., 1995).    
Considerable variability has been observed in CD36, especially in individuals of 
African and Asian descent, with naturally occurring polymorphisms being linked to a 
variety of diseases. Five intronic SNPs present within the African-American 
population were shown to be linked to a significant increase in risk of metabolic 
syndrome (Love-Gregory et al., 2008). Five SNPs in the Caucasian population have 
been linked to an increased incidence of cardiovascular disease (Ma et al., 2004). 
Three polymorphisms in Thai patients infected with P. falciparum, T14C, G53T and 
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a TG12 repeat within intron 3, were associated with protection against severe malaria 
(Omi et al., 2003). 
 
1.5. Post-translational modification of CD36 
1.5.1. Phosphorylation 
 
Protein phosphorylation is the most commonly observed post-translational 
modifications (Khoury et al., 2011). Through recognition of kinase consensus 
sequences, present on many proteins, phosphorylation and dephosphorylation is 
known to regulate a number of physiological processes (Ubersax and Ferrell, 2007, 
Hunter, 1995, Ehrlich et al., 1990). 
In work carried out by Asch et al., a single phosphorylation site was identified on 
human CD36. CD36 domains were randomly expressed in a recombinant expression 
system and subsequently screened using a peptide (amino acids 504-509, CSVTCG) 
which corresponds to the TSP-1 sequence that is known to bind CD36. The binding 
site on CD36 (amino acids 88-99, RGPYTYRVRFLA) that recognises this TSP-1 
peptide was identified as a PKC consensus target sequence. When CD36 was 
incubated with PKC and phosphorylated, TSP-1 peptide binding was reduced by 
60%, suggesting that binding of TSP-1 to CD36 may be regulated by 
phosphorylation. Site-directed mutagenesis and repeat binding experiments 
identified Thr92 as the site of phosphorylation. It was proposed based on these 
findings that CD36 is constitutively phosphorylated but can be dephosphorylated 
extracellularly leading to increased TSP-1 binding. This could then be reversed by 
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phosphorylation by PKC (Asch et al., 1993).  However, PKC is an intracellular 
kinase and so is unlikely to be able to phosphorylate the site which is extracellular. 
In 2012, Chu and Silverstein showed that phorbol 12-myristate 13-acetate (PMA), an 
activator of PKC, substantially increased the phosphorylation of CD36 
intracellularly, and proposed that regulation of the amount of phosphorylated CD36 
on the cell surface involved synthesis of new protein rather than an external 
unknown kinase (Chu and Silverstein, 2012).   
The same phosphorylation site (Thr92) has also been shown to be important for the 
cytoadherence of P. falciparum-infected erythrocytes to microvascular endothelium. 
Studies have shown endogenously expressed CD36 on the surface of human dermal 
microvascular endothelial cells (HDMECs) allows the adhesion of infected 
erythrocytes, regulated by the Src family of kinases and alkaline phosphatase (AP). 
With the ectodomain of CD36 constitutively phosphorylated (recognised by a 
phospho-specific antibody), infected erythrocytes can bind CD36, however, maximal 
binding was achieved when the ectodomain is dephosphorylated by AP (Ho et al., 
2005). 
 
1.5.2. Glycosylation 
 
The theoretical molecular mass of CD36, based on the primary sequence, is 53kDa,  
yet it has been reported that depending on the cell type in which it is expressed, the 
molecular weight of CD36 will vary, for example, in human platelets (88kDa), 
mammary epithelial (85kDa) and erythroblasts (78kDa) (Greenwalt et al., 1990, 
Kieffer et al., 1989, Tandon et al., 1989a). As the primary amino acid sequences for 
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CD36 are identical in all these cell types, the differences have been attributed to cell-
specific post-translational modifications, in particular N-linked glycosylation 
(Nakata et al., 1993).  
There are ten putative N-linked glycosylation sites within human CD36 (recognised 
by the consensus sequence Asn-X-Ser/Thr, also referred to as a sequon, where X is 
any amino acid except proline). By using mass spectrometry on purified CD36 that 
had been deglycosylated by peptide N-glycosidase F, and by measuring the 
electrophoretic mobility of different N-linked glycosylation site mutants, 9 of the 10 
putative sites were identified as occupied by a glycan (Hoosdally et al., 2009). In the 
same study it was shown by flow cytometry that mammalian cells, transiently-
transfected with these glycosylation site mutants that glycosylation was important 
for CD36 trafficking to the plasma membrane, but no individual site was essential 
for this process (Hoosdally et al., 2009). The nature and the pattern of N-linked 
glycosylation was also not important for binding of modified LDL (Hoosdally et al., 
2009), however it has been suggested by Lauzier et al., that the glycosylation status 
of Cd36 in the Spontaneously Hypertensive Rat (SHR), which is altered (along with 
the primary amino acid sequence and abundance in cardiac membranes) affects the 
ability of Cd36 to utilise LCFA in cardiac tissues (Lauzier et al., 2011).  
In CD36 purified from platelets, alkali-labile O-linked glycosylation has also been 
identified (Tandon et al., 1989b), with some groups suggesting that O-linked 
glycosylation has a role in Cd36 membrane recruitment in the cardiac tissue of both 
normal and SHR rats (Lauzier et al., 2011, Laczy et al., 2011). Polysialylated O-
linked glycans, absent on CD36 in platelets, have been found on CD36 secreted in 
human milk and are thought to be important for protection and nutrition for neonates 
(Yabe et al., 2003). Sialic acid is known to be a binding target for many viral and 
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bacterial pathogens and so it is thought that the presence of polysialylated structures 
on Cd36 could bind and prevent invasion into neonates (Karlsson, 1998, Yabe et al., 
2003). Several studies have shown the exogenous administration of sialic acids 
orally or by intraperitoneal injection increased production of gangliosides and 
improved the development of the neural system in the brains of nourished and 
malnourished young rats (Carlson and House, 1986, Morgan and Winick, 1980). 
Human milk is rich in sialic acid (Carlson, 1985). The level of CD36 polysialation 
varies during lactation with the highest levels occurring 1 month after parturition 
(Yabe et al., 2003). Polysialic acid on CD36 may therefore provide an extra source 
of sialic acid in early human development. 
 
1.5.3. Disulphide Bonds 
 
Disulphide bonds (or bridges) are covalent bonds between the two thiol groups of 
separate cysteine residue side-chains (to form covalently linked cystine residues). 
These bonds that are formed in the endoplasmic reticulum (ER) of eukaryotic cells 
are highly conserved features that are important for protein folding, stabilisation and 
overall protein structure (Sevier and Kaiser, 2002, Thornton, 1981, Creighton, 1988). 
Human CD36 has ten cysteines in total, however, four of these (C3, C7, C463 and 
C466) are intracellular and are palmitoylated (Tao et al., 1996). The remaining six 
cysteines (C243, C272, C311, C313, C323, C333) can all be found within the 
carboxy-terminal half of the ectodomain of CD36. These cysteines are highly 
conserved within the CD36 family with only C311 not being conserved between SR-
BI, CLA-1, LIMP-2 and emp. C313 is also not conserved in emp. 
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It was originally reported that the electrophoretic mobility of native CD36 under 
reducing and non-reducing conditions was the same leading to the assumption that 
Cd36 does not contain either intrachain or interchain disulphide bridges (Oquendo et 
al., 1989). This was later disproved by Gruarin et al., who showed that disulphide 
bridges do form in human CD36 and the reason for not being able to visualise a 
change in electrophoretic mobility is due to the extensive glycosylation. Prior 
deglycosylation of CD36 using PNGase F allowed the change in electrophoretic 
mobility to be observed under reducing conditions. It was further shown that in the 
presence of the reducing agent DTT, newly formed CD36 is retained within the ER, 
providing evidence that disulphide bridge formation is required for CD36 to traffic 
through the secretory pathway to the membrane (Gruarin et al., 1997).   
In 1998, the pattern of disulphide bridge formation was elucidated for bovine Cd36 
purified from milk fat globule membranes (MFGMs). From the lack of incorporation 
of 
14
C labelled iodoacetic acid, no free cysteines were identified. Fragments of Cd36 
generated from CnBr degradation were separated and analysed by amino acid 
sequencing and mass spectrometry, with the assumption that any disulphide bridges 
present had remained intact. The subsequent bonding pattern was identified: C243-
C311, C272-C333 and C313-C323 (Rasmussen et al., 1998). As all these cysteines 
are conserved between bovine and human CD36, it is highly likely that the bonding 
pattern is also conserved. 
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1.5.4.  Palmitoylation 
 
Palmitoylation, or protein S-acylation, is a common post-translation modification 
involving the covalent attachment of the sixteen carbon, saturated fatty acid 
palmitate through a thioester linkage to a cysteine residue (Smotrys and Linder, 
2004, Khoury et al., 2011). The main role of palmitoylation is thought to be to 
facilitate the reversible tethering of proteins to the cytosolic face of the cell 
membrane (Conibear and Davis, 2010, Rocks et al., 2005). Palmitoylation has also 
been shown to be involved with protein trafficking, membrane localisation, 
signalling and protein-protein interactions (Aicart-Ramos et al., 2011, Linder and 
Deschenes, 2007).  
Using site directed mutagenesis and radiolabelled palmitate, it was shown that the 
two most amino-terminal and carboxy-terminal cysteines of CD36 (C3, C7, C463 
and C466) were palmitoylated (Tao et al., 1996). Despite palmitoylation being 
thought to be important for membrane localisation, site directed mutagenesis of the 
carboxy-terminal cysteines of CD36 indicated that modification of these residues 
was unnecessary for plasma membrane localisation (Malaud et al., 2002).  
Palmitoylation of CD36 has been shown to be inhibited by the antifungal antibiotic 
cerulenin (Jochen et al., 1995). Studies involving either the inhibition of 
palmitoylation with cerulenin or site directed mutagenesis of cysteines resulted in 
delayed processing of CD36 in the endoplasmic reticulum (ER) and passage through 
the secretory pathway (Thorne et al., 2010). Additionally, it was shown that the lack 
of palmitoylation reduced the half-life of CD36 and that palmitoylation deficient 
CD36 mutants failed to localise efficiently within lipid rafts (Thorne et al., 2010). 
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Localisation within lipid rafts is thought to be a prerequisite for efficient uptake of 
modified LDL by CD36 (Rios et al., 2013, Zeng et al., 2003). It has been suggested 
that selenoprotein K (Selk), a selenium incorporated ER-resident protein (Lu et al., 
2006) may play a role in the palmitoylation of CD36. Selk
-
/
-
 macrophages showed 
decreased CD36 palmitoylation, lower CD36 stability and poor lipid raft localisation 
(Meiler et al., 2013).   
 
1.5.5.  Ubiquitination 
 
Ubiquitination is a post-translational modification that involves the addition of one 
or more ubiquitin proteins to a target protein (Komander, 2009). The addition of 
ubiquitin can have a number of effects on the target protein including tagging it for 
degradation via the proteasome, altering cellular localisation, modifying activity or 
regulating protein-protein interactions (Herrmann et al., 2007). These different 
effects are mediated by different types of ubiquitination. Mono-ubiquitination which 
is the addition of one ubiquitin protein to one target protein residue is thought to be 
involved with membrane trafficking and endocytosis. Polyubiquitination involves 
the extension of monoubiquitinated residues. The ubiquitin molecules bind to one 
another via lysine rich regions. Depending on which of these residues are used to 
form the polyubiquitin chain affects the ultimate fate of the target protein. Lysine 48-
linked polyubiquitin chains target proteins for degradation by the proteasome 
whereas lysine 63-linked polyubiquitin chains, are associated with changes to protein 
cellular localisation and function (Komander, 2009). 
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CD36 was shown to be polyubiquitinated, with both lysine 48 and lysine 63 linkages 
when expressed in CHO and HEK 293 cells (Smith et al., 2008).  It was further 
shown using CHO cells expressing both the insulin receptor and CD36, that addition 
of insulin resulted in a reduction of CD36 ubiquitination whereas addition of fatty 
acids resulted in increased ubiquitination, suggesting a mechanism for regulating the 
level of CD36 at the plasma membrane (Smith et al., 2008). Mutation of the lysine 
residues in the intracellular C-terminal tail of CD36 resulted in reduced 
ubiquitination, increased CD36 levels and enhanced fatty acid uptake, which could 
be blocked with the CD36 inhibitor SSO (Smith et al., 2008).   
In 2011, Kim et al., demonstrated that the ubiquitin ligase Parkin was capable of 
ubiquitinating CD36. When mice are fed a high fat diet, the levels of Parkin in 
hepatocytes rose in parallel to increased expression of lipid binding proteins such as 
Cd36. It was also reported that knockout mice deficient in Parkin resisted weight 
gain and did not acquire insulin resistance when fed a high fat diet. It was 
subsequently shown that addition of fatty acids to HeLa cells engineered to 
constitutively express CD36 resulted in the reduction of CD36 expression whereas in 
the presence of Parkin, there was an increase in CD36 expression levels, suggesting 
a ubiquitination-dependent mechanism to stabilise CD36 levels and in turn modulate 
fatty acid uptake (Kim et al., 2011).  These two studies present contradictory roles 
for ubiquitination in the regulation of CD36. Nevertheless these two studies would 
suggest that ubiquitination of CD36 can have multiple effects depending on the cell 
type and possibly the ubiquitin ligase involved.    
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1.6. CD36 in normal and disease pathology 
1.6.1.  Innate Immunity 
 
In 1991, CD36 was first recognised as a scavenger receptor by Savill et al., during an 
investigation of the uptake of apoptotic cells by mononuclear phagocytes (Savill et 
al., 1991). BLAST searches have shown that CD36 homologues are found in 
primitive to immunologically advanced organisms. By comparing the functions of 
these proteins it was suggested that uptake of apoptotic cells during normal 
homeostasis is one of the most ancient roles of CD36 (Febbraio and Silverstein, 
2007). The membrane of an apoptotic cell is different from that of other cells in that 
the outer leaflet becomes enriched in anionic phospholipids, such as 
phosphatidylserine (Pittoni and Valesini, 2002). Oxidation of phosphatidylserine, 
and to a lesser extent phosphatidylcholine, on the surface of apoptotic cells is 
recognised by CD36. It is thought that this interaction is required for the clearance of 
apoptosing cells by macrophages (Greenberg et al., 2006). In the eye, the removal of 
shed photo-receptor rod outer segments (PROS) has been shown to be another 
example apoptotic cell clearance mediated by CD36. Expression of CD36 on the 
surface of retinal pigment epithelial cells (RPEs) mediates the uptake of PROS 
which are shed regularly and need to be cleared to maintain normal vision. 
Antibodies to CD36 can inhibit the uptake of PROS by RPEs by 20% leading to the 
suggestion that there may be a co-receptor, with inhibition of both CD36 and the 
integrin αvβ5 reducing uptake of PROS by 80% (Ryeom et al., 1996). Further studies, 
however, have suggested that these receptors likely work independently (Finnemann 
and Silverstein, 2001).  
50 
 
In addition to apoptotic cell recognition, CD36 has been shown to recognise bacterial 
and fungal pathogens (Means et al., 2009, Hawkes et al., 2010a, Hoebe et al., 2005). 
It was suggested by Hoebe et al., that CD36 functions as a non-redundant sensor for 
the constituents of the cell wall of gram-positive bacteria, such as LTA, signalling 
through a toll-like receptor complex (TLR2/TLR6), to initiate an immune response 
(Hoebe et al., 2005). It was further proposed by Jimenez-Dalmaroni et al., that CD36 
together with CD14 bind pathogenic signals initially before presenting them to TLR 
complexes within the plasma membrane to initiate an immune response (Jimenez-
Dalmaroni et al., 2009). The immune response is therefore instigated by TLRs, but 
the initial recognition of the pathological ligand by macrophages is proposed to be 
via CD36 and CD14, independent of TLRs (Shamsul et al., 2010).    
 
1.6.2.  CD36 and Atherosclerosis 
 
Atherosclerosis is described as a progressive chronic inflammatory disease involving 
the eventual hardening and thickening of the arterial wall. This results in a reduction 
in the diameter of the arterial lumen eventually leading to ischemia with possible 
plaque rupture. One of the first stages of atherosclerotic plaque formation is in the 
dysfunction of the endothelium, which recruits, through release of cytokines, 
circulating monocytes into the arterial intima. It is thought that this endothelial 
dysfunction may be initially induced by the presence of oxLDL (Collot-Teixeira et 
al., 2007). Once within the arterial intima, CD36 on the surface of macrophages is 
able to bind and endocytose oxLDL, ultimately leading to the formation of lipid-
laden macrophages, called foam-cells. It is the accumulation of these foam cells 
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within the arterial intima that is a major contributor to plaque formation (Singh et al., 
2002).  
Despite oxLDL being identified as a ligand of CD36 (Endemann et al., 1993), its 
function in atherogenesis was not known until the development of suitable mouse 
models. It is now widely accepted, based on both in vitro and in vivo evidence, that 
the binding and endocytosis of oxLDL plays a key role in the formation of 
atherosclerotic lesions. Perhaps most important was the generation of the ApoE/Cd36 
double knockout mouse. The ApoE single knockout results in high circulating 
cholesterol levels and the more rapid development of atherosclerotic lesions when 
compared to wild-type mice (van Ree et al., 1994). ApoE/Cd36 double knockout 
mice, fed a high-fat western diet, showed a significant 76.5% reduction in the 
number aortic tree lesions detected at 12 weeks old when compared to ApoE single 
knockout mice of the same age. Additionally, macrophages isolated from 
ApoE/Cd36 double knockout mice displayed a 60% reduction in the amount of 
internalised oxLDL (Febbraio et al., 2000). Reintroduction of CD36 into ApoE/Cd36 
deficient mice, by stem cell transfusion resulted in an increase in the size of 
atherosclerotic lesions (Febbraio et al., 2004). A similar result was observed with 
older mice at the age of 35-weeks fed a high-fat western diet (Guy et al., 2007). In 
addition, it was shown that the CD36 ligand EP80317, a hexarelin derivative, 
reduced the lesion area (up to 51%) in ApoE single knockout mice, supposedly by 
competing for the oxLDL binding site on Cd36 (Marleau et al., 2005). 
However, further studies carried out by Moore et al., appear to contradict the 
conclusions drawn by Febbraio et al., that loss of Cd36 in an ApoE null background 
could reduce the size of atherosclerotic lesions. In the follow up studies ApoE/Cd36 
double knockout mice were fed a high-fat western diet for 8 weeks and the size of 
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atherosclerotic lesions formed over the aorta sinus and tree were measured. The 
results differed depending on the sex of the animal, with male mice having no 
significant reduction in aortic lesion size and female mice showing reduced lesion 
area through the aortic tree but increased lesion area in the aortic sinus. From these 
observations it was concluded that uptake and endocytosis of oxLDL was 
independent of scavenger receptors such as Cd36 (Moore et al., 2005). The apparent 
contradiction of these results have since been re-examined with questions raised in 
regards to the latter study; for example, the size of the lesions in the aortic sinus may 
have a non-linear relationship with the area of aortic tree lesions (Curtiss, 2006), and 
since the aortic sinus undergoes remodelling, only the lesion size in the constant 
aortic tree should be measured. The reappraisal of the two studies has found the 
results to be similar overall, consistent with CD36 having a role in atherogenesis. 
Slight variations in the congenic strains of mice used in the study could have also 
resulted in altered function of macrophages and endothelial cells, as well as exposure 
to pathogens such as Chlamydia pneumonia that may have increased the size of 
lesions in the absence of Cd36 (Witztum, 2005, Burnett et al., 2001).  
CD36 deficiency in macrophages (type I deficiency) has been identified in around 
3% of the Japanese population (Nozaki et al., 1995). Clinical observations in this 
population has identified a 40-50% reduction in the binding and uptake of oxLDL 
into macrophages, although no anti-atherosclerotic advantage is reported (Hirano et 
al., 2003). In contrast, several patients with type I CD36 deficiency have been shown 
to suffer from hypertension, hyperlipidemia and elevated fasting glucose levels, and 
one study has shown type I CD36 deficiency to be linked to a higher incidence of 
coronary heart disease (Yamashita et al., 2007). 
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It has recently been suggested that CD36-mediated uptake of oxLDL by 
macrophages to form foam cell is increased in the presence of AIM (Apoptosis 
inhibitor of macrophages) (Amezaga et al., 2014). AIM, also called CD5 antigen-
like (CD5L), is a soluble scavenger receptor known to bind oxLDL and to inhibit 
apoptosis of macrophages and other cell types (Sarrias et al., 2004, Arai et al., 2005, 
Haruta et al., 2001).  
  
1.6.3. CD36 and Angiogenesis 
 
The activity of both CD36 and TSP-1 as a receptor/ligand complex was first 
demonstrated as anti-angiogenic and pro-apoptotic in tumour cells, and was shown to 
be effective in countering most angiogenic inducers such as basic fibroblast growth 
factor (bFGF) and vascular endothelial growth factor (VEGF) (Good et al., 1990). 
CD36, with TSP-1, is now known to function as a negative regulator of angiogenesis 
in microvascular endothelial cells that is important in any roles that require 
neovascularisation, such as tumour growth, inflammation and wound healing (Kaur 
et al., 2009, Dawson et al., 1997). CD36 inhibits pro-angiogenic signals (such as 
bFGF and VEGF) which stimulate cell proliferation, migration and tube formation, 
while triggering pro-apoptotic signals. The proposed pathway for these effects 
requires the association of the nonreceptor protein kinase Fyn, to CD36. The kinase 
becomes activated and leads to the activation of the mitogen-activated protein kinase 
(MAPK) p38 and c-Jun N-terminal kinase (JNK), which ultimately leads to DNA 
cleavage by caspases and apoptosis of the cell (Jimenez et al., 2000). Additional 
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effectors of apoptosis, such as Fas ligand and tumour necrosis factor-α (TNF-α) are 
also upregulated as a result of this pathway (Volpert et al., 2002, Rege et al., 2009). 
   
1.6.4. Role of CD36 in the pathogenesis of Malaria and 
Sickle Cell Anaemia 
 
A key factor that influences the outcome of malarial infection is related to the ability 
of parasitized erythrocytes to adhere to the host microvasculature. Infection with P. 
falciparum can lead to erythrocytes adhering to the microvasculature of the brain, 
leading to cerebral malaria, causing encephalopathy (Miller et al., 2013). 
Ockenhouse et al, suggested that CD36 on the surface of vascular endothelium was 
involved in the sequestration and adherence of infected erythrocytes in the brain via 
the ligand Pfemp-1, or possible changes to the erythrocyte membrane as a result of 
infection (Ockenhouse et al., 1991). The CD36-mediated sequestration and 
adherence of infected erythrocytes was suggested to enable the parasite to propagate 
and avoid spleen-mediated immunity. A study by Aitman et al., tested this theory by 
looking at common CD36 frame shift and deletion mutations within the African 
population (nucleotides T1264G, G1439C and 1888delA) which all result in the 
production of a truncated CD36 without the carboxy-terminal half. The frequency of 
these mutations was significantly higher in those patients with cerebral malaria 
compared to the control group, in disagreement with the hypothesis (Aitman et al., 
2000). In contrast, another study found that the CD36 nonsense mutation T188G 
protected patients against severe malaria (Pain et al., 2001). Despite other studies 
reporting similar conflicting findings, these early population studies were generally 
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limited by small sample sizes and by the control groups used as comparators (Ayodo 
et al., 2007, Sinha et al., 2008, Omi et al., 2003). In 2009, a genetic analysis of 3420 
individuals from 66 ethnic groups showed that the T1264G polymorphism was 
abundant in sub-Saharan Africa groups but absent from nearly all non-African 
groups. However, the study, with a greater sample size than all previous studies 
combined, showed that CD36 was not linked to severe malaria (Fry et al., 2009). 
The authors, and others, have speculated that the common CD36 mutations in 
African populations may have arisen in response to evolutionary pressure of other 
severe infections or conditions that overlap with the geographical areas in which 
malaria is endemic (Fry et al., 2009, Hawkes et al., 2010b).  
Patients who suffer from sickle cell anaemia are, for example, more resistant to 
malaria. Sickle cell anaemia which is prevalent in sub-Saharan Africa (Grosse et al., 
2011), is caused by a mutation in the haemoglobin gene (Serjeant, 2013). As a result, 
erythrocytes are ‘sickle’-shaped, transiting more slowly through the vascular system, 
promoting ligand/receptor recognition and formation of complexes which contribute 
to a vascular pathology (Hebbel et al., 1980). CD36 on the surface of microvascular 
endothelial cells is considered a receptor for sickle cells although the identity of 
relevant ligand is less clear. Possible ligands include TSP-1 (Trinh-Trang-Tan et al., 
2010, Sugihara et al., 1992) and anionic phospholipids made accessible on the 
surface of the distorted sickle cell membrane (Setty et al., 2002). There is a selective 
pressure, therefore, to develop and maintain CD36 deficiency to alleviate the 
pathology of sickle-cell anaemia. This would suggest that, in sub-Saharan Africa, 
malaria, sickle-cell anaemia and CD36 deficiency, may have co-evolved.   
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1.6.5. CD36 and Fatty Acid Transport 
 
Cd36 was identified as a fatty-acid translocase by Abumrad and Harmon, through 
fatty acid uptake inhibition studies in rat adipocytes using sulfo-N-succinimidyl 
derivatives of LCFAs (Harmon and Abumrad, 1993). LCFA had previously been 
thought to simply diffuse across the plasma membrane down a concentration 
gradient. However, the distribution of Cd36 in highly metabolically active tissues 
such as adipose tissue (Abumrad et al., 1993), heart muscle (Luiken et al., 1999) and 
skeletal muscle (Bonen et al., 1999), suggested a possible transport function. In 
2000, this hypothesis was reinforced when it was shown that in Cd36 knock-out 
mice, LCFA transport is dramatically reduced in the heart, skeletal muscle and 
adipose tissue (Coburn et al., 2000). A perfused heart system from the same mouse 
strain was found to rely heavily on glucose as an energy source instead of fatty acids 
(Kuang et al., 2004). Transgenic mice which overexpressed Cd36 in skeletal muscle 
were shown to have enhanced fatty acid oxidation, with a decrease in circulating 
fatty acids and triglycerides, and decreased fat deposition, consistent with a role of 
Cd36 in catabolism of LCFA (Ibrahimi et al., 1999).   
The precise mechanism for the uptake of LCFA by CD36 remains unknown, 
however, it is thought that CD36 does not act as a typical transporter. It has been 
proposed that CD36 (in conjunction with the plasma membrane fatty acid binding 
protein; FABPpm) facilitates the disassociation of LCFA from albumin (Stremmel et 
al., 2001, Glatz et al., 2003) and promotes diffusion across the lipid bilayer by 
mediating the integration of protonated LCFA into the outer leaflet of the membrane. 
The LCFA may then flip spontaneously to the inner leaflet of the membrane, down 
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its concentration gradient where it can become activated by the addition of coenzyme 
A (Stremmel et al., 2001). Despite being shown to facilitate LCFA uptake with 
CD36, the precise role that FABPpm plays is unclear. It has been proposed that 
FABPpm may function to bind LCFA creating a local fatty acid concentration 
gradient at the plasma membrane and/or may help to localise CD36 to particular sites 
within the plasma membrane where the uptake of LCFA is most required (Glatz and 
Luiken, 2014).   
The uptake of LCFA is likely to be a rate limiting step in energy generation from 
fatty acid oxidation, therefore the cell surface expression of CD36 is metabolically 
important. Regulation of CD36 can be affected by muscle contraction or insulin 
release (Glatz et al., 2010). Recent studies have also suggested that plasma 
membrane localisation of CD36 for LCFA uptake is regulated by post-translational 
modifications such as ubiquitination (Smith et al., 2008, Kim et al., 2011). 
Glycosylation has also been suggested to regulate plasma membrane localisation of 
CD36 for LCFA uptake (Lauzier et al., 2011), however these studies were based on 
the SHR Cd36 which has an altered primary amino acid sequence (Aitman et al., 
1999).  
 
1.6.6. CD36, Insulin Resistance and Metabolic 
Syndrome 
 
Insulin resistance is a feature of a number of complex human disorders such as type 
2 diabetes, obesity, combined hyperlipidaemia and primary hypertension (Aitman et 
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al., 1997a, Aitman et al., 1997b, Groop et al., 1989, Reaven, 1988, Reaven et al., 
1996). The SHR is used as a model organism in the study of these disorders because 
it displays similar symptoms of insulin resistance, hypertriglyceridemia, abdominal 
obesity and hypertension (Iritani et al., 1977, Reaven et al., 1989). By using a 
combination of cDNA microarrays, quantitative trait loci mapping and radiation 
hybrid mapping, it was shown by Aitman et al,  that some SHR strains have a 
defective Cd36 gene (Aitman et al., 1999). Replacement of the mutant allele with a 
wild-type copy allowed the reversal of glucose tolerance and increased insulin 
responsiveness, although hypertension remained unaffected. These observations led 
to the conclusion that Cd36 deficiency was the cause of the insulin resistance in SHR 
(Pravenec et al., 2001).  This was not surprising considering at the time CD36 had 
just been identified as a possible transport protein for LCFA, with insulin resistance 
syndromes being attributed to defects in fatty acid metabolism (Aitman et al., 
1997a). Further studies however, working with different SHR lines showed the Cd36 
mutations were absent from these strains, suggesting that mutations in Cd36 did not 
necessarily contribute to the symptoms observed (Gotoda et al., 1999). Furthermore, 
in Cd36 knock-out mice insulin resistance is not observed (Febbraio et al., 1999). 
Cd36 knock-out mice were, however, shown to have higher whole body glucose 
uptake and lower glucose storage in basal conditions compared to wild type mice. 
Under hyperinsulinemic conditions the whole body glucose uptake was higher than 
observed in the wild type (Goudriaan et al., 2003). These data are consistent with 
studies performed by Kuang et al., showing that in the absence of efficient LCFA 
uptake and subsequent oxidation, glucose is used as the main source of energy, 
especially in the heart (Kuang et al., 2004). However, under these conditions it was 
also noted that hepatic glucose production was not inhibited suggesting some hepatic 
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insulin resistance (Goudriaan et al., 2003).  The differences observed between the 
mouse and rat models could be attributed to differences in genetic background or 
nutritional intake. A simple relationship between Cd36 status and insulin resistance 
seems unlikely, and Kennedy et al, using Cd36 knock-out mice, have demonstrated 
the presence of an oxLDL-Cd36 dependent paracrine loop between macrophages and 
adipocytes that links inflammation, oxidative stress, hyperlipidaemia and insulin 
resistance (Kennedy et al., 2011).   
Studies of the causes of insulin resistance in humans remain inconclusive. There 
have are conflicting reports of whether the type I CD36 deficiency in the Japanese 
population results in insulin resistance (Furuhashi et al., 2003, Furuhashi et al., 
2004, Kajihara et al., 2001, Kuwasako et al., 2003, Miyaoka et al., 2001, Yanai et 
al., 2000). CD36 polymorphisms have also been reported to be associated with 
insulin resistance (Corpeleijn et al., 2006, Lepretre et al., 2004).  
It is currently thought that insulin resistance and cardiac disease involves interplay 
between CD36 and the glucose transporter GLUT4. Cd36 facilitated LCFA uptake 
and GLUT4 mediated glucose uptake in the cardiac and skeletal muscle of rats 
showed that both are subject to short-term cellular redistribution on muscle 
contraction (Bonen et al., 2000, Steinbusch et al., 2011). Furthermore it has been 
shown that in rats with insulin resistance and type 2 diabetes that Cd36 becomes 
permanently localised to the sarcolemma in cardiomyocytes whereas GLUT4 is 
internalised (Ouwens et al., 2007, Steinbusch et al., 2011). 
There is increasing evidence to suggest that the use of pharmacological agents to 
bind and inhibit the CD36-mediated uptake of LCFA could provide a means to 
restrict the progression of a number of conditions such as insulin resistance and 
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cardiac failure (and also atherosclerosis). As a result of myocardial infarction and 
ischaemia insult the heart shifts metabolic substrate preference from fatty acids to 
glucose, the substrate with highest oxygen efficiency (Glatz et al., 2006). Despite a 
lower contribution from fatty acids for energy production under acute hypoxic 
conditions, localisation of Cd36 at the sarcolemma has been shown not to be 
diminished. Studies working with rat myocytes and perfused hearts have shown that 
acute hypoxic conditions activates AMP-activated protein kinase (AMPK) actually 
induces translocation of Cd36 to the sarcolemma, increasing fatty acid uptake 
(Chabowski et al., 2006). Due to reduced beta-oxidation, incoming fatty acids are 
redirected into intracellular lipid droplets. The accumulation of these lipid droplets is 
associated with the development and progression of cardiac contractile dysfunction 
(Sharma et al., 2004, Glatz et al., 2010). This increase in fatty acid uptake despite a 
reduction of beta-oxidation has also been associated with insulin resistance of 
skeletal muscle and the heart in obesity and type 2 diabetes (Glatz et al., 2010).  
Inhibition of Cd36-mediated uptake using the small molecules AP5055 and AP5258 
have been shown in rodent models to alleviate atherosclerosis (46% reduction in 
plaque size) and diabetes (>50% reduction in plasma glucose levels) with a reduction 
of plasma triglyceride concentration (Geloen et al., 2012). Additionally, the Cd36 
peptide EP 80317 has been shown to protect mice from post-ischemic myocardial 
damage (Bessi et al., 2012) and antibody inhibition of Cd36 in a cardiomyocyte cell 
model enhanced basal glucose uptake while reducing elevated palmitate uptake 
(Angin et al., 2012). These studies highlight the importance of CD36 as a therapeutic 
target and the requirement of a better understanding of ligand binding to help 
development pharmacologically effective agents.  
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1.6.7. CD36 and Fibrosis 
 
Fibrosis is characterised by overgrowth, hardening and scaring of dysfunctional 
tissue with excess deposition of collagen as the end result of chronic inflammatory 
reactions (Wynn, 2008). This can be caused by a number of factors including a 
persistent infection, an autoimmune response, radiation, chemical insults and/or 
physical tissue damage (Wynn, 2008).  CD36 has been implicated in a number of 
fibrotic states including pulmonary (Yehualaeshet et al., 1999) and renal fibrosis 
(Yang et al., 2007). Pulmonary fibrosis involving CD36 has been suggested to 
involve the interplay of CD36, TSP-1 and the transforming growth factor (TGF)-β1. 
Using a rat model of pulmonary fibrosis it has been shown that blocking the 
interaction of TSP-1 with macrophage Cd36 reduces the inflammation, most likely 
by preventing the activation of TGF-β1  (Yehualaeshet et al., 2000). Through the use 
of monoclonal antibodies against TSP-1 and Cd36 it was concluded that TSP-1 
bound to inactive TGF-β1 which bound, as a complex, to Cd36 on the alveolar 
macrophage where the protease plasmin was recruited to cleave and activate TGF-β1 
(Yehualaeshet et al., 1999). A role for Cd36 in pulmonary fibrosis was further 
supported by a study which used a lentiviral vector to silence expression of Cd36 in 
rat alveolar macrophages following silica-induced fibrosis. Silencing of Cd36 
resulted in a decrease in the level of active TGF-β1 and subsequent fibrosis (Wang et 
al., 2009, Wang et al., 2013).  
In renal fibrotic disease a similar process of TGF-β1 activation that induces an 
inflammation response is thought to be responsible, however it should be noted that 
in both organs TGF-β1 activation can occur via other membrane receptors such as 
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integrin αvβ6  (Munger et al., 1999, Nishimura, 2009, Sheppard, 2005). Yang et al., 
have also demonstrated that albumin-induced renal tubule fibrosis could be 
supressed using siRNA against Cd36, resulting in a decrease in active TGF-β1 and 
fibronectin, further supporting the potential of Cd36 as a target for anti-fibrotic 
therapies (Yang et al., 2007). 
 
1.6.8.  CD36 and Alzheimer’s Disease 
 
Alzheimer’s disease is the most common neurodegenerative disorder in adults and is 
characterised by the formation of senile plaques in the brain parenchyma, composed 
of insoluble fibrillar β-amyloid protein surrounded by activated microglia, 
astrocytes, and dystrotrophic neurites (Selkoe, 2000, Salawu et al., 2011).  One 
school of thought believes the pathogenesis of Alzheimer’s disease is caused by the 
inflammatory response triggered by the deposition of insoluble fibrillar β-amyloid 
(Akiyama, 1994). Microglia are thought to be the main cell type involved in 
mediating this inflammatory reaction (Pan et al., 2011, Krabbe et al., 2013). A 
potential role for CD36 was suggested by Coraci et al., who showed that transient 
expression of the scavenger receptor allowed cells to specifically bind to surfaces 
coated with fibrillar β-amyloid (Coraci et al., 2002). CD36 is upregulated in 
microglia and the vascular endothelial cells in patients with Alzheimer’s disease. 
Futhermore, it has been shown that monoclonal antibodies against CD36 can inhibit 
the production of pro-inflammatory ROS from N9 microglia and human 
macrophages adhered to β-amyloid coated surfaces by around 50% (Coraci et al., 
2002). This ROS production could be inhibited by anti-CD36 antibodies however it 
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did not affect adherence, leading to the suggestion that other receptors also play a 
role in adherence to fibrillar β-amyloid such as class A scavenger receptors and SR-
BI (El Khoury et al., 1996, Husemann et al., 2001). In 2003 it was further reported 
that microglia and macrophages isolated from Cd36 knock-out mice showed a 
significant reduction in the response to fibrillar β-amyloid, with reduced release of 
pro-inflammatory cytokines, chemokines and ROS, highlighting the role of Cd36 in 
the initiation of the inflammatory response in Alzheimer’s disease (El Khoury et al., 
2003). From a study of THP-1 macrophages and mouse microglia binding to 
immobilised fibrillar β-amyloid Bamberger et al., propose that a cell surface receptor 
complex consisting of Cd36, Cd47 and integrin α6β1 mediate microglial activation 
(Bamberger et al., 2003). More recently it was demonstrated that the inflammatory 
pathways triggered by β-amyloid (or oxLDL) were initiated through formation of a 
complex including CD36, TLR4 and TLR6 (Stewart et al., 2010).  
 
1.7. Objectives of the current study 
 
How the relatively small ectodomain of CD36 can bind such a diverse range of 
ligands remains unexplained. We can speculate on the nature of the polyspecificity 
from homology models based upon the LIMP-2 structure, but the lack of resolution, 
and the evolutionary distance and separation of function of LIMP-2, will always 
limit the relevance of conclusions drawn. An actual CD36 structure derived from a 
crystal remains elusive. CD36 binds a wide range of ligands which links the receptor 
to an equally wide range of disease states, however, a detailed understanding of the 
binding kinetics, of ligands and also of inhibitors that are being identified, is lacking. 
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The main objectives of this doctoral study is to develop an expression and 
purification system to purify significant amounts (milligram quantities) of human 
CD36 suitable for crystallisation studies, and also ligand binding experiments in 
order to calculate the microkinetics of interaction. 
In chapter 3, insect and mammalian cell systems are compared to drive the synthesis 
and secretion of the CD36 ED tagged with a polyhistidine tail. The ED is purified 
from insect cells using nickel affinity chromatography and the retention of the native 
protein fold demonstrated by binding of fluorescently-labelled acLDL. The process 
is then scaled up to offer the possibility of milligram quantities of highly enriched 
CD36 ED. In chapter 4, the glycosylation status of the purified protein is explored, 
and mass spectrometric analysis used to determine the diversity and complexity of 
the actual glycan structures present. Finally, in chapter 5, purified CD36 ED is 
immobilised on a sensor chip for surface plasmon resonance experiments and, as 
proof of principle, the microkinetics of monoclonal antibody binding to CD36 are 
determined.  
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2. Materials and Methods 
 
2.1. Bacteria culture medium 
 
Lysogeny Broth (LB):  1% tryptone, 0.5% yeast extract, 1% NaCl 
 
LB Agar:    1% tryptone, 0.5% yeast extract, 1% NaCl 
 
SOC Medium:  2% tryptone, 0.5% yeast extract, 0.05% NaCl, 0.02% 
KCl, 0.04% glucose, 0.01M MgCl2, 0.01M MgSO4 
 
Solid or liquid growth media were supplemented with ampicillin to a final 
concentration of 100µg/ml, where appropriate.  
 
2.2. Bacterial Culture and Storage 
 
Bacteria were grown in liquid growth media with shaking (230rpm), or on plates in 
an incubator set to 37°C. Bacteria were frozen for long term storage at -80°C in a 
mixture of LB medium and 15% glycerol. 
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2.3. Molecular Biology 
2.3.1. Plasmids 
 
The baculovirus transfer vector, pBacPAK9-CD36 ED-12His, provided by Kenneth 
Linton, encodes human CD36 ED (amino acids 36-435) with a C-terminal 12 
histidine tag and an N-terminal honeybee melittin secretory signal.  The vector was 
constructed in three steps. First, the coding sequence for the ED was amplified by 
mutagenic primers: CD36-ED-SacI 5’-
TGGAGACCTGCTGAGCTCGAAGACAATTAAAAAGC-3’ and CD36-ED-
BstEII 5’-GGCCAAGGAGGTTTAGGTGACCAGTTACTTGAC-3’ which 
introduce sites for the restriction enzymes SacI and BstEII (underlined), respectively 
at the 5’ and 3’ end of the coding sequence for the ED. The PCR product was 
digested with SacI and BstEII and cloned into similarly digested BlueBac-CD36-
12His, described previously (Hoosdally et al., 2009). Cloning into the BstEII site 
fused the ED coding sequence in frame with the coding sequence for a 12 x histidine 
carboxy-terminal tag and a translation stop codon. Second, the coding sequence was 
excised from the BlueBac vector using SacI and SalI (the latter being 3’ to the stop 
codon) and cloned into similarly digested pMelBac B (Invitrogen). This fused the 
coding sequence for the honeybee melittin secretion signal (HMSS) in frame at the 
5’ end of the CD36-ED. Third, the entire coding sequence of the HMSS-CD36-ED-
12His was excised from the MelBac vector using the EcoRV site in the polyhedrin 
promoter and the XbaI site (that is 3’ to the translation stop codon but 5’ to the SalI 
site of BlueBac-CD36-12His) and subcloned into equivalent sites in pBacPAK9 to 
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generate pBacPAK9-CD36 ED-12His. The construct was sequenced to ensure 
veracity. The relevant sequence elements are shown in Appendix 1.  
The mammalian expression plasmid pOPING-CD36ED-6His was generated by Dr 
Joanne Nettleship at the Oxford Protein Production Facility (OPPF). CD36 ED was 
subcloned from pBacPAK9-CD36ED-12His into the pOPING vector (Oxford 
Protein Production Facility, UK) resulting in a construct encoding CD36 ED with an 
N-terminal RPTPmu secretory signal and a C-terminal 6 histidine tag. 
 
2.3.2. Preparation of plasmid DNA 
 
Small-scale (µg-quantities) plasmid DNA preparations were generated using the 
GenElute HP Plasmid Miniprep Kit, following the manufacturer’s protocol (Sigma-
Aldrich). The protocol is based upon the rapid alkaline lysis procedure to isolate 
plasmid DNA, first described by Birnboim and Doby (Birnboim and Doly, 1979). 
Bacterial cells from a 3ml overnight culture were harvested by centrifugation for 10 
minutes at 14,000rpm (EBA 12, Hettich, Germany). The cell pellet was resuspended 
in 200µl Resuspension solution (50mM Tris-HCl pH 8, 10mM EDTA, 100µg/ml 
RNase A). Once the cell pellet was completely resuspended, 200µl Lysis buffer (1% 
SDS, 0.2M NaOH) was added to the solution, mixed by inversion and incubated at 
room temperature for 5 minutes. Nucleic acids and proteins within the lysate were 
subsequently denatured due to the alkalinity of the Lysis buffer. Following 
incubation in Lysis Buffer, 350µl of Neutralisation Buffer (3M potassium acetate, 
pH 5.5) was added to the solution, causing the aggregation of insoluble genomic 
DNA and high molecular weight RNA as well as the precipitation of protein-SDS 
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complexes. To remove these aggregates, the lysate was centrifuged at 14,000rpm for 
10 minutes. GenElute HP Miniprep Binding Columns were prepared by adding 
800µl of Column Preparation Solution (50mM MOPS pH7.0, 0.75M NaCl, 15% 
ethanol, 0.15% Triton X-100) followed by centrifugation at 14,000rpm for 2 
minutes. The supernatant from the cell lysate was then added to the prepared 
columns and incubated for 2 minutes at room temperature before centrifugation at 
14,000rpm for 2 minutes. The columns were washed by adding 500µl of Wash 
Solution (50mM MOPS pH8.5, 1M NaCl, 15% ethanol) and centrifuging at 
14,000rpm for 2 minutes. The flow through was discarded and the columns were 
centrifuged as before to remove traces of Wash Solution. Plasmid DNA was eluted 
by adding 50µl Tris-HCl (pH 8.5) to the columns and incubating at room 
temperature for 5 minutes followed by centrifugation for 2 minutes at 14,000rpm. 
Recovered plasmid DNA was quantified using a NanoDrop (ND-100, Thermo 
Scientific), measuring the optical density at a wavelength of 260nm. Estimation of 
purity of the plasmid DNA was achieved through measuring the A260:A280 ratio; a 
ratio of 1.8-2.0 was indicative of a pure sample. 
Large-scale (mg-quantities) plasmid DNA preparations were generated using the 
Plasmid Mega Kit (Qiagen), following a similar protocol as before. Bacterial cells 
from a 500ml overnight culture were harvested by centrifugation for 20 minutes at 
6,000xg, 4°C in a Sorvall RC-5C Plus centrifuge (Thermo Scientific). The resulting 
cell pellet was resuspended in 50ml Resuspension Buffer. Following complete 
resuspension, Lysis Buffer was added before mixing by inversion and incubation at 
room temperature for 5 minutes. Chilled Neutralisation Buffer (50ml) was added, 
and the solution was mixed by inversion and incubated at 4°C for 30 minutes. 
Centrifugation for 30 minutes at 20,000xg, 4°C in a Sorvall RC-5C Plus centrifuge 
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(Thermo Scientific) was then used to clear the lysate. The supernatant was decanted 
onto a Qiagen 2500 column, pre-equilibrated with 35ml Column Preparation 
Solution. The column was washed with 200ml of Wash Solution before elution of 
the DNA with 35ml of Buffer QF (50mM Tris-HCl pH 8.5, 1.25M NaCl, 15% 
ethanol). Eluted DNA was precipitated by adding 100% isopropanol  (24.5ml), and 
pelleted by centrifugation for 30 minutes at 15,000xg, 4°C, in a Sorvall RC-5C Plus 
centrifuge (Thermo Scientific). The resulting pellet was carefully rinsed with 70% 
ethanol (7ml), centrifuged as before, air-dried and then resuspended in 200µl Tris-
HCl (pH 8.5). Recovered plasmid DNA was quantified as before. 
 
2.4. Insect Cell Culture 
2.4.1.  Insect Cell Culture Medium and Reagents 
 
Sf900 II SFM and TC100 insect cell media was purchased from Life Technologies. 
Ex-cell 405 media insect cell media was purchased from Sigma-Aldrich. Antibiotic-
antimycotic solution (GE Healthcare) was added to all insect cell culture media to a 
final concentration of 100units/ml penicillin G, 100µg/ml streptomycin sulphate, and 
25µg/ml amphotericin B, unless otherwise stated.  In addition, TC100 media was 
routinely supplemented with 10% foetal bovine serum (FBS; Sigma-Aldrich). All 
manipulations were performed in a sterile environment, with disposable plasticware 
and glassware reserved specifically for that purpose. All suspension cultures of 
insect cells were grown at 27°C with shaking at 110rpm or within a Wave Bioreactor 
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Cellbag with variable rocking per minute and rocking angle depending on culture 
size (see 2.4.6).  
 
2.4.2. Insect Cell Co-transfection and Baculovirus 
Generation 
 
Sf21 cells were co-transfected with transfer vector and flashBAC (Oxford Expression 
Technologies, OET), flashBAC Gold (OET) or Profold-ER1 (AB Vector) genomic 
DNA as instructed by the manufacturer. 1.5x10
6
 cells were seeded onto a 35mm 
tissue culture dish (BD Biosciences, San Jose, CA) in TC100 medium without FBS 
or antibiotics.  
 
For each co-transfection, the following reagents were mixed: 
 100ng   Baculoviral genomic DNA 
 500ng   Transfer Plasmid – pBacPAK9-CD36 ED-12His) 
 5µl   Lipofectamine transfection reagent (Life Technologies) 
 1ml   TC100 media without FBS or antibiotics 
The solution was gently mixed and incubated at room temperature for 15 minutes. 
Medium was then aspirated from the monolayer of insect cells and replaced quickly, 
but carefully, with the transfection mixture.   Each dish was then incubated overnight 
at 27°C in a humidified sealed box containing (lined with paper soaked in 50mM 
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EDTA). After 24hrs, 1ml TC100 containing 10% FBS and antibiotics was added to 
each dish and incubated for a further 120 hours, as before. Following incubation, the 
medium was recovered as ‘Co-T’ baculovirus. 
 
2.4.3.  Plaque assay to determine baculovirus titre 
 
Plaque assays were used to assess the titre of recombinant baculoviruses. For each 
baculovirus, six 35mm tissue culture dishes (BD Biosciences) were seeded with 
1.5x10
6 
Sf21 insect cells in TC100 medium, and left to settle on a flat surface. A 
series of dilutions of the baculovirus stock were made (10
-4
, 10
-5
, 10
-6
) in TC100 
media. The culture medium was aspirated from the dishes, replaced by 200l of each 
baculovirus dilution. Each infection was performed in duplicate. The cells were 
incubated at room temperature for 2 hours. The medium covering the insect cells was 
aspirated and replaced with a 1.5ml layer of 1% low melting point agarose (LMP-
Ag; Sigma-Aldrich) prepared from a 4% stock in dH2O diluted to 1% using 
prewarmed TC100 media plus FBS and antibiotic-antimycotic. The dishes were 
placed on a flat surface and incubated at room temperature to allow the agarose to 
solidify after which 1ml of TC100 media was added onto the agarose ‘plug’ and the 
dishes placed inside a humidified box and incubated at 27°C for 72 hours. To 
visualise plaques, 1ml solution of 0.03% neutral red (Sigma-Aldrich) in PBS was 
added to each dish and incubated for 3-4 hours. The liquid medium was then 
aspirated, the dishes inverted and left at room temperature, overnight in the dark. 
Neutral red stains live cells, allowing the visualisation of virus plaques of lysed or 
dying cells as clear regions within the red background monolayer.  
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The titre (in plaque forming units/ml; pfu/ml) was calculated as the number of 
plaques multiplied by the dilution factor.  
 
2.4.4. Amplification of Baculovirus 
 
To obtain working stocks, baculovirus was amplified over a number of stages. At 
each stage the premise remains the same; with a low ratio of virus particles to insect 
cells (multiplicity of infection; MOI) used to permit cell growth to continue whilst 
allowing multiple cycles of viral infection, replication and budding to occur.  
Co-T-to-intermediate stock amplification  
A suspension culture containing 25ml Sf21 insect cells at a density of 1x10
6
cells/ml 
in Sf900 II SFM media was infected with 250µl Co-T baculovirus. The cells were 
incubated overnight, before being diluted with 25ml of fresh Sf900 II SFM media. 
After a total of 5 days, the cells were removed by centrifugation at 1000xg for 10 
minutes (Hettich rotanta 46R). The supernatant was recovered, filtered through a 
0.2µm syringe filter (Minisart, filters, Sartorius) and stored at 4°C as ‘intermediate 
stock’. The baculovirus titre was calculated by plaque assay. 
Intermediate stock-to-working stock amplification  
A suspension culture containing 100ml Sf21 insect cells at a density of 2x10
6 
cells/ml (2x10
8
cells/ml in total) in Sf900 II SFM media was infected with 1x10
7 
pfu/ml intermediate stock baculovirus (MOI=0.05). The cells were incubated 
overnight, before being diluted with 100ml fresh SF900 II SFM media. After a total 
of 5 days, the cells were removed by centrifugation at 1000xg for 10 minutes 
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(Hettich rotanta 46R). The supernatant was recovered, filtered through a 0.2µm 
syringe filter (Sartorius) and stored at 4°C as ‘working stock’. The baculovirus titre 
was calculated by plaque assay. 
 
2.4.5. Small-scale infection for protein production 
 
Small-scale infections were performed in either 35mm tissue culture dishes or in 
100ml suspension cultures. 
Small-scale infection in tissue culture dishes 
Tissue culture dishes were seeded with either 1x10
6 
Hi5
 
insect cells (in Ex-cell 405 
media) or Sf21 insect cells (in Sf900 II SFM media) which were left to settle on a 
flat surface. For synchronous infection, a high MOI of 3 (3 virus particles per insect 
cell) was used.  The culture medium was aspirated from the dishes and replaced with 
1ml of baculovirus dilution containing 3x10
6
 pfu. The cells were incubated for 3 
hours at 27°C. Following this, medium containing the baculovirus was aspirated and 
replaced with 2ml of fresh media. Cells were incubated at 27°C for a total of 72 
hours before harvesting spent media by centrifugation at 1000xg for 10 minutes to 
remove cells and cell debris. Spent media was filtered through a 0.2µm syringe filter 
(Sartorius) and stored at 4°C.  
Small-scale infection of suspension cultures 
A suspension culture containing 50ml of either Hi5 insect cells (in Ex-cell 405 
media) or Sf21 insect cells (in Sf900 II SFM media) at a density of 2x10
6
cell/ml 
(totalling 1x10
8
 cells) was infected with 3x10
8 
pfu of working stock baculovirus for a 
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Hi5 insect cell culture (MOI=3) or with 5x10
6 
pfu of working stock baculovirus for a 
Sf21 insect cell culture (MOI=0.05) (see 3.3.2). Cells were incubated at 27°C for a 
total of 72 hours before harvesting spent media by centrifugation at 1000xg for 10 
minutes to remove cells and cell debris. Spent media was filtered through a 0.2µm 
syringe filter (Sartorius) and stored at 4°C.  
 
2.4.6. Large-scale infection for protein production 
 
A 2.5 litre suspension culture containing Sf21 insect cells in Sf900 II SFM media at 
a density of 2x10
6 
cells/ml (5x10
9
 cells in total) was grown in a 10L Cellbag 
bioreactor chamber (GE Healthcare) on a Wave Bioreactor (20/50EHT, GE 
Healthcare), rocking at 15 rocks per minute with a rocking angle of 8°. The cells 
were infected with 2.5x10
8 
pfu of working stock baculovirus (MOI=0.05) (see 3.3.2) 
and incubated overnight at 27°C, at 18 rocks per minute with rocking gradient of 8°, 
before being diluted to 5L with fresh Sf900 II SFM media. At 100% capacity (5L for 
a 10L Cellbag) the rocking was adjusted to 25 rocks per minute with a rocking angle 
of 10°. The culture was harvested 72 hours post-infection by centrifugation at 
1500xg for 20 minutes to remove cells and cellular debris. Spent media was filtered 
through 0.2m 500ml bottle top filter units (Corning) and stored at 4°C.  
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2.5. Mammalian Cell Culture 
2.5.1. Mammalian Cell Culture Medium and Reagents 
 
TrypLE Express and Dulbecco’s Modified Eagle Medium (DMEM) plus glutamax, 
were purchased from Life Technologies. The cationic polymer polyethyleneimine 
(PEI), used as a transfection agent, and FBS were supplied by Sigma-Aldrich.  
Human embryonic kidney cells (HEK293T) were grown as monolayers and 
maintained by regular passage in DMEM supplemented with 10% FBS under 5% 
CO2 at 37°C within a water vapour-saturated atmosphere. All manipulations were 
performed in a sterile environment, with disposable plasticware and glassware 
reserved specifically for that purpose.  
 
2.5.2. Transient transfection of HEK293T cells 
 
For transfection in a 35mm tissue culture dish (BD Biosciences), HEK293T cells 
were grown to 80% confluency as a monolayer. A solution containing 5µg DNA 
(pOPING-CD36ED-6His) at a concentration of 0.5µg/µl in 5% glucose was mixed 
with 1.5µl PEI solution (prepared by addition of 45mg 25kDa PEI (Sigma-Aldrich) 
to 8ml dH2O, pH to 7.2 with dilute HCl) and incubated at room temperature for 5 
minutes. DMEM (2ml) with 10% FBS was added to the transfection mixture before 
applying to the cells. After 48 hours, spent media was harvested and any cells or cell 
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debris removed by centrifugation at 1000xg for 10 minutes. Spent media was filtered 
through a 0.2um syringe filter (Sartorius) and stored at 4°C.  
 
2.6. Protein Biochemistry 
2.6.1. Materials used for protein biochemistry 
 
General chemicals were purchased from Sigma-Aldrich. EDTA-free protease 
cocktail tablets (cOmplete) were purchased from Roche, and used at a final 
concentration of 1x, according to manufacturer’s recommendations.  
 
2.6.2. Buffer exchange with concentration of harvested 
media 
2.6.2.1. Small-scale buffer exchange and sample 
concentration 
 
Harvested media from small-scale suspension cultures (100ml) was buffered 
exchanged and concentrated using a 30kDa nominal molecular weight cut-off 
(NMWCO) polyethersulfone (PES) VivaFlow 200 cassette as part of a tangential 
cross-flow diafiltration system, following manufacturer’s protocols (Sartorius).  
Harvested media was buffer exchanged against 1L of purification buffer (50mM 
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HEPES pH7.4, 300mM NaCl, 20mM Imidazole) before concentration of the sample 
to around 20-30ml.   
 
2.6.2.2. Large-scale buffer exchange and sample 
concentration 
 
Harvested media from large-scale suspension cultures (5L) was first concentrated 
and then buffer exchanged using 30kDa NMWCO Xampler Ultrafiltration Hollow 
Fiber Cartridge along with a QuixStand Benchtop System as part of a tangential 
cross-flow diafiltration system, following manufacturer’s protocols (GE Healthcare). 
Harvested media was first concentrated to around 500ml and then buffer exchanged 
against 5L of purification buffer (50mM HEPES pH 7.4, 300mM NaCl, 20mM 
Imidazole). The sample was then further concentrated to around 300-400ml. 
 
2.6.3. Purification of CD36 ED-12His using affinity 
chromatography 
2.6.3.1. Batch affinity chromatography 
 
CD36 ED-12His from small-scale suspension cultures was purified in batch using 
Ni-NTA agarose (Qiagen). Ni-NTA agarose was washed in dH2O (1ml of 50% 
agarose slurry/10ml of sample) and pre-equilibrated with purification buffer (50mM 
HEPES, 300mM NaCl, 20mM Imidazole, pH7.4) at a volumetric ratio of 1:10 
(packed resin to purification buffer). At each stage of the purification process, the 
78 
 
resin was packed by centrifugation at 300rpm for 1 minute, 4°C (Hettich rotanta 
46R). A low concentration of imidazole (20mM) was present in the initial 
purification buffer to reduced non-specific binding between other proteins and the 
resin. Protein sample and resin were incubated with continuous gentle mixing for 2 
hours at 4°C to ensure binding of the 12 histidine tag of CD36 ED. The non-bound 
proteins were decanted (flow-through), and the resin washed seven times with 20-
bed volumes of ice-cold purification buffer containing increasing concentrations of 
imidazole (20-100mM). Bound CD36 ED-12His was then eluted using four 8-bed 
volumes of purification buffer containing 500mM imidazole.  
 
2.6.3.2. Column affinity chromatography 
 
CD36 ED-12His from large-scale suspension culture was purified using a 5ml 
HisTrap HP column (GE Healthcare) on an AKTA Prime Plus automated protein 
purification system (GE Healthcare), within a refrigerated room (4°C). The HisTrap 
HP column was first washed with 10 column volumes of dH2O and then equilibrated 
with 10 column volumes of purification buffer (50mM HEPES, 300mM NaCl, 
20mM Imidazole, pH7.4) at a flow rate of 1ml/min. The protein sample was loaded 
onto the column at a low flow rate (0.3ml/min) overnight to ensure efficient binding 
of the 12 histidine tag of CD36 ED. Protein flowing through the column was 
measured by absorbance at 280nm (A280). The column was then washed with 
purification buffer containing 100mM imidazole at 0.5ml/min, until the A280 
dropped to around baseline levels. Purification buffer containing 500mM imidazole 
79 
 
was passed through the column to elute CD36 ED-12His with 2ml fractions 
collected using the automated fraction collector.  
 
2.6.4. Concentration of purified protein samples 
 
Proteins eluted from the chromatography procedures were concentrated using 
Amicon Ultra-4 and Amicon Ultra-15 centrifugal devices with a 30kDa NMWCO 
(EMD Millipore), spun at 4000xg, 8°C (Hettich rotanta 46R), for between 10 and 30 
minutes until the sample volume had reduced to 20% of the starting volume. 
 
2.6.5. Dialysis 
 
Dialysis was performed using Slide-a-Lyzer G2 dialysis cassettes with a 20kDa 
NMWCO (Thermo Scientific), following the manufacturer’s protocol. Briefly, 
protein samples were added to dialysis cassettes and dialysed against 300x the 
volume of sample with dialysis buffer (50mM HEPES, 300mM NaCl, pH 7.4), in a 
beaker at 4°C for 1 hour with gentle stirring. The process was repeated for another 
hour with fresh dialysis buffer and then allowed to dialyse overnight in a third batch 
of dialysis buffer. 
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2.6.6. Size-exclusion chromatography 
 
Purified proteins from a large-scale suspension culture, dialysed into dialysis buffer 
were further separated using size-exclusion chromatography (SEC). SEC was 
performed using a Superdex 200 10/300 GL column (GE Healthcare) attached to an 
AKTA Explorer 100 automated protein purification system (GE Healthcare), 
operated at room temperature. The column has a globular protein separation range of 
10-600kDa. A concentrated purified protein sample (500µl) was passed down the 
SEC column at a flow rate of 0.5ml/min, with 1ml fractions being collected by an 
automated fraction collector. 
 
2.6.7. Trichloroacetic acid precipitation of protein 
samples 
 
Dilute protein solutions were precipitated using tricholoroacetic acid. This was 
performed prior to separating dilute protein samples by SDS-PAGE. 0.1% (v/v) of 
0.15% sodium deoxycholate was added to the protein sample and incubated at room 
temperature for 5 minutes. Following this, 0.1% 72% trichloroacetic acid was added, 
the sample mixed well and incubated at room temperature for 5 minutes. Protein was 
recovered by centrifugation at 20000xg for 15 minutes (Hettich EBA 12). The 
supernatant was carefully removed and discarded, and the pellet resuspended in 10µl 
resuspension buffer (4%SDS, 0.2M Tris pH 7.4, 0.15M NaOH).   
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2.6.8. Preparation of protein samples for SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Protein samples were prepared for SDS-PAGE as described by Laemmli (Laemmli, 
1970). Laemmli sample buffer (LSB; 100mM Tris-HCl pH 6.8, 20% glycerol, 10% 
2-mercaptoethanol, 4% SDS, 0.1% bromophenol blue) was added to the protein 
sample (2:1 v/v, sample to LSB) and incubated at 75°C for 10 minutes prior to 
loading the gel. LSB without 10% 2-mercaptoethanol was used when preparation 
samples under non-reducing conditions. 
 
2.6.9. SDS-PAGE 
 
Proteins were separated by electrophoresis through vertical 1mm thick 
polyacrylamide gels (0.1% SDS, 8% acrylamide), using the procedure described by 
Laemmli (Laemmli, 1970). The required reagents and volumes to make the 
separating and stacking gel, along with SDS-PAGE running buffer were as follows: 
 
10X SDS-PAGE running buffer: 250mM Tris Base 
     1.92M glycine 
     1% SDS 
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Separating gel:   1.3ml 1.5M Tris-HCl (pH8.8) 
     2.3ml H2O 
1.3ml 30% Acrylamide/Bis-acrylamide mix   
(37:5:1 ratio) 
50µl 10% SDS 
50µl 10% ammonium persulphate 
3µl TEMED 
 
 
Stacking gel:    380µl 1.0M Tris-HCl (pH6.8) 
     2.1ml H2O 
500µl 30% Acrylamide/Bis-acrylamide mix 
(37:5:1 ratio) 
30µl 10% SDS 
30µl 10% ammonium persulphate 
3µl TEMED 
 
Polymerisation of the separating gel was initiated by the addition of N,N,N’,N’-
tetramethylethan-1,2-diamine (TEMED). The stacking gel was overlaid onto the 
polymerised separating gel after addition of TEMED to initiate polymerisation. Prior 
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to sample loading, the wells of the gel were rinsed with running buffer. Gels were 
run at 100V for 2 hours or until the dye front had reached the bottom of the gel.  
 
2.6.10. Detection of protein by colloidal blue staining 
 
Following separation by SDS-PAGE, proteins were visualised using the colloidal 
blue staining kit (Life Technologies), according to the manufacturer’s protocol. 
Briefly, following electrophoresis, the SDS-PAGE gel was placed in freshly made 
colloidal blue solution (per gel: 20ml Stainer A solution, 5ml Stainer B solution, 
20ml 100% methanol and 55ml dH2O) and incubated for 3-12 hours at room 
temperature on an orbital shaker. Staining solution was then removed and the gel 
washed three times, for 5 minutes, 1 hour and then overnight in dH2O at room 
temperature on an orbital shaker to de-stain. 
 
2.6.11. Protein Quantification 
 
The protein content of samples were calculated using a BSA standard curve. Serially 
diluted protein samples and BSA standards were separated by SDS-PAGE and 
stained with colloidal blue stain. The gel was scanned and the density of the BSA 
standards was measured using ImageJ software (NIH) and the standard curve plotted 
using GraphPad Prism software version 5 (CA, USA). Using the BSA standard 
curve, the linear equation (Equation 1) was used to measure the concentration of 
protein based on the density of protein bands. 
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Equation 2.1. The Linear Equation 
 
Where y and x are the co-ordinates that satisfy the equation, m is the gradient of the 
straight line and c is the intercept on the y-axis.  
 
The percentage purity of a protein sample was also calculated using the ImageJ 
analysis of stained SDS-polyacrylamide gels by comparing the density of the protein 
of interest (as a percentage) against the summed densities of all proteins bands in the 
sample (representing 100%). 
 
2.6.12. Detection of proteins by western blotting 
 
For western blotting analysis, proteins were separated by SDS-PAGE and then 
electroblotted onto a polyvinylidene fluoride (PVDF) membrane (EMD Millipore, 
MA, USA). The method is based on the western blotting procedures first 
demonstrated in 1979 (Towbin et al., 1979). The PVDF membrane was prepared by 
soaking in 100% methanol for 5 minutes, followed by a 5 minute wash in dH2O. 
Finally, both the PVDF membrane and 3MM filter paper (Whatman, Maidstone, 
UK) were soaked in transfer buffer (25mM Tris-HCl pH8.3, 192mM glycine, 20% 
methanol). Electroblotting was carried out at 400mA for 1 hour at room temperature 
using a Mini Trans-blot cell (Biorad, CA, USA), according to manufacturer’s 
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instructions. Following electroblotting, the PVDF membrane was washed for 5 
minutes with PBST (0.1% v/v Tween 20 in PBS) before being incubated in block 
buffer (5% w/v skimmed milk powder in PBST) for 1 hour at room temperature on 
an orbital shaker. The membrane was then incubated with 1ml primary antibody 
diluted in blocking buffer inside a heat-sealed pocket for 2 hours at room 
temperature, shaking on an orbital shaker. For detection of CD36, a rat monoclonal 
anti-CD36 antibody, clone 1955 (R&D systems) was used at a dilution of 1:1000. 
For detection of the C-terminal poly-histidine tag, a mouse monoclonal anti-His 
antibody, clone 3D5 (Life Technologies) was used at a dilution of 1:5000. Following 
incubation with primary antibody, the membrane was given three 15 minutes washes 
with PBST before incubation with 1ml of secondary antibody, conjugated with to 
horseradish peroxidase (HRP) diluted in blocking buffer inside a heat-sealed plastic 
pocket for 1 hour at room temperature, shaking on an orbital shaker. The secondary 
antibodies used (Dako) were either a rabbit-anti rat (for anti-CD36 blots) or a goat-
anti mouse (for anti-His). The membrane was subsequently given four 15 minute 
washes with PBST before visualisation of protein-bound HRP using Immobilon 
Western Chemiluninescence HRP Substrate (EMD Millipore, MA, USA), together 
with ECL Hyperfilm (GE Healthcare). 
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2.6.13. Glycosidase digestion of glycoproteins 
 
Proteins were deglycosylated using Peptide-N-glycosidase F (PNGase F) (New 
England Biolabs) according to the manufacturer’s protocol. Briefly, 1-20µg of 
protein was incubated for 10 minutes at 100°C in the presence of denaturing buffer 
(0.5% SDS, 1% 2-mercaptoethanol) and incubated on ice for 2 minutes. 500U of 
PNGase F was added with G7 buffer (50mM Sodium phosphate) supplemented with 
1% NP40 and incubated at 37°C for 2 hours. 
For deglycosylation of native purified protein, 1µg of protein was incubated with 
500U of PNGase F in the presence of G7 buffer and incubated at 37°C for up to 72 
hours. 
 
2.6.14. Solid-phase ligand binding assay 
 
1µg of purified CD36 ED-12His in 100µl binding buffer (PBS, 1mM MgCl2, 1mM 
CaCl2) was added to each well of a Ni-NTA HisSorb white plate (Qiagen) and 
incubated at 4°C overnight with gentle agitation. After unbound purified CD36 ED-
12His had been aspirated, the wells were rinsed with 200µl binding buffer before 
addition of diluted alexa fluor 488-acLDL (Life Technologies). Alexa fluor 488-
acLDL was diluted in ice-cold ligand binding buffer (binding buffer plus 1% fatty-
acid free (FAF) BSA) to the following concentrations: 0, 2.5, 5, 10, 20, 30, 40µg/ml 
each in a final volume of 100µl. The plate was incubated for 2 hours at room 
temperature with gentle agitation. After removal of unbound alexa fluor 488-acLDL 
87 
 
by aspiration, the wells of the plate were rinsed three times with 100µl wash buffer 
(binding buffer with 0.2% FAF BSA). The bound fluorescence was measured using 
a microplate reader with an absorption and excitation maxima of 495 and 519nm, 
respectively (Synergy HT, Bio-Tek). 
 
2.7. Mass Spectrometry 
 
Following separation of purified CD36 ED-12His by SDS-PAGE and staining with 
colloidal blue, the protein was excised and sent to the Advanced Mass Spectrometry 
Facility at Birmingham University. The protein was digested in-gel using either 
trypsin or chymotrypsin, with subsequent peptide fragments being dissolved in 0.1% 
formic acid prior to separation by liquid chromatography and analysis using tandem 
mass spectrometry (LC-MS/MS). 
Protein samples were analysed using a Dionex 3000 Ultimate nano-LC instrument 
(Dionex, CA, USA) with a zwitterionic hydrophilic interaction liquid nano 
chromatography column, 150mm x 75µm, 5µm, 200Å (ZIC-HILIC, Sequant, UK) 
coupled with a Triversa Nanomate nanospray source (Advion Biosciences, NY, 
USA) which was further interfaced with an LTQ Orbitrap Velos ETD mass 
spectrometer (Singh et al., 2012). 
The data from LC-MS/MS was analysed using the software Mascot (Matrix 
Services) and Byonics (Protein Metrics, CA, USA) to identify peptide sequences and 
glycan structures, respectively. 
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2.8. Biacore 
 
All studies were performed at 25°C using a Biacore T200 (GE Healthcare) using 
NTA S series sensor chips, following manufacturer’s protocols (GE Healthcare). 
Data was analysed using BIAevaluation software. A working temperature of 25°C 
was used as this was the temperature recommended for optimal surface activation 
and ligand immobilisation following manufacturer’s instructions.  
Prior to use, NTA sensor chips were removed from their sealed pouch and allowed to 
equilibrate at room temperature for 15 minutes. Following docking of the sensor chip 
into the Biacore T200, the instrument was equilibrated with filtered running buffer 
(10mM HEPES, 150mM NaCl, 0.05% v/v Surfactant P20, 50µM EDTA). Addition 
of 50µM EDTA to the running buffer counteracted the effect of metal ion 
contaminants present in the buffer, without stripping nickel from the activated sensor 
chip surface. The NTA sensor chip was activated by passing 0.5mM NiCl2 in dH2O 
over the surface of the chip. Purified CD36 ED-12His (ligand) and antibodies 
(analytes) were diluted into running buffer prior to use. Regeneration of the NTA 
sensor was achieved by passing 350mM EDTA in dH2O over the sensor surface. 
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3. Expression and Purification of the 
Ectodomain of CD36 
 
3.1. Introduction 
 
Protein expression and purification of recombinant proteins has become fundamental 
in many areas of academia as well as the pharmaceutical industry. The first 
recombinant protein produced more than 30 years ago was human insulin (Johnson, 
1983). Expressed in E. coli, this recombinant protein replaced animal sourced insulin 
(primarily porcine) providing a readily available supply with enhanced purity. Now 
the use of recombinant proteins has become widespread ranging from diagnostic 
tools and enzymes used within the laboratory to vaccines and therapeutic agents used 
within the clinic. Despite these advances, the ever increasing drive to learn more 
about protein structure and function through use of sophisticated biophysical 
techniques has driven the need to produce substantial quantities of high purity 
protein. Through exploitation of a number of expression systems it has become 
increasingly possible to express high yields of heterologous protein and in turn 
challenge these ever increasing demands. 
Bacteria, yeast, insect cells and mammalian cells, are the four most commonly used 
hosts for expression of recombinant proteins, each with their own advantages and 
disadvantages. For expression of heterologous proteins, a bacterial host (in particular 
E. coli) is usually the first and most preferred choice, mainly because it is 
inexpensive, divides rapidly and has the ability to produce high protein yields. 
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However, for more complex recombinant proteins, particularly those from higher 
eukaryotes, difficulties in efficient expression can be encountered as bacteria lack the 
same biochemical pathways required for post-translational modifications, such as N-
linked glycosylation. This can lead to misfolding and aggregation, ultimately 
resulting in the formation of insoluble inclusion bodies. Yeast, like bacteria are also 
inexpensive and capable of producing high protein yields but have the added 
advantage, as a simple eukaryote, to produce some of the modifications observed on 
native mammalian proteins. Nevertheless, these modifications are limited with many 
mammalian recombinant proteins still being expressed incorrectly and tending to 
also end up within inclusion bodies. With insect and mammalian cells, much longer 
incubation times (with an 18-24 hour doubling time) are necessary to achieve the 
biomass required. Mammalian and insect cells generally tend to be more expensive 
to culture and harder to maintain than both bacteria and yeast. Insect cells can be 
particularly difficult to manipulate, with expression of recombinant proteins 
primarily relying on the use of baculovirus expression vectors. Despite these 
inconveniences, both insect and mammalian cells can be used to generate 
recombinant proteins with more complex post-translational modifications and often 
produce recombinant proteins more closely resembling the native form. Although 
mammalian cells may well be the vehicle of choice to express recombinant 
mammalian proteins and are more likely to produce more native-like post-
translational modifications, higher protein yields can usually be obtained using insect 
cells, with scale-up of insect cell cultures easily achievable. Perhaps counter-
intuitively, the use of insect cells to produce proteins with simpler and more uniform 
glycans can be an advantage for downstream biophysical and structural studies.   
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The scavenger receptor CD36 was first described nearly 40 years ago and has since 
been implicated in a large variety of roles both in normal and patho-physiology. 
Despite the physiological importance there is still no crystal structure for CD36 and 
data characterising ligand binding remains poor. In 2013, the crystal structure of the 
soluble domain of a related scavenger receptor found in lysosomes (LIMP-2) was 
solved to a resolution of 3Å (Neculai et al., 2013). Although molecular models of 
CD36 were generated based on the LIMP-2 crystal structure, more reliable structural 
information is needed to model interactions with the diverse ligands of CD36 and 
this will only be obtained through studying the ligand binding domain of CD36 
directly.  
Previous attempts to express CD36 in both bacteria and yeast have led to the 
formation of insoluble inclusion bodies (Linton, K; personal communication). On the 
other hand, insect cells have been shown to be a good host for expression of CD36 
(Jimenez-Dalmaroni et al., 2009, Martin et al., 2007, Hoosdally et al., 2009), and 
little data is available on the recombinant expression of CD36 in mammalian cells. 
This chapter describes the use of baculovirus/insect cell expression systems to 
express recombinant CD36 with a C-terminal 12xHistidine tag (-12His) for 
subsequent purification using nickel affinity chromatography. The general aim is to 
produce milligram quantities of soluble functional CD36 to allow biochemical, 
biophysical and structural studies. 
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3.1.1. Full-length CD36 vs. Ectodomain of CD36 
 
Although membrane proteins make up around 30% of the proteome of most 
organisms (Krogh et al., 2001), they continue to be a challenging target for structural 
and biophysical studies. Many difficulties are encountered when working with 
membrane proteins, one of which being their typically low expression level in their 
native environment (Seddon et al., 2004). Even with the use of heterologous 
expression systems to produce higher levels of membrane-targeted recombinant 
protein, obstacles still remain. Membrane proteins with their amphiphilic nature 
must first be solubilised from the membrane, usually through the use of detergents. 
Much time has to be spent in selecting the right detergent as well as deducing the 
most suitable ratio of detergent to protein to ensure that the membrane is solubilised 
efficiently without protein denaturation in the process (Prive, 2007). Detergents may 
also have a detrimental impact on subsequent chromatography steps leading to 
reduced yield and negatively affect the activity of the purified recombinant protein 
(Hammond and Zarenda, 1996, Tan and Ting, 2000). 
The most common way to improve the expression and subsequent handling of a 
membrane protein, particularly a receptor with a large ectodomain that is simply 
anchored in the membrane, is to remove the transmembrane portion of the protein 
and just express the ectodomain (ED) as a secreted protein (Hulst et al., 1993). This 
is of course dependent on the assumption that the secreted protein retains the fold 
and function to permit reliable biophysical studies. The majority of CD36 is 
extracellular in what is likely to be a single domain. It is this large, heavily 
glycosylated, ED that is responsible for ligand binding. In 2009, mCd36 ED was 
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expressed and secreted from insect cells and used to demonstrate the binding 
negatively-charged diacylglycerol ligands to the ED. This highlighted the ability of 
this domain to be expressed independently of the rest of the protein and still retain 
the ability to bind ligand (Jimenez-Dalmaroni et al., 2009). Through expression and 
subsequent secretion of soluble CD36 ED, the need for detergents is removed, 
making the subsequent purification more straightforward, negating a number of 
possible complications with downstream applications. The additional advantage of 
this method is that the recombinant protein can be secreted into the surrounding 
media, acting as a crude preliminary purification step and avoiding the need to lyse 
cells.   
 
3.1.2. Baculovirus Expression Systems 
 
Originally harnessed for use as biological pesticides to control insect populations 
(Cory and Bishop, 1997), baculovirus expression systems have since become 
powerful tools for the expression of genes in insect cells (Smith et al., 1983). The 
most commonly used baculovirus for infection of insect cells is the Autographa 
californica multiple nuclear polyhedrosis virus (AcMNPV), which primarily relies 
on members of the lepidopteran species such as Spodoptera frugiperda and 
Trichoplusia ni as host insects for viral replication. The life-cycle of wild-type 
AcMNPV is biphasic involving the formation of two forms of virus: budded virus 
(BV) and occlusion-derived virus (ODV). These two forms are functionally and 
morphologically distinct (Miller, 1989). In vivo, the baculoviral infection process 
begins with ingestion of foliage contaminated with baculovirus, leading to the uptake 
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of baculoviral capsids into the epithelia of the midgut by direct fusion with the 
microvillus membrane. Once inside the epithelium, baculoviral capsids translocate to 
the nucleus, aided by the actin-cytoskeleton (Ohkawa et al., 2010), where upon 
uncoating of the viral genome occurs in preparation for transcription and viral 
replication. Around 10-12 hours following initial infection, new baculoviral capsids 
translocate through the cytoplasm to the plasma membrane where they bud from the 
cell surface, enclosed in a membrane envelope modified with the viral fusion protein 
gp64 (Blissard and Wenz, 1992).  These highly infectious BV particles are then free 
to diffuse throughout the surrounding extracellular matrix, infecting neighbouring 
cells through uptake by endocytosis, leading to a systemic infection. Approximately 
20-24 hours post-infection, formation of BV greatly diminishes while ODV begins 
to be synthesised. During ODV synthesis baculoviral capsids become embedded 
within large proteinaceous occlusion bodies consisting of a matrix of polyhedrin 
protein (Summers and Smith, 1978, Rohrmann, 1986). ODV synthesis continues for 
another 50 hours (up until ~72 post-infection), driven by the strong transcriptional 
activity of the polyhedrin gene (polh) promoter. During this period the level of 
polyhedrin protein within each cell can represent up to 50% of the total protein 
content (Possee and Howard, 1987).  When the insect host cuticle begins to break 
down following systemic cell lysis, ODV is released allowing infection of new hosts. 
The polyhedrin occlusion body protects the virus from environmental stresses, only 
to be degraded once inside the alkaline environment of the midgut in the next host.  
Under cell culture conditions, baculoviruses no longer need to resist the 
environmental stresses encountered in the wild, making the expression of the 
polyhedrin protein and formation of ODV redundant. As a consequence by 
exchanging the polyhedrin gene with cDNA encoding a protein of interest, the strong 
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polh promoter can be exploited to drive the expression of recombinant protein in 
cultured insect cells. This results in the formation of large quantities of BV early in 
the infection process, capable of infecting other cells, followed by expression of 
large quantities of recombinant protein under the control of the polh promoter at the 
late stage of the infection. 
Although infection of insect cells with baculoviruses exploiting the polh promoter 
(such as Bac-to-Bac from Life Technologies and BacPAK6 from Clontech) have 
been shown to be effective at producing high levels of recombinant proteins, the 
increasing demand to produce more complex mammalian-like proteins has driven the 
development of more advanced baculovirus expression systems. These advances go 
beyond the use of baculoviruses lacking only the polh gene. Systems have been 
engineered with other non-essential baculoviral genes removed, thus reducing the 
burden on the cell machinery during recombinant protein expression (e.g. FlashBAC 
expression systems), or with additional mammalian chaperone proteins included that 
when co-expressed, help to stabilise recombinant mammalian proteins which may be 
prone to misfold in the heterologous host (e.g. the Profold ER1 expression system). 
  
3.1.2.1. The FlashBAC Expression System 
 
Although the genome of the baculovirus AcMNPV has been sequenced (133804bp; 
NC_001623), most of the 156 predicted protein-coding genes remain uncharacterised 
(Ayres et al., 1994, Chen et al., 2013). Despite this, many genes have been shown to 
not be required for the efficient propagation of baculovirus in cell culture (Li et al., 
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2008, Wang et al., 2007, Carpentier et al., 2008).  In the flashBAC expression system 
(Oxford Expression Technologies, OET), in addition to the removal of the polh gene, 
the non-essential chitinase gene (ChiA) has been deleted from the baculovirus 
genome.  The ChiA gene encodes an enzyme with both endo- and exo-chitinase 
activity (Hawtin et al., 1995) that, in partnership with the enzyme cathepsin, 
facilitates the breakdown and liquefaction of the chitin-rich cuticle of insect host 
during the very late stages of the infection process allowing release of ODV to infect 
more hosts (Hawtin et al., 1997). Observations using confocal and electron 
microscopy of AcMNPV-infected insect cells has shown chitinase to accumulate 
within the endoplasmic reticulum (ER) where it is packed into a para-crystalline 
array, reducing the function and efficiency of the secretory pathway (Thomas et al., 
1998, Saville et al., 2004). The deletion of the ChiA gene therefore is designed to 
improve efficiency of the secretory pathway and in turn improve the yield of 
secreted and membrane-targeted recombinant proteins.  
 
3.1.2.2. The FlashBAC Gold Expression System 
 
The FlashBAC Gold expression system (also from OET) is an improvement on the 
FlashBAC system with an additional non-essential gene deleted to further aid 
recombinant protein production. In the FlashBAC Gold system the v-cath gene is 
deleted in addition to the ChiA gene (Hitchman et al., 2010). The v-cath gene 
encodes V-cath endopeptidase which is a papain-like cysteine protease (Slack et al., 
1995). V-cath accumulates in the ER as an inactive precursor form (Pro-v-cath). 
Upon cell death the proenzyme is processed by chitinase into its active form 
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whereupon it facilitates breakdown of the host cuticle (Hom et al., 2002, Hom and 
Volkman, 2000). The deletion of both ChiA and v-cath from the flashBAC Gold 
baculovirus genome is therefore designed to free up more processing space within 
the ER, potentially enhancing the yield of secreted and membrane-targeted proteins. 
 
3.1.2.3. The Profold-ER1 Expression System 
 
As nascent proteins traffic through the ER to the Golgi apparatus, a number of 
chaperones facilitate post-translational modification of the membrane or secreted 
proteins and drive correct folding into the appropriate three-dimensional 
conformation. Although much is now known about protein folding and quality 
control mechanisms in the ER of mammalian cells (Braakman and Bulleid, 2011, 
van Anken and Braakman, 2005), less is known about similar processes in insect 
cells. To improve the folding of complex mammalian-like recombinant proteins in 
insect cells, a number of baculoviral expression systems have been engineered to co-
express mammalian chaperones (Hsu and Betenbaugh, 1997, Hsu et al., 1996). In the 
Profold-ER1 expression system (AB Vector) the baculovirus genome encodes the 
human molecular chaperones calreticulin and protein disulphide isomerase (PDI). 
Both calreticulin and PDI are known to aid protein folding in the ER (Williams, 
2006, Appenzeller-Herzog and Ellgaard, 2008). Calreticulin is a lectin chaperone 
that aids the folding of nascent glycoproteins only allowing correctly folded and 
processed glycoproteins to traffic from the ER to the Golgi apparatus (Williams, 
2006). PDI is chaperone that participates in the formation of disulphide bonds and 
also facilitates correct protein folding (Appenzeller-Herzog and Ellgaard, 2008). 
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Several studies have shown that co-expression of these chaperones in a baculovirus 
expression system enhances the production of biologically active secreted and 
membrane-targeted recombinant proteins (Zhang et al., 2003, Hsu et al., 1996).   
 
3.1.2.4. Generation of recombinant baculoviruses 
by homologous recombination 
 
Due to the large size of the AcMNPV baculovirus genome (Ayres et al., 1994), 
direct manipulation and insertion of cDNA to encode recombinant protein is 
difficult. Instead, production of recombinant baculoviruses usually takes place in two 
steps, the first involving the cloning of the target gene into a transfer vector with 
sequences that flank the polh gene in the baculovirus genome. The second step 
involves introducing both the baculoviral genome and the transfer vector together 
into host insect cells, allowing simultaneous homologous recombination between the 
common flanking sequences (Smith et al., 1983). This results in the insertion of the 
target gene of interest into the baculovirus genome in place of the polh gene, under 
the control of the strong polh promoter.  
The use of homologous recombination within insect cells to produce recombinant 
baculoviruses has generally resulted in a mixture of wild-type parental baculovirus in 
addition to recombinant baculovirus (recombination frequency was low initially at 
less than 1%) (Fraser, 1989). The consequence of this was the need to use labour 
intensive, time-consuming plaque assay and plaque purification techniques to isolate 
the recombinant baculovirus. This was not usually a one-off process as recombinant 
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baculovirus was often enriched but not pure and, eventually, the parental baculovirus 
would out-compete the recombinant baculovirus and necessitate the re-isolation of 
the recombinant form.  
Many improvements to the baculoviral system have since been made to allow the 
separation of recombinant and parental baculoviruses. Initial attempts to address this 
involved insertion of the lacZ gene from E. coli into the transfer vector along with 
the target gene of interest. The lacZ gene encodes β-galactosidase, an enzyme that 
breaks down lactose. Through use of the stain X-gal (5-bromo-4-chloro-3-indoyl β-
D-galactopyaranoside), an analogue of lactose, insect cells containing recombinant 
baculovirus would stain blue compared to cells containing parental virus that 
remained colourless. Although this improved identification of recombinant 
baculovirus, it did not improve the frequency of recombinant baculovirus formation 
that still required plaque purification. There was also the added problem of β-
galactosidase contamination in the subsequent recombinant protein sample. 
The problem of identification and separation of recombinant and parental 
baculovirus was partially solved by the use of linearised baculovirus DNA which 
could not become infectious unless rescued by recombination with a transfer vector 
(Kitts et al., 1990). In this method a unique enzyme restriction site (Bsu36 I) was 
introduced into the polyhedrin gene of the baculovirus DNA. By linearising the 
baculovirus DNA prior to homologous recombination,  parental baculovirus became 
up to 150 times less infectious than the circularised form (Kitts et al., 1990). Only 
after homologous recombination between transfer vector and linearised baculoviral 
DNA would re-circularisation take place, restoring infectivity and allowing 
baculovirus replication. Despite this improvement in the selectivity of recombinant 
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baculovirus over parental baculovirus, the frequency of successful homologous 
recombination events remained around 30% (Kitts et al., 1990).  
Shortly thereafter a more efficient method was devised which resulted in ~100% 
frequency of recombination baculovirus generation (Kitts and Possee, 1993). In this 
system, the baculovirus genome was engineered with two Bsu36 I restriction sites 
flanking the polh gene locus. Restriction digestion of the baculoviral DNA using 
Bsu36 I resulted in the formation of two DNA fragments (Figure 3.1 (a)). The 
smaller of these fragments included part of a downstream gene (ORF1629), essential 
for replication of the baculovirus (Possee et al., 1991). If the larger fragment were to 
re-circularise in the absence of the smaller fragment, the lack of a complete 
ORF1629 gene would prevent the resultant baculovirus from replicating. However, 
through a double homologous recombination event between the linearised 
baculovirus DNA and a transfer vector containing the complete sequence of the 
ORF1629 gene, in addition to the recombinant gene of interest, the baculoviral DNA 
could re-circularise allowing a viable baculovirus to be rescued (Figure 3.1 (b)).  
Both the Profold-ER1 and flashBAC expression systems work using this 
methodology.   
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Figure 3.1 Schematic representation of recombinant baculovirus expression vector generation 
by double homologous recombination.  
(a) Digestion of the baculovirus genomic DNA with Bsu36 I results in removal of the polyhedrin gene 
(polh) along with part of the essential ORF1629 gene. Lack of a complete ORF1629 gene prevents 
baculoviral synthesis if the baculoviral genomic DNA were to self-ligate. (b) Double homologous 
recombination between the linearised baculoviral genomic DNA and a transfer vector containing a 
complete copy of the ORF1629 gene, along with target gene results in the restoration of the ORF1629 
gene and insertion of the target gene under the control of the strong polyhedrin promoter. With a 
complete ORF1629 gene the resultant baculoviruses can replicate. 
(b) 
(a) 
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3.1.3. Insect Cells 
 
Combined with the use of customised baculoviruses, insect cells have become a 
good option for the generation of large quantities of eukaryotic recombinant proteins. 
The main advantage of using insect cells is in their ability to incorporate post-
translational modifications similar to those found in mammalian cells while still 
producing high yields of cytosolic, membrane and secreted proteins. Although N-
linked glycosylation reliably occurs within the same sequon (Asn-X-Ser/Thr) in both 
insect and mammalian cells, glycosylation in insect cells has been shown to be less 
complex (Salmon et al., 1997, Jarvis, 2003).  For some proteins, like full-length 
CD36, this simplicity in glycosylation is sufficient for the protein to be properly 
expressed, folded, trafficked to the plasma membrane and retain ligand binding 
activity (Hoosdally et al., 2009). Other proteins, like the influenza A virus 
hemagglutinin, show decreased function when expressed in insect cells due to the 
difference in glycosylation (de Vries et al., 2010). Glycosylation, in particular glycan 
heterogeneity, can lead to difficulties in producing good structural and biophysical 
data. For example, the ability the produce suitable crystals for use in X-ray 
crystallography can be hindered by large, complex and heterogeneous glycan 
structures. This therefore makes insect cells, which recognise mammalian 
glycosylation sites but modify with simpler glycan structures, a popular alternative 
host for production of mammalian recombinant proteins. Although many insect cell 
lines have been derived from over a 100 insect species (Lynn, 1996), three 
lepidopteran cell lines have become most frequently used for the baculovirus 
expression system: Sf21/Sf9 and Hi5 insect cells.  
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3.1.3.1. Sf21 Insect Cells 
 
Sf21 insect cells (officially called IPLB-Sf21AE) are derived from the pupal ovarian 
tissue of the fall army worm, Spodoptera frugiperda (Vaughn et al., 1977). Sf21 
cells and Sf9 cells, a clonal isolate of the Sf21 cell line, grow well in both adherent 
monolayers and in suspension cultures. Both cell lines are suitable for baculovirus 
generation, amplification and plaque assay as well as for the expression of 
recombinant proteins. It has been suggested previously that Sf21 insect cells can 
express more recombinant protein that Sf9 insect cells with some baculoviruses 
(Hink et al., 1991). 
 
3.1.3.2. High-Five™ Insect Cells 
 
High Five™ insect cells (Hi5, officially called BTI-TN-5BI-4), commercially sold 
by Life Technologies, are derived from the ovarian cells of the cabbage looper, 
Trichoplusia ni (Wickham et al., 1992). Hi5 insect cells have become one of the 
most commonly used insect cell lines for the expression of recombinant proteins 
using baculoviruses, having been shown in a number of cases to express more 
recombinant protein than other lepidopteran cell lines such as Sf9 and Sf21 cells 
(Davis et al., 1992, Wickham and Nemerow, 1993). Despite having a doubling time 
of around 24 hours and being able to grow well in serum-free media in suspension as 
well as in adherent cultures, Hi5 cells form irregular monolayers which makes 
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baculovirus generation and plaque assay difficult in this cell line. Virus amplification 
from Hi5 cells is also inefficient. 
 
3.1.4. Aims of Chapter 3  
 
 Test three different baculovirus expression systems to determine which 
produces the highest yield of secreted CD36 ED. 
 Determine the amount of baculovirus required to infect insect cells for the 
generation of a high yield of secreted CD36 ED. 
 Determine on a small scale the conditions required for efficient purification 
of CD36 ED using nickel affinity chromatography.   
 Explore the ability to deglycosylate CD36 ED 
 Test ligand binding to purified CD36 ED to ensure it is properly folded 
 Scale up expression and purification of CD36 ED to generate milligram 
quantities of protein for biophysical analyses 
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3.2.  Results 
3.2.1. Comparison of expression systems 
 
The pBacPAK9 transfer vector was engineered to express human CD36 ED 
(residues 36-435) with an N-terminal honeybee melittin secretory signal (HMSS) 
and a C-terminal 12 histidine tag (Figure 3.2; Linton, personal communication). 
Through homologous recombination in insect cells, three baculoviruses: FlashBAC-
CD36ED, FlashBAC Gold-CD36ED and Profold-ER1-CD36ED, were generated as 
described in section 2.4.2. The recombinant baculoviruses were used in a series of 
Sf21 insect cell infections to amplify the baculovirus titre. Each infection was 
performed using a low multiplicity of infection (MOI; 0.05 = 5 viruses per 100 cells) 
to produce intermediate and then working stocks of baculovirus. Baculovirus titres 
were estimated by plaque assay. 
 
 
Figure 3.2. Schematic representation of recombinant CD36 ED expressed in insect cells.  
The fusion protein has an N-terminal honeybee melittin secretory signal (HMSS; amino acids 1-25), 
the CD36 ED (amino acids 26-425) with a C-terminal 12 histidine tag (amino acids 426-440). HMSS 
is cleaved upon secretion. For full sequence see Appendix 1. 
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To identify the baculovirus that gave the highest protein yield, Sf21 and Hi5 insect 
cell monolayers (1x10
6 
cells) adhered to 35mm tissue culture dishes were infected 
with each of the baculovirus at an MOI=3 in an equal volume of culture media 
(2ml). Expression and secretion of CD36 ED-12His was allowed to proceed for 72 
hours, at which point spent culture media was harvested and analysed by western 
blot (Figure 3.3). Equal volumes of harvested media were loaded to allow direct 
comparison of secreted CD36 ED-12His protein levels. In parallel, a mammalian 
expression vector (pOPING; generated by Dr Joanne Nettleship, Oxford Protein 
Purification Facility) encoding CD36 ED-6His with a N-terminal secretory signal 
(RPTPmu) was used in the transient transfection of HEK293T mammalian cells 
(1x10
6
) adhered to the surface of a 35mm tissue culture dish, again grown in 2ml 
media. 
 
Figure 3.3. Western blot analysis showing CD36 ED-12His secretion from insect cells and 
HEK293T mammalian cells.  
Adherent Sf21 and Hi5 cells (1x10
6
) were infected in 35mm dishes with recombinant baculoviruses 
engineered to express human CD36 ED-12His. HEK293T cells (1x10
6
) were transiently transfected 
with pOPING encoding human CD36 ED-6His. The culture media (2ml) was recovered 72 hours 
post-infection (insect cells) or 48 hours post-transfection (HEK293T cells). Samples (10µl) were 
loaded onto a SDS polyacrylamide gel and the proteins separated by electrophoresis. The blot was 
prepared on PVDF membrane and probed using anti-CD36 antibody clone 1955 (R&D systems). FB, 
FlashBAC; FBG, FlashBAC Gold; Pro, Profold-ER1. Arrows indicate two different glycosylation 
forms of CD36 ED-12His. 
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With both insect cells lines, the flashBAC gold baculovirus produced a higher yield 
of secreted CD36 ED-12His compared to the other baculoviruses. Profold-ER1 
baculoviruses produced the least amount of secreted CD36 ED-12His in both Sf21 
and Hi5 insect cells. The levels of CD36 ED-12His secreted from Hi5 insect cells 
using the flashBAC and flashBAC Gold baculoviruses appeared to be higher than the 
level obtained from mammalian cells. The level of CD36 ED-12His secreted from 
Sf21 using the flashBAC Gold baculovirus appeared comparable to the level of 
CD36 ED-12His secreted from mammalian cells. The difference in electrophoretic 
mobility between CD36 ED-12His produced in insect cells and mammalian cells was 
expected due to the differences in glycosylation. Mammalian cells are known to add 
complex glycans to secreted and membrane proteins, but this has previously been 
shown not to be important for CD36 interaction with its ligand acetylated-LDL 
(Hoosdally et al., 2009). Based on these findings it was determined that insect cells 
would be suitable for the expression and secretion of CD36 ED-12His and that 
maximal expression is from the flashBAC Gold baculovirus. 
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3.2.2. Determining the multiplicity of infection required 
for maximum CD36 ED-12His expression. 
 
When using baculoviruses to infect insect cells for the production of recombinant 
protein, determination of the optimal MOI is important. For maximum recombinant 
protein production, many studies have used a high MOI (at least 3) (Lazarte et al., 
1992, Yamaji et al., 1999). Using a high MOI results in a synchronous infection with 
all insect cells expressing protein at the same time. This approach requires using 
large amounts of baculovirus, making the protein production process costly and 
time-consuming, requiring baculovirus stocks to be replenished more frequently. In 
contrast to using a high MOI, there is growing evidence that the use of very low 
MOI could be a good alternative for generating recombinant protein (Nguyen et al., 
1993, Licari and Bailey, 1992), especially for large-scale protein production which 
would otherwise require a significant volume of baculovirus stock. Using this 
method only a small percentage of cells are infected allowing the rest to grow and 
divide. The uninfected cells and their progeny only become infected later on by 
baculovirus budded from the originally infected cells. Compared to a high MOI 
infection where the kinetics of infection are simple (all cells becoming infected and 
expressing protein simultaneously), a low MOI infection produces more complicated 
kinetics arising from the serial infection of cells in the population and the ensuing 
protein synthesis (Wong et al., 1996).  
To explore the effect of low MOI on expression and secretion of CD36 ED-12His 
from Sf21 and Hi5 insect cells, adherent cells (1x10
6
 cells) in 35mm tissue culture 
dishes were  infected with flashBAC Gold baculovirus encoding CD36 ED-12His at 
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a range of MOIs (0.001-3) in equal volumes of culture media (2ml). Expression and 
secretion of CD36 ED-12His was allowed to proceed for 72 hours, at which point 
spent culture media was harvested and analysed by western blot (Figure 3.4). Equal 
volumes of harvested media were loaded to allow direct comparison of secreted 
CD36 ED-12His protein levels. 
 
 
Figure 3.4. Effect of MOI on the expression and secretion of CD36 ED-12His from Sf21 and Hi5 
insect cells.  
Adherent (a) Hi5 and (b) Sf21 cells (1x10
6
) were infected in 35mm dishes with flashBAC Gold 
baculovirus encoding CD36 ED-12His at a range of MOIs. The culture media (2ml) was recovered 72 
hours post-infection. Samples (10µl) were loaded onto a SDS polyacrylamide gel and the proteins 
separated by electrophoresis. The blot was prepared on PVDF membrane and probed using anti-CD36 
antibody clone 1955 (R&D systems). MOI, multiplicity of infection. 
 
 
 
(b) 
(a) 
110 
 
When Hi5 insect cells were infected with a range of MOIs (Figure 3.4 (a)), 
increasing levels of secreted CD36 ED-12His were detected from MOI=0.05 to 
MOI=3, suggesting that a higher MOI is favourable for maximum CD36 ED-12His 
yields in Hi5 insect cells. This is consistent with inefficient budding of recombinant 
virus from Hi5 cells and a requirement for high MOI to infect all cells in the 
population. However, when Sf21 insect cells were infected with the same range of 
MOI (Figure 3.4 (b)), CD36 ED-12His secretion was detected with an MOI as low 
as 0.005. Maximum CD36 ED-12His was observed with an MOI of 0.05. No further 
increase in CD36 ED-12His production was detected at higher MOI. This result 
showed that a low MOI could be used when infecting Sf21 insect cells, producing 
the same amount of CD36 ED-12His as that achieved when using a high MOI. 
Although Sf21 insect cells were shown to express and secrete less CD36 ED-12His 
than Hi5 insect cells overall, the ability to generate more CD36 ED-12His using a 
lower MOI, and therefore less demand for high viral titres, suggests that Sf21 may be 
a good compromise and a suitable host for large-scale cultures.   
 
3.2.3. Buffer exchange is necessary prior to nickel 
affinity purification of CD36 ED-12His  
 
Using the recombinant flashBAC Gold-CD36ED, small-scale insect cell infections 
were performed in suspension (100ml) to optimise purification by nickel affinity 
chromatography. Spent insect cell media containing secreted CD36 ED-12His was 
collected and centrifuged to pellet any cells or cell debris present. Before purification 
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could be performed the spent media was buffered exchanged into purification buffer 
(50mM HEPES, 300mM NaCl, 20mM imidazole, pH 7.4) using a tangential cross-
flow diafiltration system (Vivaflow 200, Sartorius), increasing the low pH (to ~pH 
7.4) and removing small contaminants (e.g. divalent cations, histidine, glycine) 
which would interfere with the purification process. The same system was also used 
to concentrate the sample to a final volume of 20ml. Samples were taken before and 
after diafiltration and analysed by western blot to measure any loss of CD36 ED-
12His during the process ( 
Figure 3.5).  
 
Figure 3.5. Western blot analysis of harvested CD36 ED-12His before and after diafiltration.  
Spent Sf21 insect cell media (100ml) containing secreted CD36 ED-12His was buffer exchanged 
using a tangential flow diafiltration system (Vivaflow 200, Sartorius) into 50mM HEPES, 300mM 
NaCl, 20mM Imidazole, pH 7.4 and concentrated to a final volume of 20ml. Samples pre- (1) and 
post- (2) diafiltration were taken and loaded onto an SDS polyacrylamide gel and the proteins 
separated by electrophoresis. The blot was prepared on PVDF membrane and probed using either (a) 
anti-CD36 antibody clone 1955 (R&D systems) or (b) anti-His (C-term) antibody clone 3D5 (Life 
Technologies). For equal volume lanes, 5µl of either pre- and post-diafiltration samples were loaded. 
For equivalent volume lanes, 5µl of pre- and 1µl of post-diafiltration samples were loaded to account 
for differences in total sample volume. A similar result was obtained using CD36 ED-12His secreted 
from Hi5 insect cells in spent Hi5 insect cell media (not shown). 
 
 
 
(a) (b) 
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Following diafiltration of spent culture media into purification buffer, no loss of 
CD36 ED-12His was observed. Additionally, probing the western blot with an anti-
His antibody (Figure 3.5 (b)) confirmed that the secreted CD36 ED retained the 
poly-histidine tag required for nickel affinity purification.  
 
3.2.4. Batch purification of CD36 ED-12His by nickel 
affinity chromatography 
 
Once the spent media had been buffer exchanged and concentrated, nickel affinity 
chromatography was performed to purify CD36 ED, utilizing the C-terminal 12x 
histidine tag. In nickel affinity chromatography, nickel ions are immobilised by the 
chelator nitrilotriacetic acid (NTA) (Hochuli et al., 1987), which for these batch 
purification processes, is bound to an agarose resin (Ni-NTA agarose Qiagen). The 
poly-histidine tag of CD36 ED has a high affinity for Ni-NTA allowing separation of 
CD36 ED from other proteins present. Any proteins which may bind to the resin 
non-specifically (or with low avidity) can be removed by washing the resin with low 
concentrations of imidazole which competes with the imidazole ring of histidine for 
binding sites on the Ni-NTA. CD36 ED-12His can then be eluted from the resin 
using a high concentration of imidazole.  
CD36 ED-12His in purification buffer (50mM HEPES, 300mM NaCl, 20mM 
Imidazole, pH 7.4) was incubated with Ni-NTA agarose at a sample to resin 
volumetric ratio of 10:1. The resin was washed seven times with 20 bed volumes of 
purification buffer containing 20-100mM imidazole. Bound CD36 ED-12His was 
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eluted using purification buffer containing 500mM imidazole (4x4ml). Samples from 
each stage of the purification process were separated by SDS-PAGE and stained with 
colloidal blue to show total protein present (Figure 3.6 (a)). A corresponding western 
blot, probed with an anti-CD36 antibody confirmed purification of CD36 ED-12His 
(Figure 3.6 (b)). The major eluted protein was also confirmed as CD36 ED-12His 
using LC-MS/MS (see chapter 4).  
Elution fractions were pooled and concentrated using an Amicon Ultra-15 
centrifugation device (Millipore). The concentration of protein was estimated using 
densitometry in comparison with a BSA standard curve. Densitometric analysis was 
also used to measure the purity of sample. From a 100ml insect cell suspension 
culture infected with flashBAC Gold baculovirus encoding CD36 ED-12His, 
maximum yields of 115µg and 55µg were purified from Hi5 and Sf21 insect cells, 
respectively. Purity was estimated to be ~91% and ~82%, for purified CD36 ED-
12His from Hi5 and Sf21 insect cells, respectively. 
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Figure 3.6. Small-scale nickel affinity purification of CD36 ED-12His secreted from Hi5 insect 
cells.  
(a) Crude protein sample (start, 0.4% of total) was incubated with Ni-NTA agarose at a sample to 
resin volumetric ratio of 10:1. Unbound sample (0.4% of total) contains protein not bound to resin. 
Washes with increasing concentration of imidazole (20-100mM, 4% of total) were used to remove 
protein bound non-specifically. CD36 ED-12His was eluted with 4x4ml washes of 500mM imidazole 
(4% of total). Samples were loaded onto a SDS polyacrylamide gel and the proteins separated by 
electrophoresis and stained with colloidal blue stain. (b) Equivalent samples were diluted 1 in 1000 
and loaded onto a SDS polyacrylamide gel and the proteins blotted onto PVDF membrane and probed 
using anti-CD36 antibody clone 1955 (R&D systems). A similar profile was obtained for purification 
from Sf21 insect cells (not shown). 
 
3.2.5. Deglycosylation of purified CD36 ED-12His 
 
CD36 is heavily glycosylated at nine asparagines in the ED (Hoosdally et al., 2009). 
Although this post-translational modification could serve many roles including 
modulation of ligand binding, providing protease resistance or ensuring correct 
folding and trafficking to the membrane, the addition of large heterogeneous glycans 
can be detrimental to crystal formation. Despite insect cells not producing glycans 
with the same complexity as those seen in mammalian cells, these simple glycans 
may still present difficulties for later structural studies. To overcome this possible 
(b) 
(a) 
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difficulty, the enzyme PNGase F was used to try and remove N-linked glycans 
present on CD36 ED-12His secreted from both Hi5 and Sf21 insect cells. PNGase F 
is an endoglycosidase capable of cleaving nearly all forms of glycan from the 
asparagine residues of N-linked glycoproteins (Tretter et al., 1991). 
Spent culture media from Hi5 and Sf21 insect cells infected with flashBAC Gold 
encoding CD36 ED-12His was denatured and treated with PNGase F before analysis 
by western blot (Figure 3.7).   
 
 
Figure 3.7. Deglycosylation of CD36 ED-12His secreted from Hi5 and Sf21 insect cells using 
PNGase-F.  
Spent media containing, 3µl and 9µl, CD36 ED-12His from Hi5 and Sf21 insect cells, respectively, 
was treated with 500U of PNGase-F for 2 hours at 37°C. Samples were loaded onto a SDS 
polyacrylamide gel and the proteins separated by electrophoresis. The blot was prepared on PVDF 
membrane and probed using anti-CD36 antibody clone 1955 (R&D systems). 
 
Digestion of CD36 ED-12His secreted from Sf21 insect cells with PNGase F 
resulted in an increase in electrophoretic mobility and formation of a sharp band 
migrating with an electrophoretic mobility corresponding to a molecular weight just 
above 50kDa. The predicted molecular weight of the mature CD36 ED-12His (in the 
absence of the cleaved signal sequence) without post-translational modifications is 
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48kDa. Digestion of CD36 ED-12His secreted from Hi5 insect cells also resulted in 
an increase in electrophoretic mobility but the effect was not as pronounced with the 
treated protein migrating as a diffuse band around 60kDa suggesting failure to 
remove all glycan groups. These data suggest that the glycans introduced by Hi5 
cells are distinct from those introduced by Sf21 cells. 
Having found that the maximum yield of recombinant protein from Sf21 insect cells 
could be achieved by using a low MOI and that the glycans introduced by Sf21 cells 
could be removed from CD36 ED-12His using PNGase F, it was decided that further 
experiments to optimise expression and purification of CD36 ED-12His should be 
performed using the Sf21 insect cell line.  
 
3.2.6. Native CD36 ED-12His produced from Sf21 cells 
can be deglycosylated by PNGase F 
 
The standard protocol for using PNGase F to deglycosylate proteins requires the 
sample to first be heated to 95°C in the presence of detergent and reducing agent. 
This causes the protein to unravel allowing PNGase F to gain access to all glycans 
that may have otherwise been buried within the tertiary structure. Although the 
resulting protein lacks heterogeneous glycan groups, it has also lost its three-
dimensional structure making subsequent structural studies pointless. Having 
deglycosylated the CD36 ED-12His under denaturing conditions, experiments were 
undertaken to determine whether deglycosylation could be achieved under native 
conditions, thus preserving protein structure important for future biochemical and 
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biophysical studies. Purified protein was therefore treated with PNGase F without 
detergent or reducing agents, for a period of up to 3 days (Figure 3.8). The results 
suggest that it is possible to deglycosylate native CD36 ED-12His secreted from 
Sf21 insect cells within 2hrs and that the molecular weight of the deglycosylated 
protein is stable for several days thereafter.  
 
Figure 3.8. Deglycosylation of purified CD36 ED-12His secreted from Sf21 insect cells under 
native conditions.  
Purified ED produced in Sf21 cells was treated with PNGase  F (500U) under denaturing conditions 
for 2 hours at 37°C or  for 2, 24, 48 or 72 hours at 37°C, without detergent or reducing agents. 
Samples were loaded onto a SDS polyacrylamide gel and the proteins separated by electrophoresis. 
The gel was stained with colloidal blue. – CD36 ED-12His not treated with PNGase F. + treated with 
PNGase F.  
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3.2.7. Affinity of purified CD36 ED for modified LDL 
 
Although it was shown that CD36 ED-12His can be expressed and secreted from 
insect cells and purified, there was no evidence as yet to show that the protein was 
folded correctly and able to bind ligand. A ligand binding assay was therefore 
performed using fluorescently-labelled acetylated low-density lipoprotein (alexa 
fluor 488-acLDL, Life Technologies) to mimic the modified lipoprotein ligand, 
oxidised low-density lipoprotein (oxLDL) (Hoosdally et al., 2009). AcLDL is known 
to be more stable than oxLDL and have a similar binding affinity as oxLDL for 
CD36 on the surface of cells. In this binding assay, increasing concentrations of 
alexa fluor 488-acLDL were added to purified CD36 ED-12His immobilised on a 
microtitre plate coated with Ni-NTA (see section 2.6.14). The data were analysed 
using GraphPad Prism software version 5.0 with a saturation binding curve which 
was best fitted by the Langmuir adsorption equation (Equation 3.1), that describes a 
single binding site being bound by a single ligand. When applied to alexa fluor 488-
acLDL binding to immobilised CD36 ED-12His, B is bound alexa fluor 488-acLDL 
(relative fluorescence units), [L] is the concentration of alexa fluor 488-acLDL 
(µg/ml) and KD is the concentration of alexa fluor 488-acLDL that gives half 
maximal binding and is used as a measure of the affinity of alexa fluor 488-acLDL 
for CD36 ED-12His  
 
 
Equation 3.1. The Langmuir Adsorption Equation. 
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The calculated mean KD for the binding of alexa fluor 488-acLDL with immobilised 
CD36 ED-12His purified from Sf21 insect cells +/- standard error (SE) was 
6.2µg/ml +/- 0.9µg/ml (n=3) (Figure 3.9). In 2009, it was shown that full-length 
CD36 purified from Sf21 insect cells bound acLDL with a KD value +/- SE of 
6.4µg/ml +/- 1.5µg/ml. It was also shown that the KD value for the binding of acLDL 
to CD36 expressed transiently on the surface of mammalian HEK293T cells +/- SE 
was 8.3µg/ml +/- 1.4µg/ml (Hoosdally et al., 2009). Comparing the data obtained 
here with previously published data shows that the affinity of acLDL for CD36 ED-
12His is similar to that of full-length CD36 suggesting that the ED is folded 
correctly and retains the ability to bind modified LDL independent of the rest of the 
protein.  
 
Figure 3.9. Interaction of CD36 ED-12His purified from Sf21 insect cells with alexa fluor 488-
acLDL. 
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3.2.8. Deglycosylated CD36 ED retains affinity for 
acetylated low-density lipoprotein 
 
It has been shown previously that N-linked glycosylation is necessary for efficient 
trafficking of CD36 to the plasma membrane, but the pattern of glycosylation sites 
occupied is not important and did not appear to have an impact on binding of acLDL 
(Hoosdally et al., 2009). This suggested but did not prove that the glycans were 
unimportant for acLDL binding. To investigate this further, purified CD36 ED-
12His was deglycosylated under native conditions using PNGase F and immobilised 
on a microtitre plate coated with Ni-NTA. A ligand binding assay was performed as 
described previously and the KD value for binding of alexa fluor 488-acLDL to 
deglycosylated CD36 ED-12His +/- SE was measured as 5.8µg/ml +/- 0.6µg/ml 
(Figure 3.10). This value is not significantly different to the KD obtained for 
glycosylated CD36 ED-12His and demonstrates that N-linked glycosylation of CD36 
ED is not required for binding of modified LDL. It also shows that the glycan 
structures can be removed from native CD36 with no loss in the ability of the CD36 
ED to bind ligand and demonstrates the potential utility of this protein for 
biochemical and biophysical analyses.  
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Figure 3.10. Interaction of deglycosylated CD36 ED-12His purified from Sf21 insect cells with 
alexa fluor 488-acLDL. 
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3.2.9. Large scale expression and purification of CD36 
ED-12His from Sf21 insect cells 
 
Scale-up of protein production is necessary for production of milligram quantities of 
CD36 ED-12His. I have shown already that Sf21 insect cells can produce maximum 
protein yields using a low MOI and that subsequent purification of CD36 ED-12His 
from a 100ml suspension culture could yield ~0.5mg of pure protein per litre of 
culture. To obtain milligram quantities of CD36 ED-12His, 5 litres of Sf21 insect 
cells were grown in suspension using a Wave Bioreactor (GE Healthcare) and 
infected with flashBAC Gold-CD36ED at an MOI of 0.05. Spent media was 
harvested 72 hours post-infection and centrifuged to remove cells and cell debris. 
Concentration and buffer exchange of spent media was achieved through use of a 
tangential cross-flow filtration hollow fibre cartridge. The spent media was 
concentrated to 500ml before buffer exchange using 5L of purification buffer.  
An automated protein purifier (AKTA Prime Plus, GE Healthcare) was used to 
purify the CD36 ED-12His. The main advantage of this system is the ability to 
purify protein on a much larger scale while reducing the amount of contact time 
needed. In addition, protein binding and elution can be monitored in real-time with 
sensors recording numerous parameters including absorbance of the solution at 
280nm (A280). The crude sample in binding buffer was passed through a 5ml a 
HisTrap HP binding column (GE Healthcare) at a low flow rate (0.3ml/min) to allow 
CD36 ED-12His to bind. To remove non-specific protein, the column was washed 
with purification buffer containing 100mM imidazole, passed continuously through 
the column for 20 column volumes at a flow rate of 0.5ml/min. The bound CD36 
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ED-12His was then eluted in purification buffer containing 500mM imidazole also at 
a flow rate of 0.5ml/min and collected in 2ml fractions. Fractions containing protein 
were identified based on the A280 reading (Figure 3.11 (a)). Samples from fractions 
18-44 were separated by SDS-PAGE in the presence (Figure 3.11 (b)) and absence 
(Figure 3.11 (c)) of reducing agent and then stained with colloidal blue to identify 
fractions containing CD36 ED-12His. 
Major contaminants that bound to the column in addition to CD36 ED-12His eluted 
early in the elution profile, causing a defined peak in the A280 trace (fractions 21-
27). CD36 ED-12His eluted gradually (fractions 22-44) leading to the formation of a 
shoulder to the right of the initial A280 peak. This slow dissociation of His-tagged 
CD36 ED and subsequent A280 shoulder is characteristic of his-tagged proteins. 
Fractions separated by SDS-PAGE, prepared with reducing agents, showed that 
CD36 ED-12His eluted between fractions 22 to 44 (Figure 3.11 (b)). Compared to 
batch purification, performed previously (see section 3.2.4), purification of a large-
scale suspension culture using this column format resulted in the elution of more 
non-specific proteins along with CD36 ED-12His. In the absence of reducing agent, 
clearly defined species were also evident migrating more slowly through the gel 
(Figure 3.11 (c)).  These bands corresponded roughly to double, triple, and higher 
order molecular weights than would be expected for purified monomeric CD36 ED-
12His, suggesting that these might represent higher order homo-multimers of CD36 
ED-12His. Due to the complexity of the banding pattern generated following SDS-
PAGE it was not possible to accurately calculate the yield from the large scale 
purification by the method used for the small scale purification (see section 3.2.4). 
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To understand the nature of the higher molecular weight species observed and to 
further purify CD36 ED-12His, size-exclusion chromatography (SEC) was 
performed under non-reducing conditions.  
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Figure 3.11.  Large-scale nickel affinity purification of CD36 ED-12His secreted from a 5L culture 
of Sf21 insect cells.  
CD36 ED-12His was eluted in 2ml fractions from a 5ml HisTrap HP column using 500mM Imidazole. 
(a) Eluted protein was observed as an increase in the A280 reading. Fractions (0.5% of the total volume) 
under the A280 peak and shoulder (18-44) were loaded onto a SDS polyacrylamide gel and the proteins 
separated by electrophoresis and stained with colloidal blue. Samples prior to loading were either heated 
at 75°C for 10mins in the presence (b) or the absence (c) of 5% β-mercaptoethanol. Arrows indicate 
predicted CD36 ED-12His. 
 
 (a) 
(b) 
(c) 
126 
 
3.2.10. Separation of purified proteins by size-exclusion 
chromatography 
 
SEC is a chromatographic technique that allows the separation of proteins by size 
(Fekete et al., 2014).  The basic principle is that as a protein mixture in solution is 
passed down a column packed with a porous matrix, the flow of smaller proteins is 
hampered as they pass through the pores in the matrix, whereas larger proteins 
cannot enter the pores as readily and so pass through the column with less hindrance. 
This results in large proteins eluting from the column first followed by the elution of 
progressively smaller proteins.  
Previously, I showed that purification of CD36 ED-12His from a large-scale 
suspension culture resulted in the co-purification of proteins of sizes other than that 
the size expected of CD36 ED-12His. SEC was therefore employed to try to separate 
these proteins, further purifying CD36 ED-12His. Fractions (29-44) collected during 
nickel affinity purification (see 3.2.9) were pooled, dialysed against dialysis buffer 
(50mM HEPES, 300mM NaCl, pH7.4) and then concentrated to around 1ml.  The 
sample was electrophoresed through an SDS-polyacrylamide gel in the presence and 
absence of reducing agent (Figure 3.12 (a)). When stained with colloidal blue, the 
complexity of the overloaded sample is apparent, but the highly enriched CD36 ED-
12His migrating at around 63kDa remained evident. More monomeric CD36 ED-
12His could still be observed in the reduced sample compared to the non-reduced 
sample. The sample was then passed through a Superdex 200 10/300 GL SEC 
column (GE Healthcare), with a separation range of 10-600kDa. Eluted protein was 
collected in 1ml fractions (Figure 3.12 (b)). The proteins in the fractions were then 
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separated by SDS-PAGE, prepared in the presence and absence of reducing agent 
(Figure 3.12 (c)). CD36 ED-12His eluted from the column in every fraction collected 
(Figure 3.12 (c)), suggesting that CD36 ED-12His existed at a range of molecular 
weights from 10kDa to 600kDa (the separation range of the column). More 
monomeric CD36 ED-12His could be seen at the expected molecular weight in the 
reduced samples. The lower amount of CD36 ED-12His detected in non-reduced 
samples corresponded with the appearance of clearly defined higher molecular 
weight proteins. 
Taken together, these observations suggest that CD36 ED-12His may homo-
associate in solution and that the higher molecular weight species detected represent 
oligomeric forms of the protein. To determine whether these higher molecular 
weight proteins were indeed CD36 ED-12His of origin, SEC elution fractions were 
analysed by western blotting using an antibody against CD36.  SEC fractions (A7-
A11) were separated by SDS-PAGE in the presence and absence of reducing agent 
prior to electroblotting onto a PVDF membrane and probing with the anti-CD36 
antibody (Figure 3.13). 
In addition to detecting CD36 ED-12His at the expected monomeric molecular 
weight of around 63kDa, higher molecular weight species were also detected. As 
shown previously with colloidal blue staining (Figure 3.12 (c)), more CD36 ED-
12His was present at the monomeric molecular weight in reduced samples while the 
majority of the CD36-ED12His in the non-reduced samples migrated much more 
slowly through the gel. The presence of CD36 ED-12His at the monomeric 
molecular weight in early fractions, expected to elute proteins up to 600kDa (e.g. 
A6-A7) suggests the aggregation process may be dynamic and reversible. If this 
assumption is true then the detection of CD36 ED-12His predominantly at the 
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monomeric molecular weight in later fractions might suggest that homo-association 
may be concentration dependent.  
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Figure 3.12. Separation of purified CD36 ED-12His and co-purifying proteins using size 
exclusion chromatography.  
(a) Concentrated HisTrap-purified CD36 ED-12His (1%) was loaded onto a SDS polyacrylamide gel 
having in the absence (-) or presence (+) of 5% β-mercaptoethanol and then separated by 
electrophoresis and stained with colloidal blue. Arrow indicates the expected molecular weight of 
monomeric CD36 ED-12His (b) Separation of concentrated proteins was performed using a Superdex 
200 10/300 GL size exclusion column (GE Healthcare). The separation range of the column was 10-
600kDa. 1ml fractions were collected. (c) SEC fractions (1% of total volume) were loaded onto a SDS 
polyacrylamide gel in the absence (-) or presence (+) of 5% β-mercaptoethanol and then separated by 
electrophoresis and stained with colloidal blue. 
 
(c) 
(b) (a) 
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Figure 3.13. CD36 ED-12His exists as higher molecular weight species in solution.  
SEC fractions (0.01%) were loaded onto a SDS polyacrylamide gel in the absence (-) or presence (+) 
of 5% β-mercaptoethanol. Proteins were separated by electrophoresis, blotted onto PVDF membrane 
and probed using anti-CD36 antibody, clone 1955 (R&D systems). Arrows indicate different 
molecular weight forms of CD36 ED-12His detected. 
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3.3. Discussion 
 
The use of baculovirus expression systems to produce recombinant proteins is an 
attractive alternative to bacteria, yeast and mammalian expression systems. Although 
bacteria have now been discovered to be able to produce post-translational 
modifications such as N-linked glycosylation (Schwarz and Aebi, 2011), these 
biochemical pathways do not appear to be sufficient to mimic the type of glycans 
required for efficient trafficking of mammalian-like proteins such as CD36 to the 
plasma membrane. It is shown in this chapter that it is possible to express and secrete 
the ED of CD36 successfully from insect cells with protein yields comparable to the 
yield obtained from a mammalian cell line. Despite insect cells producing simpler N-
linked glycosylation than mammalian cells, this simplicity may be an advantage for 
structural studies. During these studies the crystal structure of the soluble domain of 
another class B scavenger receptor, the lysosomal protein, LIMP-2, was solved 
(Neculai et al., 2013). Expressed and secreted from Sf9 insect cells this soluble 
domain was purified by nickel affinity chromatography and size-exclusion 
chromatography to produce milligram quantities of protein which subsequently led 
to the formation of crystals with the deduction of a 3Å resolution model. 
Furthermore, this domain was crystallised with glycans present on all 9 putative N-
linked glycosylation sites. The LIMP-2 crystal structure has been used to model the 
structure of CD36, however the usefulness of such a model is debatable given the 
medium resolution of the LIMP-2 structure. The relevance of a homology model to 
CD36-ligand interaction would also be limited given that LIMP-2 is unlikely to 
share many ligands with CD36. A true structure of CD36, based on direct 
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biophysical analyses remains elusive, but would be needed to answer these 
questions.   
The flashBAC Gold baculovirus expression system which lacks the non-essential 
ChiA and v-cath genes was found to produce more secreted CD36 ED-12His in both 
Hi5 and Sf21insect cell lines compared to both the flashBAC and the Profold-ER1 
expression systems. Despite the removal of the v-cath gene which encodes the 
protease v-cath endopeptidase, the increased yield of CD36 ED-12His generated 
using flashBAC Gold compared to the flashBAC system is unlikely to be caused by 
decreased proteolytic digestion of the newly translated protein. This is because v-
cath endopeptidase is expressed as the inactive pro-v-cath form which is only 
activated to v-cath in the presence of chitinase, which is absent from both flashBAC 
expression systems. Increased CD36 ED-12His secretion using the flashBAC Gold 
system is therefore likely to be due to the absence of pro-v-cath accumulation within 
the ER, freeing up space within the secretory pathway, allowing the cellular 
mechanisms to fold and modify CD36 ED-12His more efficiently. The profold-ER1 
expression system produced the least amount of secreted CD36 ED-12His of all the 
baculovirus expression systems tested. It has been shown on numerous occasions, 
including during this study, that CD36 can be expressed, modified and trafficked to 
the plasma membrane without the aid of mammalian-like chaperones in insect cells 
(Hoosdally et al., 2009, Martin et al., 2007, Jimenez-Dalmaroni et al., 2009). A 
lower yield of CD36 ED-12His using the Profold-ER1 system may be due to the 
insect cells having to produce two additional recombinant proteins (calreticulin and 
PDI) which may, effectively, compete with CD36 ED-12His for translation and 
translocation sites on the ER. 
133 
 
The ability to produce CD36 ED-12His using Sf21 insect cells infected with 
flashBAC Gold at a low MOI increases the appeal of using this baculovirus/insect 
cell system for large-scale protein production which would normally require large 
amounts of baculovirus to achieve optimal protein yields. Using a low MOI saves on 
cost and also saves on time by removing the need to amplify baculovirus as 
frequently to replenish working stocks. Other studies have shown that similar yields 
of protein can be obtained using a low MOI to produce recombinant within 72 hours 
and, by incubating the cells for longer, the overall yield of protein can be increased 
over infections using a high MOI over the same time period (Liebman et al., 1999). 
However, the production of heterologous proteins using baculoviruses is ultimately a 
cell-lytic expression system in insect cells and so therefore care should be taken to 
ensure longer infection times do not also increase the amount of cytosolic proteins, 
including proteases, released into the media which could have a negative impact on 
the yield. 
Immobilised metal ion affinity chromatography (IMAC) is one of the most popular 
methods for purification of heterologous recombinant proteins (Cheung et al., 2012). 
Polyhistidine tags offer a simple purification process needing only the fusion of a 
few extra amino acids at either the N- or C-terminus of the protein (Paramban et al., 
2004), which rarely have an impact on the protein fold or function (Terpe, 2003). 
The use of a double hexahistidine tag has been shown to improve the affinity of 
tagged protein for nickel (Khan et al., 2006) and has been shown previously to 
improve recombinant CD36 binding to a Ni-NTA matrix (Martin et al., 2007), 
allowing a higher degree of purification. Small-scale purification using nickel 
affinity chromatography exploiting the C-terminal double hexahistidine tag on CD36 
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ED was shown in these studies to be an effective method of purification, resulting in 
purified CD36 ED-12His of around 80-90% purity. 
Deglycosylation experiments showed that Hi5 insect cells produced N-linked 
glycans on CD36 ED-12His which were insensitive to PNGase F. The inability to 
remove glycans from the Hi5 insect cell derived mouse Cd36 (mCd36) ED has been 
observed previously (Jimenez-Dalmaroni et al., 2009), and was attributed to the 
ability of Hi5 insect cells to produce core α(1-3)-linked fucose saccharides which 
would make N-linked glycans insensitive to cleavage by PNGase F (Tretter et al., 
1991). The nature of N-linked glycosylation found on human CD36 ED-12His 
secreted from both Sf21 and Hi5 insect cells is explored in more detail in Chapter 4. 
The CD36 ED-12His derived from Sf21 insect cells was found to be sensitive to 
cleavage by PNGase F, and the resultant deglycosylated protein migrated with an 
observed molecular weight of ~50kDa. The subtle difference between this observed 
molecular weight and the predicted molecular weight based on the unmodified 
primary structure (~48kDa) is most likely attributed to anomalous migration through 
the gel. It is, however, possible that additional post-translational modifications such 
as O-linked glycosylation, (which has been identified previously on recombinant 
proteins expressed in insect cells (Klenk, 1996, Thomsen et al., 1990, Altmann et al., 
1999) may be present that would slow migration. Thr92 of CD36 has also been 
shown previously to play an important regulatory role preventing the binding of 
TSP-1 to CD36 (Chu and Silverstein, 2012), however, mass spectrometry provided 
no evidence of phosphorylation of CD36 ED-12His secreted from either cell type.  
CD36 ED-12His secreted from Sf21 insect cells retained affinity for modified LDL 
comparable with full-length CD36 purified from insect cells and CD36 on the 
surface of mammalian cells (Hoosdally et al., 2009). Furthermore, it was shown that 
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native CD36 ED-12His could be deglycosylated and still retain affinity for modified 
LDL, suggesting that N-linked glycosylation is irrelevant for the binding of this 
ligand. Previous studies suggested that N-linked glycosylation of CD36 is important 
for efficient trafficking of the protein to the plasma membrane (Hoosdally et al., 
2009). Lauzier et al., have also shown that the glycosylation status of Cd36 in the 
Spontaneously Hypertensive Rat is altered (along with significant changes in 
primary amino acid sequence, and abundance in cardiac membranes) leading them to 
suggest that glycosylation affects the ability of Cd36 to utilise long chain fatty acids 
in cardiac tissue (Lauzier et al., 2011). 
Large-scale purification of CD36 ED-12His revealed the possible presence of higher 
molecular weight forms of CD36 ED-12His when fractions were analysed in the 
presence and absence of reducing agent. The inability to separate these different 
forms of CD36 ED-12His using SEC suggests that oligomer formation may be 
dynamic and reversible. During the purification of the soluble domain of LIMP-2, 
Neculai, et al., reported similar higher molecular weight species. Despite this, they 
were able to isolate enough ‘monomeric’ protein following SEC to produce crystals 
(Neculai et al., 2013). They suggested that the hydrophobic face of a helical-bundle 
located towards the apex of the protein may have been responsible for dimerization 
(a site also identified for ligand binding). The ability of CD36 to form oligomers has 
been documented previously. In 1997, it was shown that CD36 on the surface of 
platelets and transiently-transfected COS-7 cells formed multimers that could be 
disrupted by reducing agents (Thorne et al., 1997). It was proposed that the 
association was mediated through intermolecular disulphide bridges. However, 
CD36 has no free cysteine residues within the ED, with all six involved in 
intramolecular disulphide bridging (Rasmussen et al., 1998). A more likely 
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explanation is that the reducing agent disrupts the intramolecular disulphide bridging 
resulting in conformational change within the ED, to indirectly disrupt homo-dimeric 
interaction. 
Further studies should be employed to assess the stability and possible disruption of 
these higher molecular weight species. The higher molecular weight species can be 
observed prior to buffer exchange or purification (Figure 3.5 (a)), suggesting that 
interaction occurs as soon as the protein is secreted from the insect cell with the rate 
of oligomer formation accelerated at higher concentrations. The use of additives, 
such as glycerol, to minimise aggregation (Vagenende et al., 2009, Hamada et al., 
2009) was ineffective at reducing CD36 ED self-association (data not shown). 
However, imidazole has been reported to result in protein aggregation (Hefti et al., 
2001). It was shown by Martin et al., that full-length rat Cd36 expressed in insect 
cells and purified using nickel affinity purification in the presence of the detergent 
octylglucoside could be isolated as a monomeric form. Interestingly, Cd36 was 
eluted from the nickel resin using only 250mM imidazole, compared to the 500mM 
imidazole that was used in the work presented here (Martin et al., 2007). Imidazole, 
like any other salt, at low concentration can help to stabilise a protein in solution. 
However, at high concentrations, imidazole may lead to a decrease in protein 
stability and encourage protein aggregation (Hamada et al., 2009). If this is the case, 
then it may be possible to avoid these effects by eluting CD36 ED-12His from the 
nickel surface by lowering of the pH instead of using imidazole, or by switching to a 
different affinity tag altogether. 
 
137 
 
The formation of higher molecular weight species of CD36 ED-12His may not 
ultimately be a problem for crystal formation and subsequent structural studies. 
Formation of crystals is based on the ability of the protein to form a regular lattice at 
high concentrations following dehydration (Smyth and Martin, 2000). The presence 
of CD36 ED-12His as homo-oligomers may therefore aid the formation of crystals. 
An empiric test of crystallisation conditions using the purified CD36 ED-12His 
should therefore be explored.  
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4. Analysis of CD36 Ectodomain N-linked 
Glycosylation in Insect Cells 
 
4.1.  Introduction 
 
Protein post-translational modifications (PTMs) are enzyme-driven covalent 
chemical modifications of proteins following translation. These modifications can 
have a profound effect on both protein conformation and stability. Additionally, 
PTMs can influence cellular localisation as well as playing a role in the activity of 
those modified proteins. Currently there are over 400 known post-translational 
modifications, with phosphorylation, acetylation and glycosylation being among the 
most commonly encountered (Khoury et al., 2011, Creasy and Cottrell, 2004). 
The ectodomain (ED) of CD36 is known to be heavily glycosylated, with 10 putative 
N-linked glycosylation sites. The glycosylation site occupancy has previously been 
characterised for full-length human CD36 heterologously expressed in both insect 
and mammalian cells (Hoosdally et al., 2009). Despite identifying nine of the ten 
glycan sites as being occupied, the nature of these glycans has never been 
characterised. In chapter 3 it was shown that CD36 ED could be secreted from Sf21 
and Hi5 insect cells. It was subsequently shown that glycans present on CD36 ED 
secreted from Hi5 insect cells were insensitive to enzymatic cleavage using PNGase 
F. In contrast, the glycans present on purified CD36 ED from Sf21 insect cells were 
shown to be sensitive to PNGase F treatment. To better understand the nature of the 
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glycans added to the CD36 ED in insect cells, mass spectrometry was used to 
determine putative N-linked glycan site occupancy and the composition of the 
structures generated in each insect cell line. 
 
4.1.1. N-linked Glycosylation 
 
There are two main types of glycosylation; N-linked glycosylation and O-linked 
glycosylation (Moremen et al., 2012). These two modifications occur with 
attachment of a glycan to proteins either via an amide group (N-linked) or a hydroxyl 
group (O-linked). Another form of glycan attachment, termed C-linked 
glycosylation, involves the addition of a glycan via the indole C2 carbon atom on the 
side chain of tryptophan residues (Hofsteenge et al., 1994, Furmanek and 
Hofsteenge, 2000). 
N-linked glycosylation is known to be important for a range of cellular functions 
including signal transduction, cell adhesion and cell migration (Isaji et al., 2004, 
Ono et al., 2000, Zhong et al., 2004). It has also been shown to confer protease 
resistance on proteins (Sareneva et al., 1995). Abnormal N-linked glycosylation has 
been implicated in a number of diseases including cancer (Leroy, 2006, Kobata and 
Amano, 2005). 
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4.1.1.1. Biosynthesis of N-linked glycosylation 
 
The synthesis of N-linked glycans on proteins in eukaryotes occurs in two separate 
compartments within the cell, the endoplasmic reticulum (ER) and the Golgi 
apparatus. The initial synthesis, addition and trimming of a core oligosaccharide to a 
growing nascent polypeptide chain occurs in the ER. At this stage all of the glycans 
are homogeneous. Correctly folded glycoproteins are then transported to the Golgi 
apparatus where the oligosaccharides are trimmed further before becoming elongated 
to form glycosylation which can be complex and heterogeneous. 
 
4.1.1.2. N-linked glycosylation in the ER  
 
The N-glycosylation process begins with the formation of a 14 saccharide core unit 
attached to the amide nitrogen of asparagine residues within the N-linked 
glycosylation sequon, Asn-X-Ser/Thr, where X can be any amino acid except for a 
proline residue. This core glycan is shared by all eukaryotes, with a predefined 
structure of Glc3Man9GlcNAc2 (Kornfeld and Kornfeld, 1985)(Figure 4.1). 
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Figure 4.1. Common core N-linked glycan.  
This predefined glycan is common to all eukaryotes. The core oligosaccharide which is initially 
synthesised on a lipid carrier molecule consists of two N-acetylglucosamines, nine mannoses and 
three glucoses. Arrows indicate sites of cleavage which occur as part of the quality control processes 
present within the ER. Modified from Helenius, A. & Aebi, M. 2001. Intracellular functions of N-
linked glycans. Science, 291, 2364-9. Reprinted with permission from AAAS. 
 
 
Presynthesis of the oligosaccharide occurs at the cytosolic face of the ER with the 
addition of saccharides to the lipid carrier molecule, dolichol-pyrophosphate (DPP), 
by monosaccharide transferases (Burda and Aebi, 1999) (Figure 4.2). Following the 
addition of the first seven saccharide units, an ATP-independent bi-directional 
floppase ‘flops’ the sugars to the luminal side of the ER membrane (Hirschberg and 
Snider, 1987, Helenius et al., 2002). Once the final terminal glucose unit has been 
added to form the core glycan, oligosaccharyltransferase (OST) recognises this 
structure and transfers it to the Asn on the nascent polypeptide (Burda and Aebi, 
1998, Spiro, 2000, Zufferey et al., 1995). It is thought that the addition of glycans 
aids the folding of the protein either directly through stabilisation of the local protein 
structure (Petrescu et al., 2004) or indirectly through association with the molecular 
chaperones calnexin and calreticulin, which recognise and bind sugar groups 
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(Williams, 2006). It is in combination with calnexin and calreticulin that a quality 
control cycle is established to ensure proteins are processed correctly (Caramelo and 
Parodi, 2008). Immediately following transfer of the core glycan to the nascent 
polypeptide, the first and second glucose saccharides are cleaved by glucosidase I 
and then glucosidase II, respectively (Hammond et al., 1994). The resultant 
monoglucosylated glycan is then free to bind either calnexin (for a transmembrane 
ER proteins) or calreticulin (for soluble ER proteins), which facilitates the folding of 
the protein (Ou et al., 1993, Helenius et al., 1997). The remaining glucose saccharide 
is then cleaved by glucosidase II, releasing the protein from the chaperone. If the 
protein has folded incorrectly, it is recognised by UDP-Glc:glycoprotein 
glucosyltransferase (UGT), which re-glycosylates the glycan resulting in binding to 
the chaperone again to allow refolding (Sousa et al., 1992, Caramelo and Parodi, 
2008). The process of binding to and release from the chaperone continues until the 
protein either folds correctly or alternatively is targeted to the proteasome in the 
cytosol for degradation (Caramelo and Parodi, 2008). Once the protein has been 
folded properly, ER α-mannosidase I cleaves one mannose saccharide from the 
glycan before export of the protein from the ER to the Golgi apparatus (Hammond et 
al., 1994).  
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Figure 4.2. Processing of N-linked glycans in the ER.  
N-linked glycans are synthesised initially as a precursor on the cytosolic side of the ER membrane 
before being flipped into the ER lumun. The core glycan is transferred onto the asparagine within the 
sequon of the growing polypeptide before being trimmed prior to entering a quality control cycle with 
calnexin/calreticulin. Following removal of one mannose saccharide, the correctly folded protein can 
be transported to the Golgi apparatus. Modified from Helenius, A. & Aebi, M. 2001. Intracellular 
functions of N-linked glycans. Science, 291, 2364-9. Reprinted with permission from AAAS. 
 
 
4.1.1.3. N-linked glycosylation in the Golgi 
apparatus 
 
As proteins pass through the Golgi apparatus, they are further modified before they 
are trafficked to their final destination. In the lumen of the cis-Golgi, core glycans 
are initially trimmed by a series of mannosidases to remove more mannose 
saccharides (Figure 4.3). As the protein passes from the cis- to the trans-Golgi, the 
glycans are elongated by a wide variety of glycosyltransferases with the use of 
soluble precursors such as nucleotide sugars (Hirschberg et al., 1998). The addition 
of saccharide units is dependent on both the presence of a particular 
glycosyltransferase and also the accessibility of the growing glycan (Hsieh et al., 
1983, Elbein, 1991). Trafficking through the Golgi apparatus usually takes 5-15 
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minutes (Pelham and Rothman, 2000), allowing a high degree of glycosylation as 
well as diversity due to the lack of a quality control system. Once glycans have 
finished being added to the glycoprotein, it is trafficked to its final localisation. The 
Golgi apparatus lacks the quality control mechanisms of the ER resulting in 
glycoproteins with defective moieties still being readily exported (Elbein, 1991, 
Stanley, 1984). 
 
 
Figure 4.3. Processing of N-linked glycans in the Golgi apparatus.  
N-linked glycans undergo further trimming, followed by elongation with the addition of different 
sugar units depending on the protein, or cell types in which the protein has been expressed. Modified 
from Helenius, A. & Aebi, M. 2001. Intracellular functions of N-linked glycans. Science, 291, 2364-
9. Reprinted with permission from AAAS. 
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4.1.1.4. Insect and Mammalian N-linked 
Glycosylation 
 
There are three main types of N-linked glycans produced as glycoproteins traffic 
through the Golgi apparatus: high mannose, hybrid and complex (Figure 4.4). High 
mannose glycans consist of two N-acetylglucosamines with multiple mannose units 
attached, resembling the core N-linked glycan structure initially created in the ER. 
Complex glycans consist of many different types of saccharide, including more than 
the two core N-acetylglucosamines. Hybrid glycans consist of both high mannose 
and complex glycans. As eukaryotes, both insect and mammalian cells recognise the 
same consensus sequon when it comes to addition of the core N-linked glycan in the 
ER. It is in the Golgi apparatus however that the glycosylation events in insect cells 
and mammalian cells differ. Whereas mammalian cells can produce glycans with 
diverse terminally sialylated complex glycan structures (Beyer et al., 1979, Aricescu 
and Owens, 2013), glycans from insect cells have traditionally been seen as high 
mannose, pauci-mannosidic in structure (Hsieh and Robbins, 1984). Despite this, 
there is increasing evidence that some insect cells lines may be capable of producing 
more complicated glycans, more closely resembling hybrid structures (Rendic et al., 
2008). With the use of insect cells as a popular alternative host for the expression of 
recombinant proteins, it is therefore important to characterise the glycosylation status 
of these proteins to improve the understanding of the role that glycosylation may 
have on protein function, and also because the glycans may have an impact on 
downstream biophysical studies. This type of analysis is possible by mass 
spectrometry. 
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Figure 4.4. Three main types of N-linked glycans.  
As glycoproteins move from the medial to trans- portion of the Golgi apparatus a variety of 
glycosyltransferases add sugar units to the core glycan forming three main types of glycans. 
 
 
4.1.2. Mass Spectrometry 
 
Mass spectrometry (MS) is an analytical chemistry technique that is used to 
determine the mass of a molecule by measuring the mass/charge (m/z) ratio of its 
ions. The use of MS has expanded greatly over the last few decades with MS playing 
an important role in the study of proteins, peptides and other biological molecules 
(Aebersold and Mann, 2003). Applications of MS include amino-acid sequencing to 
characterise peptides and identify interacting proteins, monitoring enzyme reactions, 
establishing purity of a sample and also the determination of post-translational 
modifications (Bantscheff et al., 2012). 
Despite many different forms of mass analysers having been developed, the 
underlying principle remains the same (Figure 4.5). Following introduction into the 
instrument, the sample is converted into gaseous charged ions within an ionisation 
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chamber. These ions are then accelerated through a mass analyser consisting of an 
electric or magnetic field which deflects and separates ions according to the m/z 
ratio. Ions bombard a detector which amplifies the signal, displaying the relative 
abundance of each ion that is detected as a function of the m/z ratio. By correlating 
known masses or characteristic fragmentation patterns with those masses detected, 
sample identification is possible. To ensure that the sample is not hindered by air 
molecules when passing through the instrument, the ionisation chamber, mass 
analyser and detector are under a high vacuum. 
 
 
Figure 4.5. Basic components of a mass spectrometer.  
A vaporised sample is ionised to form charged ions in the ionisation chamber. Ions are then 
accelerated through a mass analyser, deflected by a strong electromagnetic field onto a detector. 
Deflection of ions is based on the m/z ratio. The relative abundance for each ion as a function of the 
m/z ratio can be used in the identification of protein samples. 
(http://www.chemguide.co.uk/analysis/masspec/howitworks.html#top, website accessed: 31/08/14). 
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4.1.2.1. Liquid chromatography tandem mass 
spectroscopy (LC-MS/MS) 
 
LC-MS/MS, using electrospray ionisation (ESI), combines the physical separation of 
a protein solution (using liquid chromatography, LC) with the mass analysis of a 
mass spectrometer (MS). The protein sample having been enzymatically digested is 
passed down a capillary liquid chromatography column to separate peptide 
fragments, reducing the complexity of the sample. As fragments are eluted from the 
column they pass through a needle in the presence of a strong electric field resulting 
in vaporisation of the sample forming a spray of multiply charged droplets, directed 
to the mass analyser.  
Tandem mass spectrometry (MS/MS) consists of multiple mass spectrometric steps, 
usually involving further fragmentation of charged ions. Although multiple complex 
systems have been developed, they all follow the same basic principles. Ionised 
sample is introduced into the mass analyser (e.g. via ESI). These charged ions, 
termed precursor ions, are deflected and separated based on their m/z ratio. Isolated 
precursor ions are then further fragmented usually through high energy 
bombardment. The resulting charged product ions can provide more detailed 
information about the structure and composition of a protein compared to single step 
MS, a fact that has greatly enhanced the ability to study post-translational 
modifications such as glycosylation. 
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The successful fragmentation of precursor ions is critical for MS/MS. There are 
many different methods now available to further fragment precursor ions, each 
capable of producing different types of fragmentation. Collision-induced dissociation 
(CID) and other related fragmentation techniques have been used extensively of late 
to study the glycosylation status of many different proteins (Singh et al., 2012, 
Gonzalez et al., 1992).  
 
4.1.2.2. Collision-induced dissociation 
 
During CID, one or more collisions occur between precursor ions and neutral gas 
molecules (such as helium, nitrogen or argon), producing a vibrational energy that 
redistributes over the precursor ion. This vibrational energy results in breakage of 
peptide bonds along the peptide backbone, generating b- and y-type fragments 
(Figure 4.6) (Paizs and Suhai, 2005) and/or leading to loss of small neutral 
molecules, such as water and/or ammonia or other fragments derived from side 
chains (Kertesz et al., 2009). By detecting progressively larger b-ions from the N- to 
C-termini and y-ions from the C- to N-termini it is possible to sequence the peptide 
fragment by correlating observed masses with the characteristic mass of each 
individual amino acid residue. 
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Figure 4.6. Fragmentation of charged precursor ions during LC-MS/MS.  
Collision induced dissociation (CID) creates vibrational energy resulting in breakage of peptide bonds 
along the peptide backbone, generating b- and y-type ions. Other fragmentation methods can cause 
breakage of other bonds along the peptide backbone, such as electron transfer dissociation (ETD) 
which breaks N-Cα bonds, generating c- and z-type ions. 
 
 
4.1.2.3. Higher Energy Collision Dissociation 
Product Ion-Triggered Electron Transfer 
Dissociation  
 
Although CID is effective for analysis of small, low-charged peptide ions, CID is not 
suitable for detection of peptides with post-translational modifications. These 
modifications hinder the ability of CID to efficiently break peptide bonds and form 
b- and y-ions. Consequently it is possible to identify glycans present within a 
fragment population but not possible to localise the glycan to a particular amino acid 
residue. In contract to CID, which induces fragmentation of peptides at the site of 
peptide bonds, electron transfer dissociation (ETD) induces cleavage of N-Cα bonds 
generating c- and z-type ions (Figure 4.6) which can also be used for peptide 
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fragment sequencing. Another important feature of ETD-type dissociation is that it 
does not lead to the loss of post-translational modifications and so is therefore able 
to provide both sequence information and the localisation of modified sites. Another 
type of fragmentation method similar to CID is beam-type CID, as opposed to 
conventional ion-trap CID. Beam-type CID, also known as higher energy collision 
dissociation (HCD), uses higher activation energy over a shorter activation time, 
compared to traditional ion-trap CID. This results in not only producing b- and y-
ions and glycan-peptide fragments, as with ion-trap CID, but also formation and 
detection of low-abundance oxonium product ions, such as N-acetylglucosamine 
(m/z 204) and mannose-N-acetylglucosamine (m/z 366), characteristic to all 
glycopeptides. One problem associated with studying N-linked glycosylation is the 
inherent heterogeneity in glycan structures found on a single protein as well as 
within a protein population. By coupling the glycan structures detected by CID and 
using the detection of oxonium ions by HCD as a trigger for subsequent ETD 
analysis of the same peptide precursor ion, it is possible to overcome the challenge 
of glycan heterogeneity, allowing targeted analysis of glycopeptides. This method of 
CID-HCD product-ion triggered ETD provides information on the site of 
glycosylation and peptide sequence (ETD spectrum) and through HCD (and CID) 
provides information on glycan structure (Singh et al., 2012). 
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4.2. Results 
4.2.1. Enzymatic deglycosylation of CD36 ED 
 
To confirm the identity of the purified CD36 ED and to provide the first indication 
of glycosylation site occupancy approximately 2µg of purified CD36 ED-12His from 
both Sf21 and Hi5 insect cells was treated with endoglycosidase peptide-N-
glycosidase F (PNGase F), which cleaves the innermost N-acetylglucosamine and 
asparagine (N) residue of high mannose, hybrid and complex N-linked 
oligosaccharides present on glycoproteins (Maley et al., 1989)(Figure 4.7 (a)). 
PNGase F cleaves N-linked glycans by hydrolysing the side chain of the asparagine 
residue, converting the asparagine residue into an asparartic acid. This process of 
deamidation is characterised by a mass increase of approximately +1Da. As PNGase 
F will only convert an asparagine residue into an aspartic acid when a cleavable 
glycan is present, protein sequencing by mass spectrometry can easily identify sites 
which have been occupied with a glycan. 
One type of N-linked glycan is insensitive to PNGase F; where the innermost N-
acetylglucosamine saccharide is attached to an α(1-3)-linked fucose sugar (Tretter et 
al., 1991). Fucose attached by this particular linkage is absent from mammalian 
glycoproteins but present on glycoproteins produced in plant cells, and some insect 
cells. The α(1-3)-linked fucose has been found to be immunogenic, acting as an 
epitope for antisera raised against plant glycoproteins (Kurosaka et al., 1991) as well 
as for IgE from individuals allergic to plant and insect material (Altmann, 2007).  
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Figure 4.7. N-linked glycan cleavage using the enzyme PNGase F.  
(a) PNGase F will cleave high mannose, hybrid and complex N-linked glycans between the innermost 
N-acetylglucosamine and asparagine residue. (b) An exception to this rule is found when a fucose 
residue is attached to the innermost N-acetylglucosamine residue via an core α(1-3) linked fucose. 
 
 
4.2.2. Preparation of protein for mass spectrometry 
 
Purified CD36 ED-12His derived from both Sf21 and Hi5 insect cells was sent to the 
Advanced Mass Spectrometry Facility at Birmingham University for mass 
spectrometric analysis. Both glycosylated (25µg) and deglycosylated (2µg) purified 
CD36 ED-12His were excised from a SDS-PAGE gel and digested (in-gel) with 
trypsin to yield peptide fragments of known sizes, seven of which contain putative 
N-linked glycosylation sites (Error! Reference source not found.). Trypsin is a 
erine protease which preferentially cleaves at the carboxyl terminal of the amino 
(a) 
(b) 
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acids lysine and arginine, except if these residues are followed by a proline (Pan et 
al., 2014). Purified CD36 ED-12His derived from Hi5 cells was also digested with 
chymotrypsin in an attempt to improve coverage of CD36 ED-12His detected by 
mass spectrometric analysis. Chymotrypsin is another serine protease which 
preferentially cleaves at the carboxyl terminal of large hydrophobic amino acids 
(tyrosine, tryptophan and phenylalanine). Digestion of CD36 ED-12His with 
chymotrypsin was expected to yield 10 fragments, each containing one of the 
putative N-linked glycosylation sites (Error! Reference source not found.).   
igested protein was extracted from the gel using 0.1% formic acid and then analysed 
by LC-MS/MS. 
 
Table 4.1. Complete tryptic digest of CD36 ED-12His.  
Complete digestion of CD36-12His with typsin generates 42 fragments. Of these fragments, 7 contain 
putative N-linked glycosylation sites (N). There are 10 putative N-linked glycosylation sites in total. 
The putative glycosylated asparagines are numbered 1 to 10 with respect to their position within the 
primary sequence of the ED. 
 
Mass 
Amino 
Acid 
Number 
Peptide Sequence 
6953.72 70-133 
EN(2)VTQDAEDNTVSFLQPNGAIFEPSLSVGTEADN(3)FTVLN
LAVAAASHIYQNQFVQMILNSLIN(4)K 
3535.87 307-337 PVYISLPHFLYASPDVSEPIDGLNPNEEEHR 
3352.79 153-182 DPFLSLVPYPVTTTVGLFYPYN(5)NTADGVYK 
2959.27 204-229 N(7)LSYWESHCDMIN(8)GTDAASFPPFVEK 
2783.1 33-55 QFWIFDVQNPQEVMMN(1)SSNIQVK 
2294.36 401-419 SQVTGHHHHHHTGHHHHHH 
2175.47 377-395 NYIVPILWLN(10)ETGTIGDEK 
2035.24 268-285 AFASPVENPDNYCFCTEK 
1957.26 338-354 TYLDIEPITGFTLQFAK 
1529.74 230-242 SQVLQFFSSDICR 
1484.67 243-255 SIYAVFESDVNLK 
1367.65 356-367 LQVNLLVKPSEK 
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1333.55 10-21 QVVLEEGTIAFK 
1299.47 290-301 N(9)CTSYGVLDISK 
936.08 146-152 ELLWGYR 
922.09 193-200 VAIIDTYK 
854 136-142 SSMFQVR 
824.89 26-32 TGTEVYR 
755.83 58-63 GPYTYR 
703.84 256-261 GIPVYR 
689.85 262-267 FVLPSK 
637.76 396-400 ANMFR 
599.77 368-372 IQVLK 
575.62 188-192 DN(6)ISK 
563.65 183-187 VFNGK 
545.64 22-25 NWVK 
532.5 1-5 DPSSK 
477.61 66-69 FLAK 
459.59 286-289 IISK 
388.47 143-145 TLR 
373.45 373-375 NLK 
360.45 6-8 TIK 
360.37 304-306 EGR 
302.33 56-57 QR 
273.34 64-65 VR 
249.33 302-303 CK 
233.27 134-135 SK 
203.24 201-202 GK 
174.2 203 R 
174.2 355 R 
174.2 376 R 
146.19 9 K 
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Table 4.2. Complete chymotrypsin digest of CD36 ED-12His.  
Complete digestion of CD36-12His with chymotrypsin generates 47 fragments. Of these fragments, 
10 contain putative N-linked glycosylation sites (N). There are 10 putative N-linked glycosylation 
sites in total. The putative glycosylated asparagines are numbered 1 to 10 with respect to their 
position within the primary sequence of the ED. 
 
Mass 
Amino 
Acid 
Number 
Peptide Sequence 
3093.76 352-378 AKRLQVNLLVKPSEKIQVLKNLKRNY 
2662.99 38-60 DVQNPQEVMMN(1)SSNIQVKQRGPY 
2469.56 318-339 ASPDVSEPIDGLNPNEEEHRTY  
2450.55 400-419 RSQVTGHHHHHHTGHHHHHH  
2190.52 1-20 DPSSKTIKKQVVLEEGTIAF 
1940.36 123-139 VQMILNSLIN(4)KSKSSMF 
1880.98 67-83 LAKEN(2)VTQDAEDNTVSF  
1783.92 208-223 WESHCDMIN(8)GTDAASF 
1663.96 295-309 GVLDISKCKEGRPVY 
1650.85 185-199 NGKDN(6)ISKVAIIDTY 
1639.81 385-399 LN(10)ETGTIGDEKANMF 
1489.73 282-294 CTEKIISKN(9)CTSY 
1442.68 105-118 TVLNLAVAAASHIY 
1418.66 224-235 PPFVEKSQVLQF  
1365.42 92-104 EPSLSVGTEADN(3)F 
1333.51 249-260 ESDVNLKGIPVY 
1313.57 140-149 QVRTLRELLW 
1043.17 237-245 SSDICRSIY  
1105.13 270-279 ASPVENPDNY 
1004.15 340-348 LDIEPITGF 
965.12 200-207 KGKRN(7)LSY 
934.1 162-170 PVTTTVGLF 
896.01 24-31 VKTGTEVY  
858.99 84-91 LQPNGAIF 
852.86 174-181 N(5)NTADGVY 
760.93 263-269 VLPSKAF 
739.96 379-384 IVPILW 
712.85 310-315 ISLPHF 
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690.84 156-161 LSLVPY 
576.7 63-66 RVRF  
535.56 119-122 QNQF 
533.59 152-155 RDPF 
507.59 349-352 TLQF  
449.51 32-34 RQF 
446.51 21-23 KNW 
392.5 182-184 KVF 
335.4 246-248 AVF 
321.38 260-261 RF 
294.35 316-317 LY  
282.3 61-62 TY 
278.35 36-37 IF 
278.31 172-173 PY 
268.34 280-281 CF 
238.24 150-152 GY 
204.23 35 W 
181.19 171 Y 
165.19 236 F 
  
 
4.2.3. Analysis of putative N-linked glycosylation sites on 
PNGase F-treated CD36 ED-12His secreted from 
insect cells 
 
To determine whether putative N-linked glycan sites were occupied on CD36 ED-
12His secreted from Hi5 and Sf21 insect cells, purified CD36 ED-12His was 
digested with PNGase F and analysed by LC-MS/MS using collision-induced 
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dissociation to allow sequencing of the protein. Peptides were first separated using a 
nano-reverse-phase liquid chromatography column before ionisation and direct 
loading into a LTQ Orbitrap Velos mass spectrometer using ESI. The resulting 
precursor ions were deflected and then subjected to ion-type CID to form b- and y-
type fragments (Figure 4.8). Subsequent fragments were then analysed together to 
deduce the peptide sequence. Using this approach, PNGase F treated peptide 
fragments containing putative N-linked glycan sites were considered as occupied by 
a glycan when conversion of an asparagine residue (N) to an aspartic acid (D) was 
observed, i.e. had become deamidated (Figure 4.9).  
 
 
Figure 4.8. Fragmentation of charged precursor ions during LC-MS/MS.  
Collision induced dissociation (CID) of precursor ions leads to breakage of peptide bonds along the 
peptide backbone generating b- and y-type ions. The fragment shown contains the sixth putative 
glycan site (N6) found within CD36 ED-12His.  
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Figure 4.9. LC-MS/MS analysis of CD36 ED-12His treated with PNGase F. 
Collision-induced dissociation of charged precursor ions generated an array of b- and y-type ions as 
shown in the resulting (a) mass spectrum and corresponding (b) table of predicted m/z fragment 
values. Values in red correspond to observed b-type ions. Values in blue correspond to observed y-
type ions. The fragment analysed here includes the sixth putative N-linked glycosylation site found in 
CD36 ED-12His (N6). Deamidated asparagine residues as a result of glycan cleavage by PNGase F 
are characterised by the conversion of asparagine (N) to an aspartic acid (D) and an apparent mass 
shift of approximately +1Da, as shown in (c). 
(a) 
(b) 
(c) 
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Seven putative N-glycosylation sites on CD36 ED-12His (N1, N5-N10) purified 
from Sf21 insect cells were detected as being deamidated, suggesting glycan 
occupancy at these sites (Figure 4.10). Six putative N-glycosylation sites on CD36 
ED-12His (N2-N3, N6 and N9 – N10) purified from Hi5 insect cells were detected 
as having been deamidated (Figure 4.10).  
 
Putative N-linked 
Glycan Site 
Sf21 Hi5 
N1 Deamidated Not found 
N2 Not found Deamidated 
N3 Not found Deamidated 
N4 Not found Not found 
N5 Deamidated Deamidated 
N6 Deamidated Deamidated 
N7 Deamidated Not found 
N8 Deamidated Not found 
N9 Deamidated Deamidated 
N10 Deamidated Deamidated 
 
Figure 4.10. Summary of putative N-linked glycosylation sites on CD36 ED-12His secreted from 
insect cells found to be deamidated after digestion with PNGase F.  
Purified CD36 ED-12His derived from Hi5 and Sf21 insect cells were treated with PNGase F and 
then analysed by LC-MS/MS using CID. Deamidated residues indicate putative N-linked 
glycosylation sites where glycans have been cleaved from asparagine residues, converting asparagine 
to an aspartic acid (becoming deamidated). Putative glycan sites on peptide fragments which were not 
detected by mass spectrometric analysis are labelled ‘not found’.   
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4.2.4.  Analysis of glycans present on CD36 ED-12His 
derived from Hi5 and Sf21 insect cells. 
 
To support the mass spectrometry data obtained using CD36 ED-12His treated with 
PNGase F, a second approach was used to try to determine the exact glycan 
structures occupying N-linked glycan sites. 
Initially LC-MS/MS using CID (ion-type) fragmentation was performed on 
glycosylated CD36 ED-12His. The CID spectrum (Figure 4.11 (a)) provided 
information about glycan occupancy on the peptide fragments. However, as the 
presence of N-linked glycans hindered the formation of b- and y-type ions from the 
associated peptides, a lack of peptide sequence information was observed. In 
separate LC-MS/MS experiments, HCD (beam-type CID) was used to produce b- 
and y-type ions as well as glycan-peptide fragments (Figure 4.11 (b)). HCD also 
resulted in the formation and subsequent detection of low-abundance oxonium 
product ions, such as N-acetylglucosamine (m/z 204) and mannose-N-
acetylglucosamine (m/z 366), characteristic to all glycoproteins. On detecting these 
ions, ETD of the same precursor ions was triggered resulting in the formation of c- 
and z-type ions which enabled the localisation of the glycan to a particular site 
within the fragment (Figure 4.11 (c)).  A list of the glycan structures identified on 
CD36 ED-12His secreted from Sf21 (Figure 4.12) and Hi5 (Figure 4.13) insect cells 
are shown. 
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Figure 4.11. CID/HCD product-ion triggered ETD in determining glycan structures occupying 
specific N-linked glycosylation sites.  
(a) Ion-trap collision induced dissociation (CID) fragmentation of precursor ions generated from 
glycosylated CD36 ED-12His was used to determine glycan structures present on a peptide fragment. 
The presence of N-linked glycans hindered formation of b- and y-type ions and prevented peptide 
sequencing and glycan localisation. (b) Higher energy collision dissociation (HCD) produced 
characteristic oxonium product ions (circled in red) which triggered (c) electron transfer dissociation 
(ETD) of the same charged precursor ion and subsequent generation of c- and z-type ions. 
Combination of glycan structures obtained from CID/HCD and peptide sequence information from 
ETD allowed identification of a glycan structure at a particular site. The fragment shown includes the 
sixth putative N-linked glycosylation site in CD36 ED derived from Sf21 insect cells.  
(c) 
(a) 
(b) 
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Figure 4.12. Summary of mass spectrometric analysis of glycosylation of CD36 ED-12His 
secreted from Sf21 insect cells.  
Using CID/HCD product-ion triggered ETD, glycan structures were observed on six putative glycan 
sites on CD36 ED-12His secreted from Sf21 insect cells. CD36 Ed-12His was digested into fragments 
using trypsin prior to analysis. Glycan heterogeneity was observed between different sites as well as 
between glycans on the same site. Glycans were simple and core-like.    - N-acetylglucosamine,      - 
Mannose,   - Fucose. Glycan structures were deduced using the protein metric software, Byonic 
(Protein Metrics) against the human CD36 sequence. Precursor tolerance of 6ppm and fragmentation 
of 0.5Da. False discovery rate (FDR) was 1%. 
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Figure 4.13. Summary of mass spectrometric analysis of glycosylation of CD36 ED-12His 
secreted from Hi5 insect cells.  
Using CID/HCD product-ion triggered ETD, glycan structures were observed on eight putative glycan 
sites on CD36 ED-12His secreted from Hi5 insect cells. CD36 ED-12His was digested into fragments 
using either trypsin or chymotrypsin prior to analysis. Glycan heterogeneity was observed between 
different sites and also between glycans on the same site. Higher mannose-type sugars were observed 
in Hi5 derived CD36 ED-12His. Hi5 derived CD36 ED-12His was also found to contain 
difucosylated glycans increasing the likelihood of core α(1-3) linked fucose being present.      - N-
acetylglucosamine,     - Mannose,      - Fucose. Glycan structures were deduced using the protein 
metric software, Byonic (Protein Metrics) against the human CD36 sequence. Precursor tolerance of 
6ppm and fragmentation of 0.5Da. False discovery rate (FDR) was 1%. 
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4.3. Discussion 
 
N-linked glycosylation on proteins is known to play an important role in a range of 
cellular functions. It was previously shown that nine of the ten putative N-linked 
glycosylation sites on full-length CD36, heterologously expressed in Sf21 insect 
cells and mammalian cells, were occupied (Hoosdally et al., 2009). In this chapter 
mass spectrometry was used to determine the putative N-linked glycosylation site 
occupancy of purified CD36 ED expressed in two separate insect cells lines and 
identify the nature of this glycosylation. 
Of the ten putative N-linked glycosylation sites found on CD36, glycan structures 
were identified on six sites from CD36 ED-12His secreted from Sf21 insect cells 
(Figure 4.12) and eight sites from CD36 ED-12His secreted from Hi5 insect cells 
(Figure 4.13). Both cell lines generated CD36 ED-12His with heterogeneous 
glycosylation. This heterogeneity was observed not only at different sites but also 
between glycans occupying the same site. Glycans found on CD36 ED-12His 
secreted from Hi5 insect cells showed greater heterogeneity. All glycans observed 
contained only N-acetylglucosamine, mannose and fucose. Although the same type 
of sugar groups were found on both CD36 ED-12His from both cells lines, Sf21 
derived CD36 ED-12His glycosylation consisted of simple short glycans, whereas 
the glycans on Hi5 derived CD36 ED-12His glycosylation were elongated. The 
presence of difucosylated glycans on CD36 ED-12His derived from Hi5 suggests the 
presence of α(1-3)-linked fucose residues and provides an explanation for the 
inability to remove all glycans with PNGase F. This data is in line with other studies 
which have shown Hi5 insect cells to produce recombinant proteins with this 
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particular linkage as part of more complex and hybrid-like glycans (Hsu et al., 1997, 
Rudd et al., 2000, Ding et al., 2003). Although the presence of singly fucosylated 
glycans on Sf21 derived CD36 ED-12His does not rule out the presence of α(1-3)-
linked fucose residues, the ability to deglycosylated the protein with PNGase F 
would suggest that these fucose residues are instead attached via α(1-6)-linkages. 
This is consistent with several studies which have failed to detect α(1-3)-linked 
fucose residues in Sf21 insect cells (Voss et al., 1993, Kuroda et al., 1990, 
Grabenhorst et al., 1993).  
Despite being able to detect glycan structures on six of the putative N-linked 
glycosylation sites on CD36 ED-12His secreted from Sf21 insect cells, glycan 
structures on an additional two putative sites (N2 and N3) were detected on CD36 
ED-12His secreted from Hi5 insect cells. This can be attributed to the chymotrypsin 
digestion of Hi5 derived CD36 ED-12His which resulted in shorter fragmentation 
with each product containing only one of the putative sites. In contrast, digestion of 
CD36 ED-12His with trypsin results in a large peptide fragment containing three 
putative N-linked glycosylation sites, which made glycan detection and assignment 
difficult (Baldwin, 2004). 
Only one putative N-linked glycosylation site was shown to lack glycosylation in 
both insect cells lines (N4). This is in agreement with Hoosdally et al., who showed 
that the same site was not glycosylated on full-length CD36 from insect and 
mammalian cell lines (Hoosdally et al., 2009). This putative site is located within 
one of two alpha helices suggested to be involved in oxLDL binding and, possibly, 
in CD36 homo-oligomerisation based on the structural model of CD36, derived from 
the LIMP-2 crystal structure. An alignment of the primary sequences of CD36, 
LIMP-2 and SR-B1 is shown in (Figure 4.14). Several residues within and around 
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this predicted alpha helix in CD36 were suggested, by mutagenesis (L158E, L161E, 
double mutant K164/K166E), to be involved in the binding of DiI-oxLDL (Neculai 
et al., 2013). This finding however is based on very severe amino acid substitutions 
which may have had an indirect impact on binding of oxLDL, as opposed to these 
residues specifically being required for oxLDL binding. 
Although the N-linked glycosylation sequon is thought to be recognised faithfully by 
oligosaccharyltransferase in the transfer of core glycan to asparagine residues 
(Schwarz and Aebi, 2011), the absence of a glycan within this proposed ligand 
binding region might suggest that there is a mechanism in place during trafficking 
through the ER to prevent glycosylation at this site. There are many examples 
reported where the presence of the sequon does not guarantee glycosylation (Gavel 
and von Heijne, 1990), and variability in site occupancy could be caused by different 
amino acids at positions +1 and +2 within the sequon (Shakin-Eshleman et al., 1996, 
Petrescu et al., 2004, Kasturi et al., 1997). Another mechanism to explain a non-
glycosylated sequon is the possibility of neighbouring Ser/Thr becoming O-
mannosylated, prior to core glycan transfer to the Asn, blocking N-linked 
glycosylation (Ecker et al., 2003). 
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hCD36   MGCDRNCGLIAGAV--IGAVLAVFGGILMPVGDLLIQKTIKKQVVLEEGTIAFKNWVKTG 
hLIMP2  MG--RCCFYTAGTLSLLLLVTSV-TLLVARVFQKAVDQSIEKKIVLRNGTEAFDSWEKPP 
hSR-B1  MGCSAKARWAAGALGVAGLLCAVLGAVMIVMVPSLIKQQVLKNVRIDPSSLSFNMWKEIP 
        **    .   **::     : :*   ::  :    :.: : *:: :  .: :*. * : 
 
                            N1                     N2 
hCD36   TEVYRQFWIFDVQNPQEVMMNSSNIQVKQRGPYTYRVRFLAKENVTQDAEDNTVSFLQPN 
hLIMP2  LPVYTQFYFFNVTNPEEILR-GETPRVEEVGPYTYRE-LRNKANIQFGDNGTTISAVSNK 
hSR-B1  IPFYLSVYFFDVMNPSEILK-GEKPQVRERGPYVYRE-FRHKSNITFNNNDT-VSFLEYR 
          .* ..::*:* **.*::  ... :*.: ***.**  :  * *:    : . :* :. . 
 
                        N3                             N4 
hCD36   GAIFEPSLSVGTEA-DNFTVLNLAVAAASHIYQNQ--FVQMILNSLINKSKSSMFQVRTL 
hLIMP2  AYVFERDQSVGDPKIDLIRTLNIPVLTV--IEWSQVHFLREIIEAMLKAYQQKLFVTHTV 
hSR-B1  TFQFQPSKSHGSES-DYIVMPNILVLGAAVMMENKPMTLKLIMTLAFTTLGERAFMNRTV 
           *: . * *    * :   *: *  .  :   :   :: *:   :.   .  *  :*: 
 
                                           N5             N6 
hCD36   RELLWGYRDPFLSLVP------YPVTTTVGLFYPYNNTADGVYKVFNGKDNISKVAIIDT 
hLIMP2  DELLWGYKDEILSLIHVFRPDISPY---FGLFYEKNGTNDGDYVFLTGEDSYLNFTKIVE 
hSR-B1  GEIMWGYKDPLVNLINKYFPGMFPFKDKFGLFAELNNSDSGLFTVFTGVQNISRIHLVDK 
         *::***:* ::.*:        *    .***   * : .* : .:.* :.  ..  : 
 
             N7           N8 
hCD36   YKGKRNLSYWES-HCDMINGTDAASFPPFVEKSQVLQFFSSDICRSIYAVFESDVNLKGI 
hLIMP2  WNGKTSLDWWITDKCNMINGTDGDSFHPLITKDEVLYVFPSDFCRSVYITFSDYESVQGL 
hSR-B1  WNGLSKVDFWHSDQCNMINGTSGQMWPPFMTPESSLEFYSPEACRSMKLMYKESGVFEGI 
        ::*  .:.:* : :*:*****..  : *::  .. * .:  : ***:   :..   .:*: 
 
                                        N9 
hCD36   PVYRFVLPSKAFASPVENPDNYCFCTEKIISKNCTSYGVLDISKCKEGRPVYISLPHFLY 
hLIMP2  PAFRYKVPAEILANTS---DNAGFCIP---EGNCLGSGVLNVSICKNGAPIIMSFPHFYQ 
hSR-B1  PTYRFVAPKTLFANGSIYPPNEGFC-------PCLESGIQNVSTCRFSAPLFLSHPHFLN 
        *.:*:  *   :*.      *  **        *   *: ::* *: . *: :* *** 
 
hCD36   ASPDVSEPIDGLNPNEEEHRTYLDIEPITGFTLQFAKRLQVNLLVKPSEKIQVLKNLKRN 
hLIMP2  ADERFVSAIEGMHPNQEDHETFVDINPLTGIILKAAKRFQINIYVKKLDDFVETGD-IRT 
hSR-B1  ADPVLAEAVTGLHPNQEAHSLFLDIHPVTGIPMNCSVKLQLSLYMKSVAGIGQTGK-IEP 
        *.  . . : *:.**:* *  ::**.*:**: :: : ::*:.: :*    :    .  . 
 
                N10 
hCD36   YIVPILWLNETGTIGDEKANMFRSQVTGKINLLGLIEMILLSVGVVMFVAFMISYCACRS 
hLIMP2  MVFPVMYLNESVHIDKETASRLKSM-INTTLIITNIPYIIMALGVFFGLVFTWLACKGQG 
hSR-B1  VVLPLLWFAESGAMEGETLHTFYTQLVLMPKVMHYAQYVLLALGCVLLLVP--VICQIRS 
         :.*:::: *:  :  *.   : :       ::     :::::* .: :.     *  :. 
 
hCD36   KTIK-------------------------------------------------------- 
hLIMP2  SMDEGTADERAPLIRT-------------------------------------------- 
hSR-B1  QVGAGQRAARADSHSLACWGKGASDRTLWPTAAWSPPPAAVLRLCRSGSGHCWGLRSTLA 
        . 
 
hCD36   -------------------------- 
hLIMP2  -------------------------- 
hSR-B1  SFACRVATTLPVLEGLGPSLGGGTGS 
 
Figure 4.14. Primary Sequence Alignment of Human CD36 Protein Family.  
Clustal
15 
sequence alignment of the human CD36 family of proteins with all 10 putative N-linked 
glycan sites underlined with corresponding asparagines highlighted in yellow. Sequences highlighted 
in green and blue indicate residues predicted to reside within the first (α5) and second (α7) alpha 
helices involved with ligand binding and homo-oligomerisation, based on the model generated by 
Neculai, et al,. LIMP-2 residues in red are those predicted to be important for homo-oligomerisation. 
Mutating CD36 residues in brown were shown to abrogate binding of DiI-oxLDL (Neculai et al., 
2013). CD36 putative N-linked glycan sites are labelled N1-10. ‘*’: identical residues, ‘:’ conserved 
residues, ‘.’ Semi-conserved residues.   
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5. Analysis of Antibody Binding to the CD36 
Ectodomain using Surface Plasmon 
Resonance 
 
5.1.  Introduction 
 
The ability to monitor binding interactions is of the upmost importance to the drug 
discovery and development process.  It has been known since the beginning of the 
20
th
 century, when the receptor theory of drug action was first proposed, that for a 
drug to work it must bind to its target receptor (Langley, 1905). Much of the drug 
discovery process since then has focused on the direct measurement of the amount of 
drug bound to a receptor at equilibrium, i.e. the binding affinity or binding strength. 
This emphasis on binding affinity which is described in terms of an equilibrium 
dissociation constant - the drug concentration required to give half-maximum 
binding, is based on the assumption that affinity is an acceptable surrogate for 
determining in vivo efficacy (Pan et al., 2013).  Although affinity determination has 
been behind the discovery of many highly efficacious drugs, it is becoming 
increasingly acknowledged that the rate of drug association and then the rate of drug 
dissociation from a receptor, i.e. the binding kinetics, has a direct effect drug 
efficacy as well as on drug safety (Swinney, 2009, Vauquelin et al., 2012, Chen et 
al., 1992, Pan et al., 2013). In an in vivo system, the concentration of drug at the 
target site will vary over time, on a timescale which may be faster than the binding 
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and unbinding to a receptor, such that a binding equilibrium may never be reached or 
maintained (Pan et al., 2013). For some drugs, reaching equilibrium may not even be 
desirable with possible toxic side effects being caused by the drug staying within the 
system too long and causing adverse effects to normal physiological processes (Chen 
et al., 1992). 
The scavenger receptor CD36 is found on many different cell and tissue Types, 
including macrophages (Savill et al., 1991), endothelial cells (Swerlick et al., 1992) 
and smooth muscle (Harmon and Abumrad, 1993). It is this diverse expression 
pattern as well as the ability of the ectodomain (ED) of CD36 to bind a wide range of 
ligands that links this receptor to many different normal physiological processes as 
well as pathological states. With this in mind, the development of any therapeutic 
agents to target CD36, with the hope to relieve or cure a related pathosis, must take 
into account possible side-effects that may affect other essential physiological 
processes. Understanding the way in which a ligand or drug might bind to the ED of 
CD36, in particular the binding kinetics, is therefore vital for the development of 
effective therapeutic agents. 
This chapter describes how Biacore™ (GE Healthcare), a technology which exploits 
the phenomena of surface plasmon resonance (SPR) spectroscopy, a label-free 
binding technique (Patching, 2014), was used to monitor the binding between 
unlabelled monoclonal antibodies and the purified ED of CD36 with the goal to 
determine binding affinities and the kinetics of these interactions. These initial 
experiments are the first steps in the development and optimisation of an approach 
which could then be used to analyse the binding affinity and binding kinetics of a 
range of CD36 ligands as well as for potential therapeutic agents designed to 
modulate or inhibit ligand binding to the ED of CD36. 
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5.1.1. Surface Plasmon Resonance 
 
Although many different methods for monitoring ligand-receptor binding have been 
employed for decades in academia and the pharmaceutical industry (Swinney and 
Anthony, 2011), these assays have generally relied on the use of labels, such as 
radioactive tags, fluorescent tags or colorimetric reactions to report binding. These 
indirect detection methods not only make analysis more expensive but also 
introduces possible experimental uncertainty either through blocking of the active 
binding epitopes by the label or the label itself contributing to the overall binding 
event leading to a false-positive result (Beher et al., 2009, Hu et al., 2012). Although 
there is now a wide variety of labelled detection methods available, the use of label-
free methods are becoming increasingly popular. Label-free methods greatly reduce 
the time and complexity required for binding analysis as well as removing the 
difficulties caused by steric hindrance or from false-positives produced by label 
participation (Fang, 2014). 
Most label-free detection methods follow the same underlining principle involving a 
transducer that is capable of measuring a physical property of a substance, whether it 
is DNA, protein, lipid or even whole cells. All molecules and cells have finite 
properties such as mass, volume, and conductivity that can be exploited to indicate 
their presence or absence from a particular sensor surface (Cunningham et al., 2004). 
The sensor, acting as a transducer, converts one of these physical properties (such as 
the mass of a compound binding to the surface) into a quantifiable signal (e.g. 
current or voltage) which can then be gathered by an appropriate instrument (such as 
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voltage meter), providing a signal proportional to the amount of binding 
(Cunningham et al., 2004).  
The phenomenon of surface plasmon resonance (SPR), which uses optical 
biosensors, has become one of the most popular label-free methods for measuring 
binding interactions in real-time (Karlsson, 2004). The use of optical biosensors in 
SPR systems is dominated by Biacore™ which in combination with their own 
microfluidic system for delivering sample to the biosensor surface, have become the 
main providers of this technology (Karlsson, 2004).  
Through molecules binding to these optical biosensors it is possible to generate a 
response which is proportional to the mass of the molecule bound (Tanious et al., 
2008). As the binding events are observed in real-time, it is possible to study a range 
of interaction characteristics which were previously unmeasurable using 
conventional equilibrium-based binding studies. By following the binding event in 
real-time, it is possible to monitor the binding kinetics of the interaction and in turn 
elucidate a clearer mechanism and understanding of the binding event (Tanious et 
al., 2008, Nordgren et al., 2001). 
 
5.1.1.1. Biacore SPR Detection System 
 
Biacore systems use the phenomenon of SPR to monitor the interaction between two 
molecules in real-time (Karlsson, 2004). The approach involves immobilising one 
interacting partner, termed the ligand (not to be confused with ligand-receptor 
terminology), to the surface of a sensor chip (Figure 5.1). The other interacting 
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partner, termed the analyte, is then passed over the sensor chip surface in solution 
where it is then able to interact with the immobilised ligand (Karlsson and Stahlberg, 
1995). 
 
 
Figure 5.1. Surface plasmon resonance basic terminology.  
The ligand is the interacting partner that is immobilised onto the surface of the sensor chip. The 
analyte is passed over the sensor chip surface in solution where it can then bind to the immobilised 
ligand. 
 
SPR takes places within a thin conducting film at an interface between media of 
different refractive indices. The refractive index is a measure of how light, or any 
other form of radiation, passes through a medium (Cooper, 2003, Piliarik et al., 
2009). In the SPR detection system the media are the glass of the sensor chip (high 
refractive index) and a buffer (low refractive index), the conducting film being a thin 
layer of gold at the surface of the sensor chip (Figure 5.2) (Hahnefeld et al., 2004). 
When polarized light, under conditions of total internal reflection, hits the 
electrically conducting gold layer interface between the two media, an 
electromagnetic field intensity, known as an evanescent wave, is generated (Cooper, 
2003). The evanescent wave once generated leaks across the gold layer interface into 
the medium with lower refractive index (the buffer). The amplitude of the 
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evanescent wave decreases exponentially with distance from the sensor chip surface 
so that the effective penetrative depth in terms of sensitivity to refractive index is 
around 150nm (Cooper, 2003, Nunez et al., 2012). With a particular combination of 
angle of incidence and energy (wavelength), the polarized light excites plasmons 
(electron charge density waves) in the gold film. This results in a characteristic 
absorption of energy via the evanescent wave with the SPR being seen as a drop in 
intensity of the reflected light. SPR is very sensitive to the refractive index of the 
solution within the effective penetrative depth of the evanescent wave (within the 
buffer) (Cooper, 2003). A change in the solute concentration at the sensor chip 
surface causes a change in the refractive index of the solution within the evanescent 
wave. The resultant shift in light energy (wavelength), which is absorbed rather than 
reflected, can be measured as change in resonance angle or resonance wavelength 
(Nunez et al., 2012). Only refractive index changes within the effective penetrative 
depth (150nm away from the sensor chip surface) will affect the SPR signal. This 
means that only analyte binding to the sensor chip surface will generate a response 
change (Cooper, 2003, Nunez et al., 2012).   
 
175 
 
 
Figure 5.2. Basic configuration of a Surface Plasmon Resonance (SPR) sensor.  
SPR is sensitive to refractive index changes that take place within close proximity to the sensor chip 
surface. As molecules bind the mass at the sensor surface increases, causing the SPR angle to shift 
(from I to II). The change in resonant angle can be monitored in real-time as a change in resonance 
signal over time. The degree of resonance increase is proportional to the mass change at the surface. 
Biacore is trademark of GE healthcare companies. © 2014 General Electric Company - Reproduced 
by permission of GE Healthcare. 
 
 
5.1.1.2. Sensor Chip Surface 
 
The sensor chip, in particular, the sensor chip surface is fundamental to SPR in 
measuring molecular interactions (Cooper, 2003). The ability to monitor the binding 
between an analyte and a ligand is dependent on first being able to immobilise the 
ligand onto the chip surface and for it to retain its native active conformation. The 
ligand must then also remain bound throughout the course of the binding experiment. 
There are several ways with which ligands may be attached to the sensor chip 
surface. The first is through covalent immobilization where the ligand is attached to 
the surface through a covalent linkage. The second method of attachment is via 
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hydrophobic absorption which exploits hydrophobic effects to either attach a ligand 
of interest or a hydrophobic carrier such as a lipid-based monolayer or bilayer to the 
sensor chip surface. The final type of immobilisation is achieved through high 
affinity capture. In this method the ligand of interest is non-covalently attached to 
another molecule (which in turn is usually attached using covalent immobilisation) 
(Cooper, 2003, Hutsell et al., 2010, Piliarik et al., 2009). The type of sensor chip 
surface that is used is based on the nature of the ligand and the analyte-ligand 
interaction that is to be studied. There is now a wide range of sensor chips available 
which are capable of immobilising anything from small peptides to whole cells 
(Figure 5.3). Every sensor chip consists of the same glass surface coated with a thin 
layer of gold which forms the basic platform from which specialised surfaces have 
been designed to immobilise a variety of ligands with very different physical 
properties (Lofas and Johnsson, 1990, Karlsson and Lofas, 2002, Knecht et al., 2009, 
Hodnik and Anderluh, 2010).  
The most widely used form of sensor chip consists of a gold layer which has been 
modified with a carboxymethylated dextran layer (Figure 5.3; CM5 Chip) (Lofas and 
Johnsson, 1990). This dextran layer creates a hydrophilic environment for the ligand 
attachment, maintaining the ligand in a native state. From this a range of modified 
surfaces have been designed which enables alternative immobilisation methods 
based on the nature of the ligand. All sensor chips (except CM1 and HPA sensor 
chips) are made up of a carboxymethylated dextran matrix covalently attached to the 
gold surface. Attachment of the ligand to this matrix is achieved through chemical 
reactions involving functional groups found on the ligand, such as aldehyde, thiol, 
and amino groups (Cooper, 2003). CM4 sensor chips have a lower degree of 
carboxymethylation than CM5 sensor chips and as such have a lower binding 
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capacity, thought to reduce non-specific binding (Lundquist et al., 2010, Hu et al., 
2009, Hahnefeld et al., 2004). The CM3 sensor chip has the same amount of 
carboxymethylation as the CM5 sensor chip but instead consists of a matrix of 
shorter dextran chains which is designed to reduce possible steric hindrance when 
investigating larger molecules such as viruses or whole cells. An extreme variant of 
the CM5 sensor chip, the C1 sensor chip has a carboxymethylated surface without a 
dextran matrix (Zhao et al., 2013, Zhang and Oglesbee, 2003). C1 sensor chips also 
allow the immobilisation of large ligands but limit freedom of movement of the 
ligand on the dextran matrix of the CM3 sensor chip (Hahnefeld et al., 2004).     
For hydrophobic ligands, HPA and L1 sensor chips are primarily used (Figure 5.3). 
The HPA sensor chip has alkanethiol molecules attached to the gold film creating a 
hydrophobic surface.  This sensor chip is used for the immobilisation of lipids and 
membrane-associated molecules (Cooper et al., 1998, Hodnik and Anderluh, 2010). 
The L1 sensor chip has a carboxymethylated dextran matrix with covalently attached 
lipophilic residues allowing the capture of vesicles and liposomes directly (Besenicar 
et al., 2006, Hodnik and Anderluh, 2010, Hahnefeld et al., 2004). 
The final types of sensor chip available are those allowing immobilisation of ligand 
through high affinity capture (Figure 5.3).  The SA sensor chip has a dextran matrix 
with streptavidin covalently attached. Streptavidin is capable of binding biotinylated 
ligands tightly with an affinity similar to that of direct covalent immobilisation 
(Hodnik and Anderluh, 2010, Hutsell et al., 2010). Another type of high affinity 
capture sensor chip is the NTA sensor chip. The NTA sensor chip has nitrilotriacetic 
acid (NTA) covalently bound to a dextran matrix, allowing the capture of 
polyhistidine-tagged ligands (Hahnefeld et al., 2004). As with NTA-agarose (see 
3.2.4), the immobilised NTA chelates metal ions, such as nickel (Ni
2+
), leaving 
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coordination sites free which can bind to polyhisitine tagged proteins (Knecht et al., 
2009).  
The binding cycle of NTA sensor chips differs from that of other chips, which rely 
on the ligand remaining immobilised for the duration of the whole experiment 
(including the use of multiple concentrations of analyte). For NTA sensor chips each 
experiment consists of multiple binding cycles; each binding cycle involving one 
concentration of analyte binding to immobilised ligand. At the start of a binding 
cycle, the sensor chip surface is first ‘activated’ with nickel ions. Injection of nickel  
over the sensor chip surface results in the nickel coordinately binding to the 
immobilised NTA. With the nickel bound, the surface is then capable of binding 
polyhistidine tagged proteins. Injection of ligand over the activated surface results in 
the polyhistidine tag of the ligand binding to the sensor chip surface through the 
coordinately bound nickel. With the ligand immobilisaed, binding interactions 
between analyte and ligand can be observed when analyte is injected over the sensor 
chip surface. Following measurement of the association and dissociation of analyte 
to ligand, the surface is regenerated, to remove all bound analyte, ligand and nickel. 
This differs from conventional CM sensor chips which rely on only removing 
analyte during regeneration, leaving the ligand immobilised. To regenerate the NTA 
sensor chip, EDTA is injected over the surface. EDTA is a metal ion chelator which 
sequesters and strips the nickel from the immobolised NTA and in turn removes the 
ligand and analyte. The sensor chip is then ready for a new binding cycle with fresh 
reagents (Hahnefeld et al., 2004). 
In the current study an NTA sensor chip was chosen for carrying out SPR analysis 
with the 12xhistidine tagged CD36 ED immobilised as a ligand. The NTA sensor 
chip surface chemistry exploits the same technology used previously in the metal-ion 
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affinity chromatography purification of the ED of CD36. The additional benefit of 
using this type of chip is that through immobilisation via the C-terminal 12-histidine 
tag, the ED is arrayed in a uniform orientation with the ED likely extending from the 
sensor chip surface and into the flow path of the analyte.    
 
Figure 5.3. Biacore Sensor Chip Surface Chemistry.  
There a number of optical biosensor chips available for the immobilisation of ligand during SPR 
analysis. The type of surface chemistry is dependent on the physical properties of the ligand that is to 
be immobilised. All sensor chips consist of the same glass surface coated with a thin layer of gold 
which forms the basic platform from which specialised surfaces have been designed. Biacore is 
trademark of GE healthcare companies. © 2014 General Electric Company - Reproduced by 
permission of GE Healthcare. 
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5.1.1.3. SPR Sensorgram 
 
Throughout an SPR experiment, the resonance (also called response), measured in 
response units (RU), is continually measured with a continuous flow of running 
buffer (or sample) over the sensor chip surface at all times. RU is an arbitrary unit 
which describes the relative change in mass at the surface of the sensor chip as 
molecules associate and dissociate. The response is directly proportional to the 
concentration of the molecules at the surface of the sensor chip. The response is 
represented in real-time on an SPR sensorgram which is a plot showing response 
against time (Figure 5.4). As the analyte comes into close proximity to the sensor 
surface and binds ligand, a refractive index change within the effective penetrative 
depth occurs, represented by in an increase in response. As more analyte binds to 
ligand, a characteristic dose-dependent response curve is observed. Eventually all 
binding sites become occupied and the response level begins to plateau. Once 
injection of analyte over the sensor chip surface has stopped, dissociation of analyte 
is measured as running buffer is passed over the sensor chip surface. For the next 
binding cycle to begin, the sensor surface is regenerated to ensure any remaining 
analyte has been removed from the surface. The regeneration solution used will vary 
depending on the type of sensor chip used. Each sensor chip is made up of four flow 
cells, allowing the measurement of different analyte/ligand binding conditions in 
parallel. To control for non-specific binding, analyte is passed through one flow cell 
without immobilised ligand. The control flow cell binding response is then 
subtracted from ligand immobilised flow cell response. For NTA sensor chips, this 
control flow cell lacks both nickel activation and immobilised ligand. 
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The rate of binding and dissociation are represented by two different constants, 
together describing the kinetics of the interaction. During association, the rate of 
analyte binding, described by the association rate constant (Ka), is dependent on both 
concentration of analyte (M) and time (s). Therefore Ka values are given with the 
units M
-1
s
-1
. During dissociation, described by the dissociation rate constant (Kd), the 
analyte freely dissociates as running buffer passes over the sensor surface. As a 
result, dissociation of analyte is dependent only on time. Kd values are therefore 
given with the units s
-1
.  
 
 
Figure 5.4. A typical SPR sensorgram showing analyte binding to immobilised ligand.  
A typical sensorgram consists of three distinct phases: analyte association, analyte dissociation and 
surface regeneration. Biacore is trademark of GE healthcare companies. © 2014 General Electric 
Company - Reproduced by permission of GE Healthcare. 
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To predict the degree of response change brought about through analyte binding, it is 
important to know how much ligand is immobilised on the sensor chip surface. The 
amount of analyte binding is dependent on the amount of ligand present and 
therefore available binding sites. As all steps of the SPR experiment are monitored 
by the system, the amount of ligand immobilised is measured directly by the increase 
in response above the baseline. The analyte binding capacity, or Rmax (Equation 
5.1) is calculated to give an indication of the expected maximum response in a 
binding cycle. The amount of ligand immobilised on the surface can be used to 
indicate the theoretical binding capacity of the surface with ligand immobilised. This 
is dependent on prior knowledge of the molecular weights of the analyte and ligand. 
For example: if the molecular weights of the analyte and ligand are 100kDa and 
50kDa, respectively, and 50RU of ligand is immobilised, then a Rmax of 100RU 
would be expected. 
 
 
Equation 5.1. Analyte Binding Capacity (Rmax) Equation.  
The theoretical Rmax is calculated to determine the expected maximum response that would be 
observed for a given binding event. Comparison of theoretical and practical Rmax values give a 
measure of activity of the surface-bound ligand. A lower practical Rmax value obtained 
experimentally compared to the theoretical Rmax would suggest a lower activity of surface-bound 
ligand. 
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The practical analyte binding capacity can be obtained experimentally by injecting 
analyte at high concentration to saturate the sensor chip surface. Alternatively, the 
practical analyte binding capacity can be determined by extrapolating binding levels 
from measurements at a series of analyte concentrations.    
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5.2. Results 
5.2.1. Immobilisation of CD36 ED-12His on a nickel-
activated NTA sensor chip. 
 
Prior to measuring analyte binding, SPR was used to determine whether purified 
CD36 ED could be immobilised onto an NTA sensor chip via the C-terminal 
12xhistidine tag (-12His), and more importantly whether it would remain 
immobilised. The sensor chip was activated by passing a 0.5mM nickel solution over 
the sensor chip surface (Figure 5.5). A subsequent rise in baseline response 
following nickel addition corresponded with the immobilisation of nickel ions and 
the successful activation of the chip surface. Purified CD36 ED-12His, pre-dialysed 
into running buffer was diluted to ~5µg/ml and then injected over the activated 
sensor chip surface (Figure 5.5), resulting in a response increase of ~500RU. 
Following immobilisation of CD36 ED-12His, running buffer was passed over the 
sensor chip surface with no decrease in response level being observed, suggesting 
stable immobilisation of CD36 ED-12His on the nickel-activated NTA sensor chip 
surface. 
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Figure 5.5. Overview of surface activation and immobilisation of CD36 ED-12His on an NTA 
sensor chip.   
An NTA sensor chip was equilibrated using running buffer (1). On injection of a 0.5mM nickel 
solution (2) over the surface of the sensor chip for 1 minute (10µl/min), a drop in resonance (3) was 
observed due to the change in the refractive index of the solution flowed over the surface. 
Equilibration of the flow cell with running buffer following surface activation (4) shows a response 
~40RU higher than the starting base-line response level, consistent with the immobilisation of nickel 
ions on the NTA coated surface. Injection of ~5µg/ml CD36 ED-12His over the activated surface (5) 
for 1 minute (10µl/min) resulted in a response increase of ~500RU (6). After CD36 ED-12His 
injection, running buffer was passed over the sensor surface to monitor dissociation of captured 
protein. CD36 ED-12His bound tightly to the nickel-activated surface of the NTA sensor chip with no 
decrease in response being observed (7). SPR was performed in a Biacore T200 (GE Healthcare) with 
all analysis undertaken at 25°C. The sensorgram was generated using BIA evaluation software 
version 2 (GE Healthcare). Experiments were performed in triplicate (triplicate traces are 
superimposed). 
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5.2.2. Analyte binding to immobilised CD36 ED-12His 
on an NTA sensor chip 
 
Having shown that purified CD36 ED-12His could be immobilised on a nickel-
activated NTA sensor chip surface without subsequent loss of attachment, SPR was 
performed to see whether analyte binding to CD36 ED-12His could be measured. 
The monoclonal antibody mAb1955 (Rat IgG2B, ~150kDa, R&D Systems, clone 
255619) is known to recognise CD36 ED-12His, having been shown previously to 
bind to CD36 ED-12His in western blotting experiments (see 3.2.1). MAb1955 has 
also been shown to bind native human CD36 expressed on the surface of transiently 
transfected mammalian cells (Linton, K; personal communication). MAb1955 was 
therefore used as analyte in initial binding experiments as proof of principle to test 
analyte binding to immobilised CD36 ED-12His. 
The NTA sensor chip was activated with a 0.5mM nickel solution followed by 
immobilisation of CD36 ED-12His (~500RU) as shown previously (see 5.2.1). Each 
binding cycle (Figure 5.6) consisted of surface activation of the NTA sensor chip 
surface with nickel, immobilisation of CD36 ED-12His, followed by injection of 
mAb1955 at set concentrations (ranging from 0nM up to 20nM) over the chip 
surface. During mAb1955 injection, association of antibody was observed as a 
response increase. After injection, running buffer alone was passed over the sensor 
chip surface to monitor mAb1955 dissociation, represented by a decrease in 
response. Following the dissociation phase, the sensor chip surface was regenerated 
using 350mM EDTA to sequester and strip nickel ions from the sensor chip surface 
and in turn remove immobilised CD36 ED-12His and mAb1955. 
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With increasing concentration of mAb1955, a greater response increase was 
observed corresponding to increased mAb1955 binding (Figure 5.7). Despite a 
concentration dependent increase in binding response, mAb1955 binding did not 
produce sensorgrams with the expected curvature. All concentrations of mAb1955 
produced a near linear response during association, as opposed to the characteristic 
curved response expected with conventional analyte/ligand interactions (Figure 5.4). 
This was especially true for higher concentrations of antibody. With the molecular 
weights of CD36 ED-12His and mAb1955 as ~63kDa and ~150kDa, respectively, 
and ~500RU of CD36 ED-12His having been immobilised, an Rmax value of 
~1190RU was expected (Equation 5.1). The Rmax is the point at which all available 
binding sites are occupied and so no further response increase should be observed 
beyond ~1190RU.  Biacore evaluation software (BIA evaluation) predicted, based on 
the binding curves generated, an Rmax value of around 7000RU. An additional point 
worth noting is that the binding curves appear similiar in their linearity to that of 
CD36 ED-12His immobilisation to the nickel-acitvated sensor chip surface. 
Together, the data suggested a non-specific interaction of mAb1955 with the nickel-
activated NTA sensor chip surface that is independent of CD36 ED-12His. 
mAb1955 concentrations up to 2.5nM produced stable binding profiles with no loss 
of binding during the dissociation phase. However, increasing the concentration of 
mAb1955 (from 5nM to 20nM) led to unstable binding, represented by a greater 
decrease in reponse during the disocciation phase with higher concentrations of 
mAb1955. 
188 
 
 
Figure 5.6. Overview of SPR analysis of the interaction of mAb1955 with CD36 ED-12His 
immobilised on an NTA Sensor Chip.   
Overview of nickel activation, immobilisation of CD36 ED-12His and binding of mAb1955. An NTA 
sensor chip was equilibrated using running buffer (1). On injection of a 0.5mM nickel solution 
(10µl/min) (2), a drop in resonance (3) was observed due to the change in refractive index of the 
solution being flowed over the surface. Equilibration of flow cell with running buffer following 
surface activation (4) revealed a response ~40RU higher than the starting base-line level, 
corresponding to nickel ions co-ordinately bound to the NTA coated surface. Injection of ~5µg/ml 
CD36 ED-12His (5) over the activated surface for 60 seconds (10µl/min) resulted in a response 
increase of ~500RU. After CD36 ED-12His injection (6), running buffer was passed over the sensor 
surface to monitor dissociation of captured protein. CD36 ED-12His bound tightly to the nickel 
activated surface of the NTA sensor chip with no decrease in response observed (7). MAb1955 was 
diluted in running buffer to concentrations from 0nM up to 20nM. One concentration of mAb1955 
was injected (30µl/ml for two minutes) over the chip surface per binding cycle (8). Association of 
mAb1955 was measured by an increase in response level (9). Following the association phase, 
running buffer alone was passed over the sensor chip surface (10) (30µl/min for 2.5 minutes) with 
dissociation of mAb1955 measured by a drop in response level (11). The sensor chip surface was 
regenerated by passing 350mM EDTA over the surface (12), resulting in a decrease in response level 
(13). Following re-equilibration with running buffer (14), starting base-line response level was 
restored (15), with the sensor chip surface ready for the next binding cycle. SPR was performed in a 
Biacore T200 (GE Healthcare) with all analysis undertaken at 25°C. Sensorgrams were generated 
using BIAevaluation software version 2 (GE Healthcare). Experiments were performed in triplicate 
(triplicate traces are superimposed). 
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Figure 5.7. SPR analysis of the interaction of mAb1955 with CD36 ED-12His immobilised on an 
NTA Sensor Chip.  
SPR sensorgram for the interaction of mAb1955 to CD36 ED-12His immobilised on an NTA sensor 
chip. mAb1955 diluted in running buffer to 0nM (blank reference), 0.625nM, 1.25nM, 2.5nM, 5nM, 
10nM and 20nM was injected over the sensor chip with immobilised CD36 ED-12His (30µl/min for 2 
minutes) in separate binding cycles. Dissociation of mAb1955 was measured by passing running 
buffer alone over the sensor chip surface.  - - -  represents the expected Rmax level based on 
immobilisation of ~500RU CD36 ED-12His with the molecular weights of CD36 ED-12His and 
mAb1955 being ~63kDa and ~150kDa, respectively. SPR was performed in a Biacore T200 (GE 
Healthcare) with all analysis undertaken at 25°C. Sensorgrams were generated using BIAevaluation 
software version 2 (GE Healthcare). Experiments were performed in triplicate (triplicate traces are 
superimposed). 
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5.2.3. Specificity of monoclonal antibodies for CD36 ED-
12His immobilised on an NTA sensor chip  
 
The shape of the sensorgram curves (the linearity of mAb1955 association and 
dissociation with the chip) and the unexpectedly high response level, prompted a 
more rigorous examination of the specificity of mAb1955 binding. In parallel, the 
binding specificity of two other monoclonal anti-CD36 antibodies for immobilised 
CD36 ED-12His was performed. In these experiments, one flow cell of a NTA 
sensor chip was activated with nickel, followed by immobilisation of CD36 ED-
12His (~50RU). A second flow cell was only activated with nickel without 
subsequent CD36 ED-12His immobilisation. Three anti-CD36 monoclonal 
antibodies; mAb1955, mAb1258 and mAbFA6-152 were flowed over the surface of 
the two flow cells in different binding cycles to determine antibody specificity for 
CD36 ED-12His.  
 
5.2.3.1. mAb1955 
 
During injection of 5nM mAb1955 over the NTA sensor chip with CD36-ED-12His 
immobilised on the surface (Figure 5.8 (a)), a near linear increase in response was 
observed with the same characteristics as shown previously (Figure 5.7). When 5nM 
mAb1955 was injected over the nickel-activated surface lacking immobilised CD36 
ED-12His (Figure 5.8 (b)), a similar response curve was generated. This result 
suggests that mAb1955 binding is non-specific and that the antibody has an affinity 
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for the nickel-activated NTA sensor surface.  This similarity is made more apparent 
when the two traces are merged (Figure 5.8 (c)). 
 
 
Figure 5.8. Specificity of mAb1955 for CD36 ED-12His immobilised on a nickel-activated NTA 
Sensor Chip.  
Curves show response generated when analyte was flown over sensor chip surface. mAb1955 (5nM) 
was injected (30µl/min for 3 minutes) over two flow cells of an NTA sensor chip. A flow cell was 
either (a) nickel-activated with CD36 ED-12His (~50RU) immobilised on the surface, or (b) activated 
with nickel alone. Dissociation was measured for 10 minutes (~30µl/min). Sensorgrams from both 
experiments were merged for comparison (c). SPR was performed in a Biacore T200 (GE Healthcare) 
with all analysis undertaken at 25°C. Sensorgrams were generated using BIA evaluation software 
version 2 (GE Healthcare). Experiments were performed in triplicate (triplicate traces are 
superimposed). 
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5.2.3.2. mAb1258 
 
The anti-CD36 antibody mAb1258 (Merck Millipore, Clone 63) is a monoclonal 
antibody (Mouse IgAκ, ~320kDa) sold primarily for use in detecting CD36 by flow 
cytometry, immunofluorescence and immunoprecipitation (Hoosdally et al., 2009, 
Keizer et al., 2004). In addition, mAb1258 has been shown to be effective at 
inhibiting the uptake of oxLDL by murine macrophages and adipocytes in vitro 
(Masella et al., 2006). However, mAb1258 has been found to be ineffective at 
detecting CD36 during western blotting analysis, suggesting that epitope recognition 
is dependent on the tertiary fold.  
During injection of 5nM mAb1258 over the NTA sensor chip with CD36 ED-12His 
immobilised on the surface (Figure 5.9 (a)), an increase in response was observed 
with similar characteristics to that of mAb1955 binding to the nickel-activated NTA 
sensor chip surface (Figure 5.9 (b)). When 5nM mAb1258 was injected over the 
nickel-activated sensor chip surface lacking immobilised CD36 ED-12His (Figure 
5.9 (b)), an almost identical response curve, as with mAb1955, was generated. 
Merged binding traces for mAb1258 are shown (Figure 5.9 (c)) to highlight this 
similarity. Like mAb1955, mAb1258 appeared to associate with the nickel activated 
NTA sensor chip surface to the same extent in the presence or absence of 
immobilised CD36 ED-12His, again suggesting a non-specific interaction 
independent of CD36 ED-12His. 
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Figure 5.9. Specificity of mAb1258 for CD36 ED-12His immobilised on a nickel activated NTA 
Sensor Chip.  
Curves show response generated when analyte was flown over sensor chip surface. MAb1258 (5nM) 
was injected (30µl/min for 3 minutes) over two flow cells of an NTA sensor chip. A flow cell was 
either (a) nickel-activated with CD36 ED-12His (~50RU) immobilised on the surface, or (b) activated 
with nickel alone. Dissociation was measured for 10 minutes (~30µl/min). Sensorgrams from both 
experiments were merged for comparison (c). SPR was performed in a Biacore T200 (GE Healthcare) 
with all analysis undertaken at 25°C. Sensorgrams were generated using BIA evaluation software 
version 2 (GE Healthcare). Experiments were performed in triplicate (triplicate traces are 
superimposed). 
 
 
5.2.4. mAbFA6-152 
 
The anti-CD36 antibody mAbFA6-152 (Abcam) is a monoclonal antibody (mouse 
IgG1, ~150kDa) sold for use in a wide range of applications including blocking and 
functional studies, flow cytometry, immunofluorescence, immunohistochemistry and 
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western blotting analysis (Chu and Silverstein, 2012, Olivetta et al., 2014, 
Maleszewski et al., 2007, Thelen et al., 2010).  
On injection of 5nM mAbFA6-152 over the NTA sensor chip with CD36 ED-12His 
immobilised on the surface (Figure 5.10 (a)), a response increase is generated as the 
antibody binds to the sensor chip surface. Unlike, mAb1955 and mAb1258, the 
response generated when mAbFA6-152 associates with the sensor chip surface has 
curvature and is more characteristic of an analyte/ligand interaction (Figure 5.4). 
After injection over the surface, no dissociation of mAbFA6-152 was detected with 
the response level remaining constant, suggesting a strong stable interaction. When 
mAbFA6-152 was injected over the nickel activated surface lacking immobilised 
CD36 ED-12His (Figure 5.10 (b)), a completely different response profile was 
generated. The maximum response achieved on the nickel-activated only surface was 
~6.5RU, whereas ~46RU were achieved when mAbFA6-152 was passed over the 
surface with immobilised CD36 ED-12His (Figure 5.10 (c)). Additionally, once the 
flow mAbFA6-152 over the nickel-activated surface (in the absence of CD36 ED-
12His) was discontinued and replaced by buffer only, the sensorgram trace returned 
to baseline, suggesting that the antibody does not stably associate with the nickel-
activated surface.  
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Figure 5.10. Specificity of mAbFA6-152 for CD36 ED-12His immobilised on a nickel activated 
NTA Sensor Chip.  
Curves show response generated when analyte was flown over sensor chip surface. MAbFA6-152 
(5nM) was injected (30µl/min for 3 minutes) over two flow cells of an NTA sensor chip. A flow cell 
either had (a) CD36 ED-12His immobilised (~50RU) on a nickel-activated surface, (b) activated with 
nickel alone. Dissociation was measured for 10 minutes (~30µ/min). Sensorgrams from both 
experiments were merged for comparison and shown in (c). SPR was performed in a Biacore T200 
(GE Healthcare) with all analysis undertaken at 25°C. Sensorgrams were generated using BIA 
evaluation software version 2 (GE Healthcare). Experiments were performed in triplicate (triplicate 
traces are superimposed). 
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5.2.5. Determination of an equilibrium dissociation 
constant for mAbFA6-152 binding to CD36 ED-
12His 
 
Of the three antibodies tested, only mAbFA6-152 failed to react with the Ni-charged 
NTA chip, but specifically recognised CD36 ED-12His. The microkinetics of 
mAbFA6-152 binding could therefore be analysed further. First, the apparent 
equilibrium binding affinity of mAbFA6-152 for CD36 ED was measured by SPR. 
As previously described, affinity is the strength of binding of one molecule to 
another and is typically measured and reported by a KD value at equilibrium, (i.e. the 
concentration of analyte at equilibrium that binds 50% of all ligand binding sites). At 
equilibrium, the rate of analyte binding is equal to the rate of analyte dissociation 
(the lower the KD, the greater the affinity).  
The affinity of a binding interaction (expressed as the KD value) can be determined 
using two independent approaches. The first is by measuring the dependence of 
steady-state binding levels on analyte concentrations and then extrapolating a KD 
value from a binding curve. The second is by calculating the KD value as the ratio 
between kinetic rate constants. Of the two methods, the simplest is by measurement 
of steady-state binding levels and involves analysing the level of binding at 
equilibrium for a range of analyte concentrations. Analysis of steady-state binding is 
achieved through plotting the amount of analyte bound against the concentration of 
analyte used. From the curve generated it is then possible to calculate the Rmax 
value and therefore the KD value.  
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MAbFA6-152 was diluted in running buffer to a range of concentrations from 
0.15625nM to 20nM (including 0nM as a blank reference). Each sample was injected 
over the nickel-activated NTA sensor chip surface with immobilised CD36 ED-
12His (Figure 5.11 (a)). Binding sensorgrams generated showed a concentration-
dependent increase in response during mAbFA6-152 injection (association) 
exhibiting the expected curvature characteristic of analyte/ligand interactions (Figure 
5.4).  
A steady-state binding curve was then plotted from the maximum response levels 
generated for each concentration of mAbFA6-162 used, having first subtracted the 
0nM blank reference (Figure 5.11(b)). The Rmax value, based on the curve plotted, 
was found to be 100.5RU ± 2.3RU (Figure 5.11 (c)). With the molecular weights of 
CD36 ED-12His and mAbFA6-152 as ~63kDa and ~150kDa, respectively, and 
~50RU of CD36 ED-12His having been immobilised, an Rmax value of ~119RU 
was expected (Equation 5.1). The KD value for the interaction between mAbFA6-
152 and CD36 ED-12His was found to be 5.06nM ± 0.4nM. The offset value (Figure 
5.11 (c)) (a constant that indicates where the curve intercepts the y-axis) is measured 
at 4.08RU ± 0.94RU and the Chi
2
 value (the total average deviation between the 
experimental data and the fitted curve) for the binding curve was found to be 
4.39RU
2
 indicative of the reliability of the data.  
198 
 
 
Figure 5.11. SPR analysis of the interaction of mAbFA6-152 with CD36 ED-12His immobilised 
on an NTA Sensor Chip.  
(a) Overlay of sensorgrams for the interaction of mAbFA6-152 to CD36 ED-12His immobilised on 
an NTA sensor chip. MAbFA6-152 diluted in running buffer to 0nM (blank), 0.625nM, 1.25nM, 
2.5nM, 5nM, 10nM and 20nM was injected over the sensor chip surface  (30µl/min for 2 minutes) in 
separate binding cycles. Dissociation of mAbFA6-152 was then measured by passing running buffer 
over the sensor chip surface (30µl/min for 15 minutes. (b) A Steady-state binding model using the 
blank-subtracted sensorgrams with maximum responses plotted against mAbFA6-152 concentration. 
From the generated binding curve, Rmax (100.5 ± 2.3RU) and KD (5.06 ± 0.4nM) values were 
determined (c), as well as an offset constant (4.08 ± 0.94RU) and a Chi
2 
value (4.39RU
2
) describing 
the closeness of experimental data to the fitted steady-state model. SPR was performed in a Biacore 
T200 (GE Healthcare) with all analysis undertaken at 25°C. Sensorgrams and steady-state curve were 
generated using BIA evaluation software version 2 (GE Healthcare). Experiments were performed in 
triplicate (triplicate traces are superimposed). 
(a) 
(b) 
(c) 
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5.2.6. Determination of binding microkinetics of the 
interaction between mAbFA6-152 and CD36 ED-
12His 
 
Having determined the equilibrium binding affinity of mAbFA6-152 for CD36 ED-
12His (KD = 5.06 ± 0.4nM), interaction models were applied to the SPR data to try 
and ascertain the microkinetics of the interaction, i.e. the on (Ka) and off (Kd) rates 
of binding and dissociation.  
Kinetic data are typically interpreted in terms of a model which best describes the 
interaction process. The binding constants obtained are apparent constants and are 
only valid within the context of the model used. As a rule of thumb, the simplest 
model is usually adequate for generating interpretable data. The simplest model that 
could potentially apply is the 1:1 binding model (O'Shannessy et al., 1993). In this 
model, the system assumes that the interaction involves one analyte binding to one 
immobilised ligand. From this it is possible to deduce a single association (Ka) and 
dissociation (Kd) rate constant for the interaction (Equation 5.2). Another model that 
may be used to describe binding data is the bivalent analyte binding model (Muller et 
al., 1998). This model is traditionally used when the analyte has two separate 
binding sites, as is the case with antibodies, such as IgG immunoglobulins, which 
have two antigen binding sites (Cuesta et al., 2010). In this model two separate 
binding events occur (Equation 5.3). The association and dissociation of the first 
binding event is described using Ka1 and Kd1, respectively, whereas the association 
and dissociation of the second interaction is described by Ka2 and Kd2, respectively. 
The first binding event yields a conventional 1:1 binding fit whereas the second 
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binding event stabilises the analyte-ligand complex and thus changes the kinetics of 
the overall reaction. The sensorgram produced from a bivalent analyte binding to a 
ligand would therefore be the result of two different kinetic processes occurring in 
tandem. 
 
 
Equation 5.2. 1:1 Binding Model Rate Equation.  
One analyte is capable of binding one ligand, described by a single association and dissociation rate 
constant. A – Analyte, B – Ligand, AB – Analyte/Ligand Complex, Ka – Association rate constant, Kd 
– Dissociation rate constant. 
 
 
Equation 5.3. Bivalent Analyte Binding Model Rate Equation.  
In a bivalent analyte model an analyte is capable of binding two separate ligands. A – Analyte, B – 
Ligand, AB – Analyte/Ligand Complex, Ka – Association rate constant, Kd – Dissociation rate 
constant.  
 
 
To determine the binding kinetics for the interaction of mAbFA6-152 to CD36 ED-
12His, a 1:1 binding fit model was first applied (Figure 5.12 (a)). The poor fit during 
association and dissociation phases suggested that the 1:1 binding model is not 
applicable for the interaction between mAbFA6-152 and CD36 ED-12His. When the 
bivalent analyte model was applied to the experimental data (Figure 5.12 (b)), a 
much better fit was observed. The closeness of the fit during both association and 
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dissociation of mAbFA6-152 to CD36 ED-12His suggests that the antibody is 
binding to either two sites on the same molecule of CD36 ED-12His or that the 
antibody is binding to one CD36 ED-12His and then binding to another in close 
proximity to the first. By fitting the bivalent analyte model to the data, two sets of 
association and dissociation constants were calculated (Figure 5.12 (c)). The first 
binding event was described by an association rate constant (Ka1) of 1.46x10
6 
± 
3.8x10
3
M
-1
s
-1 
with a dissociation rate constant (Kd1) of 8.92x10
-5 
± 2.5x10
-7
s
-1
. As 
the second binding event takes place in tandem with the first binding event, the 
second association rate constant (Ka2) was measured in RU
-1
s
-1
 with a value of 183.5 
± 19RU
-1
s
-1 
being calculated. The second dissociation rate constant value was 
determined to be 1658 ± 1.7x10
2
s
-1
. The closeness of the bivalent analyte binding 
model to the experimental data was supported by a low Chi
2
 value of 0.201RU
2
. 
Although it was possible to generate association and dissociation rate constants for 
the interaction between mAbFA6-152 and CD36 ED-12His, it was not possible to 
then deduce an equilibrium dissociation constant (KD) as a ratio of kinetic rate 
constants from this data. The ability to determine KD values based on the kinetic rate 
constants is dependent on their being a 1:1 binding event, with one analyte binding 
to one ligand. As mAbFA6-152 binding to CD36 ED-12His proceeds in two-step 
binding process, where the two binding events are linked, it is not possible to 
ascertain a single KD value. Therefore the KD value obtained previously (see 5.2.5) 
of 5.06nM is not a description of affinity, but instead avidity, which can be defined 
as the combined binding strength of multiple interactions.   
202 
 
 
Figure 5.12. Kinetic Analysis of mAbFA6-152 binding to CD36 ED-12His.  
Sensorgrams generated from seven concentrations of mAbFA6-152 (coloured lines) binding to 
immobilised CD36 ED-12His (blank subtracted) were globally fit (black lines) to (a) a 1:1 binding 
model or (b) a bivalent analyte binding model. A bivalent analyte model was found to fit 
experimental data better than a 1:1 binding model. Instead of a single set of Ka and Kd values (1:1 
binding kinetics), bivalent analyte binding is dependent on two separate binding events, and so two 
separate sets of rate constants are measured (c). The second binding event rate constants are 
dependent on the first and so second Ka values are measured relatively in response units (RU). SPR 
was performed in a Biacore T200 (GE Healthcare) with all analysis undertaken at 25°C. Kinetic 
binding models were fit to experimental data using BIA evaluation software version 2 (GE 
Healthcare). Experiments were performed in triplicate (triplicate traces are superimposed). 
(a) 
(b) 
(c) 
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5.3. Discussion 
 
The ability to monitor the rate at which a molecule binds and then dissociates from a 
target receptor is just as important as the affinity with which it binds. To begin to 
understand the way in which molecules bind the ED of CD36, SPR was used to 
monitor binding between CD36 ED and monoclonal antibodies. Purified CD36 ED 
was immobilised onto a nickel-activated NTA sensor chip and exposed to each 
antibody in the analyte flow to monitor binding events. Of the three antibodies 
tested, two showed non-specific binding to the nickel-activated sensor chip surface 
(but not in the absence of nickel). The remaining antibody was found to bind to 
immobilised CD36 ED specifically. 
The ability of both mAb1955 and mAb1258 to associate with the nickel-activated 
NTA sensor chip surface suggests that these two antibodies interact with the nickel 
ions independent of immobilised CD36 ED-12His. Based on these findings, it could 
be speculated that these antibodies may contain a polyhistidine sequence, a possible 
consequence of the purification processes used during production. However, 
according to R&D systems, the immunogen used in the production of mAb1955 is a 
recombinant protein spanning Gly30-Asn439 (covering the ED) of human CD36, 
expressed and secreted from Sf21 insect cells.  Using the hybridoma technique 
(Kennett, 1981, Tomita and Tsumoto, 2011), this recombinant protein was used to 
generate a single monoclonal anti-CD36 antibody which was then purified from a 
hybridoma cell culture supernatant using either protein A or G. The hybridoma 
technique involves the fusion of a specific antibody-producing B cell, isolated from 
the spleen of an immunised mammal (for mAb1955, a rat), with a myeloma cell to 
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form an immortalised hybridoma (Kohler and Milstein, 1975, Kohler and Milstein, 
1976). The resultant hybridoma will produce a monoclonal antibody with a single 
specificity. Based on this procedure it is highly unlikely that the antibody produced 
would contain a polyhistidine tag. MAb1258 was also produced using the hybridoma 
technique where the immunogen was a recombinant adenovirus vector encoding 
murine CD36. Both antibodies are provided in simple buffers, lacking additives 
(mAb1955, PBS; mAb1258, TBS). This affinity of mAb1955 and mAb1258 for 
nickel therefore remains unexplained. It may be possible to experimentally verify the 
presence or absence of a histidine tag on these antibodies by SPR by immobilising 
an anti-histidine antibody onto a CM5 sensor chip and then injecting either of the 
two antibodies over the surface. As both antibodies have been shown to bind the ED 
of CD36 expressed on the surface of cells previously, it was surprising not to have 
observed a greater (and biphasic) response when these antibodies were injected over 
the immobilised CD36 ED.  This may be explained by the small amount of CD36 
ED immobilised on the surface of the NTA chip, which could result in the antibody 
coming into contact with the nickel-activated surface first and binding with high 
affinity, thereby blocking subsequent binding to immobilised CD36 ED through a 
steric hindrance effect. The microkinetics of mAb1955 and mAb1258 binding to 
CD36 ED could yet be measured by immobilising ED to different chip surface that 
does not chelate divalent cations, such as a CM5 chip or, following biotinylation of 
the ED, a SA chip.   
In contrast, mAbFA6-152 was found to bind specifically to CD36 ED-12His with 
high avidity (5.06nM). The small response increase observed when the antibody was 
injected over the surface lacking CD36 ED-12His could be attributed to a number of 
factors. Firstly, mAbFA6-152 is provided in PBS buffer containing 0.1% BSA. The 
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BSA which is likely to be present as a stabilising agent may have a weak affinity for 
the nickel-activated surface. Secondly, the non-specific binding may be due to a 
mass transport effect, a diffusion-dependent supply of analyte to the sensor chip 
surface. Mass transport is a problem commonly encountered at high analyte 
concentrations or when the analyte flow rate is too low. At very high analyte 
concentrations or at very low flow rates, where the flow rate is slower than the 
association rate, the observed response increase is a measure of the diffusion rate 
rather than the interaction of analyte and ligand. In the current study the analyte flow 
over the surface was at 30µl/min, the recommended flow rate to minimise mass 
transport effects. Although increasing the flow rate further may have reduced 
possible mass transport effects, the shape of the response curve generated during 
analyte injection on the nickel-activated surface suggests a dose-dependent 
interaction with the surface. However, the non-specific interaction between 
mAbFA6-152 (and/or BSA) and the nickel-activated surface is subtle in comparison 
to the response generated when mAbFA6-152 interacts with CD36 ED and would 
only have a minimal effect on the calculated KD and microkinetic rate constants. 
Previous work by Pambakian and Poston showed that the Fc fragment of IgG 
antibodies can bind non-specifically to solid phase cationic sites in the absence of 
competing proteins (Pambakian and Poston, 1987). When the nickel coordinates 
with the NTA sensor chip, it forms a cationic surface. This therefore might be 
responsible for the observed binding of mAb1955 and mAb1258 to the activated 
sensor chip surface. Furthermore, the presence of BSA, which is a common blocking 
reagent used in antibody based assays, in the mAbFA6-152 solution might act to 
block non-specific binding allowing specific binding to take place.   
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MAbFA6-152 was found to interact with CD36 ED-12His via a 2-step binding 
process. The bivalent analyte binding model describes an analyte which has two 
identical binding sites, a property that is true of all IgG immunoglobulins (such as 
mAbFA6-152) (Cuesta et al., 2010). This bivalent binding property allows cross-
linking of two identical antigenic sites, increasing affinity and therefore improving 
retention time, maximising an immune response (Cuesta et al., 2010). The result of 
this model is the measurement of two separate sets of binding rate constant which 
together describe the avidity rather than the affinity of antibody to ED. As very little 
CD36 ED was immobilised onto the sensor chip surface, far from saturating levels 
(CD36 ED binding response does not plateau during ligand capture, Figure 5.5), it is 
unlikely based on this that mAbFA6-152 was cross-linking different CD36 ED 
molecules. This however is based on the assumption that the purified CD36 ED was 
immobilised in a monomeric, dispersed, non-aggregated-like fashion. It was shown 
previously (see 3.2.10) that at high concentrations purified CD36 ED was more 
likely to be found as higher molecular weight species with molecular weights 
equating to possible a dimer, trimer, tetramer, etc, formation. Although the 
concentration of CD36 ED in SPR experimentation was low enough to observe the 
protein in a predominantly monomeric state by SDS-PAGE, by passing the ED 
through the microfluidics of the Biacore system, the protein may have become close 
enough in proximity to self-associate either prior to or during immobilisation. 
This initial study, along with other recent publications, shows the potential of using 
SPR to study the interactions between CD36 and its associated ligands. In 2012, Bao 
et al., demonstrated a binding affinity (in the micro-molar range) for SAB and 
hexarelin for CD36 ED immobilised on the surface of a CM5 sensor chip. 
Interestingly, the binding of these molecules to the commercially bought insect cell-
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derived CD36 ED (R&D Systems, Minneapolis, MN) was fitted with a 1:1 binding 
model (Bao et al., 2012). Although it was not shown whether the CD36 ED was 
forming homo-oligomers, it is unlikely that these small ligands are bivalent and 
therefore capable of binding more than one CD36 ED at a time. In contrast to 
mAbFA6-152 which is a large bivalent IgG molecule, hexarelin is a six-amino acid 
peptide (Massoud et al., 1996) and SAB  is a  water-soluble 718.6Da phenolic acid 
derived from plants (Ho and Hong, 2011). 
With further optimisation it may be possible to measure the binding affinity, and 
more importantly the binding kinetics, of more physiologically relevant ligands such 
as oxLDL or TSP-1. In 2011, Ohki et al. demonstrated how the binding affinity of 
modified LDL binding to the LOX-1 receptor could be achieved with LOX-1 
immobilised on the surface of a SA sensor chip. From this they managed to observe 
differing binding affinities based on whether LOX-1 was immobilised as a 
monomer, dimer or as a cluster (Ohki et al., 2011). Although successful binding 
information was generated from mAbFA6-152 binding to CD36 ED immobilised to 
the surface of a nickel-activated NTA sensor chip, caution should be taken to detect 
and limit non-specific binding events which may interfere with reliable data 
acquisition. Thrombospondin-1 has been shown to associate with polyhistidine 
sequences with high affinity (Vanguri et al., 2000). This therefore most likely rules 
out being able to study thromobospondin-1 interacting with CD36 ED immobilised 
to the NTA surface via the 12His tag. Further optimisation may be required to 
measure oxLDL binding to the ED of CD36. To formulate oxLDL, LDL is typically 
incubated with the salt of a transition element, such as copper sulphate, to oxidise 
lipid and protein moieties (Heinecke et al., 1984). The NTA sensor chip is nickel-
activated and, as a transition element, nickel could potentially increase the oxidation 
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level of the analyte during the experiment leading to erroneous binding data. 
Preliminary results (not shown) suggest that native unmodified LDL binds and 
possibly undergoes modification as it is passed over a nickel-activated NTA sensor 
chip. Taken together these possible complications suggest careful consideration is 
required to identify the appropriate surface chemistry for immobilising CD36 ED 
and that this is likely to be dependent on the ligand tag used. By testing interactions 
with CD36 ED on a variety of different sensor surfaces, such as with SA and CM5 
chips, methods could be optimised to enhance the quality of the data obtained while 
reducing non-specific, erroneous binding events. 
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6. General Discussion 
 
The aim of this study was to establish a method to express and purify milligram 
quantities of CD36 to allow the initiation of crystallisation trials and to perform SPR 
to measure the microkinetics of ligand binding. In chapter 3, a mammalian 
expression system and three baculovirus expression systems in two different insect 
cell lines were compared to provide the highest yield of CD36 ED. CD36 ED 
expressed from FlashBAC Gold from Sf21 and Hi5 insect cells was purified using 
nickel affinity chromatography. The Sf21-derived material could be deglycosylated 
with PNGase F without denaturation and was shown to retain affinity for modified 
LDL irrespective of its glycosylation status. Expression and purification on a large-
scale format showed that recombinant CD36 ED forms homo-oligomers, especially 
at higher concentrations. In chapter 4, the glycosylation status and glycan 
composition of CD36 ED expressed and purified from insect cells was assessed 
using mass spectrometry. The glycans present on CD36 derived from both Sf21 and 
Hi5 insect cells lines were simple (high mannose) but heterogeneous. Hi5 insect cells 
were capable of producing glycans with a di-fucosylated core N-acetylglucosamine 
offering an explanation for the incomplete deglycosylation by PNGase F for CD36 
ED purified from these cells. No evidence was found for glycosylation at one (N4) 
of the ten putative glycan sites, as described for full length CD36 expressed in 
mammalian or insect cells (Hoosdally et al., 2009). When mapped to the structure of 
the homologous LIMP-2, N4 was localised to a helix suggested to be involved in 
ligand binding and homo-oligomerisation. Finally in chapter 5, purified CD36 ED 
was immobilised on a sensor chip and SPR was used to investigate the binding 
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affinity and microkinetic interaction of three monoclonal anti-CD36 antibodies. 
Although two antibodies, mAb1955 and mAb1258, were found to bind non-
specifically to the nickel-activated sensor chip surface, an equilibrium binding 
constant was obtained for mAbFA6-152. Microkinetic analysis was consistent with a 
two-step process with the bivalent antibody binding to two separate sites. As a result, 
the binding data was expressed as a measure of avidity, the strength of multiple 
binding events rather than affinity which is the strength of a single binding event. 
In the following sections, the findings of this study are summarized and discussed in 
relation to the data in the literature, and possible further work is considered that may 
lead to a fuller understanding of the structure as well as the ligand binding dynamics 
of human CD36.   
 
6.1. Expression and purification of CD36 ED 
 
Endogenous CD36 has previously been purified from human platelets (Tandon et al., 
1989b), human and bovine mammary epithelial cells (Greenwalt et al., 1990), rat 
adipocytes (Jochen and Hays, 1993) and rat cardiomyocytes (Brinkmann et al., 
2006) using the detergent (Triton X-100/114) to solubilize the protein from the 
membrane with a combination of different purification techniques including ion 
exchange, lectin-affinity and size-exclusion chromatography (SEC). Despite it being 
possible to isolate endogenous CD36 with high purity, for example >95% (0.2mg 
Cd36/250mg total heart protein) from rat cardiomyocytes, it required initial 
solubilisation of membrane proteins with detergent and then the continual presence 
of detergent during purification to prevent protein aggregation (Brinkmann et al., 
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2006). In addition to this, the existence of detergent might have hindered 
downstream applications such as crystallography and surface plasmon resonance 
(Tan and Ting, 2000, Garavito et al., 1996). It is therefore advantageous to express 
the ED of CD36 alone as it removes the need to solubilise the membrane and to 
maintain the protein in detergent throughout purification and downstream 
applications. 
The need for structural and ligand binding studies means that it is important to 
maximise the expression of the protein to obtain a suitable yield, preferably 
milligram quantities. In this project, CD36 ED was expressed in insect cells using a 
baculovirus expression vector. The protein was fused, in frame, to an amino-terminal 
cleavable secretory signal and a carboxy-terminal 12 histidine tag, which allowed the 
protein to be secreted into the surrounding culture media and subsequently purified 
using nickel affinity chromatography; all in the absence of detergent. This approach 
allowed 55-115µg of CD36 ED to be purified from small-scale (100ml) insect cell 
cultures. The process was scalable to 5 litre Sf21 insect cell culture despite the 
apparent formation of homo-oligomers. Similar approaches have been used in the 
past to obtain high yields of scavenger receptor protein. For example, Neculai et al., 
demonstrated that it was possible to express and secrete the ectodomain of LIMP-2 
(amino acids 35-430; LIMP-2 ED) from Sf9 insect cells and subsequently use nickel 
affinity chromatography and SEC to isolate a sufficient yield of pure protein to allow 
successful protein crystallisation. Despite the yield not being quoted, it was reported 
that the protein, following SEC, was concentrated to 15mg/ml for subsequent 
crystallisation (Neculai et al., 2013). This reinforced the idea that the 
baculovirus/insect cell expression system was indeed a good system to use for 
producing a high yield of protein which could then be used for structural studies. 
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Interestingly, the same study showed that LIMP-2 ED was also prone to forming 
homo-oligomers. However, a predominantly monomeric form could be isolated 
following SEC. The unit cell of the crystal consisted of six molecules, four of which 
formed head-to-head dimers with extensive crystal contacts between the alpha-
helical bundles including 5 and 7 (Neculai et al., 2013). It is possible that this 
reflects the homo-dimeric interaction that the purified LIMP-2 ED is prone to, but 
equally this packing arrangement could just as likely represent crystal contacts that 
have no physiological relevance.  
In 2009, Jimenez-Dalmaroni et al., also showed that it was possible to express and 
secrete the ectodomain of mCd36 using a baculovirus expression vector, this time 
from Hi5 insect cells (Jimenez-Dalmaroni et al., 2009). The protocol used nickel 
affinity, cationic exchange and SEC, to achieve ‘highly purified’ mCd36 ED, 
however, no yield or purity values were quoted. mCd36 ED did however appear to 
be monomeric in solution, eluting as a single defined peak from a SEC column. SEC 
was also used to provide evidence of mCd36 ED binding to diacylglycerides by 
observing changes in the relative protein elution times following incubation of 
mCd36 ED with the ligand (Jimenez-Dalmaroni et al., 2009). Ligand binding to 
mCd36 ED was associated with earlier elution during SEC, represented on the 
chromatogram by a defined peak shift to the left, suggesting an overall increase in 
size due to the interaction. This would be difficult with a protein that homo-
oligomerises. The primary sequences of human CD36 and mouse Cd36 within the 
regions proposed to be involved with homo-oligomerisation are almost identical 
(Figure 6.1). The primary difference is the presence of a putative N-linked 
glycosylation site within the human sequence, which is absent from the mouse 
sequence. However, as shown in chapter 4, and consistent with the data reported for 
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full length human CD36 by Hoosdally et al., this site is not occupied by a glycan and 
therefore the apparent difference in behaviour of the two proteins is not likely to be 
due to differences in glycosylation at this locus (Hoosdally et al., 2009). Overall, it 
seems unlikely that these apical helices are responsible for the homo-oligomerisation 
of CD36 ED observed in the present study.  
Another curiosity that is worth noting is that primary sequence alignment of LIMP-2 
with CD36 is far from perfect over the helical bundle. In particular, the presence of 
multiple proline residues within the primary sequence of mouse and human CD36, 
proposed to form the α7 helix makes it less likely that this region is even helical in 
CD36. It is well known that proline residues have a poor helix propensity, producing 
either kinks or breaks within helices due to sterically rigid side-chains (Pace and 
Scholtz, 1998). In addition, α5 in LIMP-2 is an amphipathic α helix with charged 
residues at three to four periodicity separated by neutral or hydrophobic amino acids. 
This is not apparent in the primary sequence proposed to form α5 from CD36. The 
meaning of this is not yet clear; it is possible that the alpha-helical bundle is 
important for ligand interaction and simply reflects that the ligands of LIMP-2 and 
CD36 are different. However, it is also possible that the fold of CD36 differs from 
LIMP-2 in these apparently important regions of the protein and should caution 
against using a low resolution LIMP-2 crystal structure to infer the structure of 
CD36. 
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Figure 6.1. Primary Sequence Alignment of Human CD36 Protein Family with the mouse CD36 
Protein.  
Clustal
15 
sequence alignment of the human CD36 family of proteins and mouse CD36. The fourth 
putative N-linked glycosylation site (N4) in CD36 is underlined with corresponding asparagine 
highlighted in yellow. Sequences highlighted in green and blue indicate residues predicted to reside 
within the first (α5) and second (α7) alpha helices involved with ligand binding and homo-
oligomerisation, based on the model generated by Neculai, et al,. LIMP-2 residues in red are those 
predicted to be important for homo-oligomerisation. Mutating CD36 residues in brown were shown to 
abrogate binding of DiI-oxLDL (Neculai et al., 2013). ‘*’: identical residues, ‘:’ conserved residues, 
‘.’ Semi-conserved residues. 
 
 
6.2. Glycosylation of CD36 ED expressed in insect cells  
 
There is increasing evidence that insect cells are capable of producing more 
elaborate forms of glycosylation than the paucimannosidic glycans previously 
described (Rendic et al., 2008). In chapter 3, it was shown that N-linked glycans on 
CD36 ED derived from Hi5 insect cells could not be cleaved using PNGase F, 
whereas those from CD36 ED derived from Sf21 insect cells could be cleaved. 
Insensitivity to PNGase F is attributed to the presence of α(1-3) core-linked fucose 
residues (Tretter et al., 1991). In chapter 4, mass spectrometric analysis of purified 
CD36 ED showed the presence of di-fucosylated glycan structures on CD36 ED 
 
 
 
                                                       N4 
CD36    GAIFEPSLSVG-TEADNFTVLNLAVAAASHIYQNQ--FVQMILNSLINKSKSSMFQVRTL 175 
mCd36   GAIFEPSLSVG-TEDDNFTVLNLAVAAAPHIYQNS--FVQVVLNSLIKKSKSSMFQTRSL 175 
hLIMP-2 AYVFERDQSVGDPKIDLIRTLNIPVL--TVIEWSQVHFLREIIEAMLKAYQQKLFVTHTV 173 
hSR-BI  TFQFQPSKSHG-SESDYIVMPNILVLGAAVMMENKPMTLKLIMTLAFTTLGERAFMNRTV 176 
           *: . * * .: * :   *: *             :: ::   :.   .  *  ::: 
 
 
 
CD36    RELLWGYRDPFLSLVP------YPVTTTVGLFYPYNNTADGVYKVFNGKDNISKVAIIDT 229 
mCd36   KELLWGYKDPFLSLVP------YPISTTVGVFYPYNDTVDGVYKVFNGKDNISKVAIIES 229 
hLIMP-2 DELLWGYKDEILSLIHVFRPDISPY---FGLFYEKNGTNDGDYVFLTGEDSYLNFTKIVE 230 
hSR-BI  GEIMWGYKDPLVNLINKYFPGMFPFKDKFGLFAELNNSDSGLFTVFTGVQNISRIHLVDK 236 
         *::***:* ::.*:        *    .*:*   *.: .* : .:.* :.  ..  :   
α5 helix 
α7 helix 
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prepared from Hi5 cells. Sf21 cells were found to produce only singly fucosylated 
glycans. This suggests that CD36 ED purified from Sf21 cells contains PNGase F-
sensitive α(1-6) core-linked glycans whereas Hi5 cells produces CD36 ED with 
glycans containing both α(1-6) and PNGase F-resistant α(1-3) core-linked glycans. 
This conclusion is supported by other studies which have also looked at the 
expression of CD36 from insect cells. In 2009, when mCd36 ED was purified from 
Hi5 insect cells, it was reported that PNGase F was not able to release all N-linked 
glycans. The theoretical molecular weight of unmodified mCd36 ED was predicted 
to be ~47.4kDa, however after digestion the electrophoretic mobility suggested a 
molecular weight above 50kDa. This inability to remove all glycans was also 
attributed to the presence of α(1-3) core-linked fucose residues (Jimenez-Dalmaroni 
et al., 2009). In contrast, Hoosdally et al., showed N-linked glycans on full-length 
CD36 purified from Sf21 cells could be removed when digested with PNGase F. 
Digested CD36 had an electrophoretic mobility corresponding to a molecular weight 
of around 50kDa (the predicted unmodified molecular weight being ~53kDa) 
(Hoosdally et al., 2009). The difference in glycosylation found in both insect cell 
lines could have a significant impact on the crystallisation of CD36. The inability to 
remove heterogeneous glycans, as was found with Hi5 derived CD36 ED, could 
hinder efficient crystal formation. On the other hand, the ED of LIMP-2, purified 
from Sf9 insect cells, was crystallised with N-linked glycans consisting of between 
1-5 mannose units still present (similar to those detected on CD36 ED (chapter 4)). 
However, the resultant crystals diffracted poorly, and the eventual resolution 
obtained was only to 3Å (Neculai et al., 2013). By removing the glycans it may be 
possible to obtain crystals that diffract to a higher resolution, and obtain a more 
accurate structural model of CD36. 
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This study is unique in that it is the first example describing the removal of N-linked 
glycans from CD36 without prior denaturation. Deglycosylated, native, CD36 ED 
(purified from Sf21 insect cells), binds modified LDL with the same affinity as the 
glycosylated native protein. It was concluded therefore that N-linked glycosylation 
does not play a role in binding of modified LDL to CD36. As discussed in chapter 4, 
there is only one sequon within CD36 that was not occupied by a glycan. This 
sequon (N4) is located within the region of CD36 suggested to be important for 
modified LDL binding. The asparagine is not buried in secondary structure (based on 
the LIMP-2 crystal structure) and none of the other sequons are located near this 
region. It is unclear why this site is not recognised by the glycosyltransferases that 
catalyse glycosylation events in the ER. There may be a mechanism which prevents 
glycosylation at this site, perhaps because it is critical for ligand binding and the 
inclusion of a glycan would inhibit ligand binding due to steric hindrance. To date, a 
precise role for N-linked glycosylation of CD36 function has not been defined. 
Hoosdally et al., demonstrated the need for a minimal level of N-glycosylation to 
ensure trafficking of CD36 to the plasma membrane in transiently-transfected 
HEK293T mammalian cells, but no individual glycosylation site or event was found 
to be critical (Hoosdally et al., 2009). This was interpreted as a requirement to 
engage lectin-like chaperones in the folding pathway, however a role in protein 
stability remains a possibility, particularly for an ectodomain exposed to proteases in 
the circulation. This remains to be tested. It was reported by Lauzier et al., that Cd36 
N-linked glycosylation, in particular on Asn102, is important for uptake of LCFA. 
This was proposed following the observation that SHR, which express Cd36 lacking 
the putative N-linked glycosylation site at Asn102 (N2), were less able to utilise 
exogenous LCFA (Lauzier et al., 2011). In SHR this residue is a serine instead of an 
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asparagine. This data is however debatable as Cd36 from SHR is known to have 
multiple alterations in its primary amino acid sequence not just at amino acid 
position 102 (Aitman et al., 1999). These variations in primary amino acid sequence 
could have a significant impact of the overall fold of the protein and potentially alter 
ligand binding sites. Additionally, Asn102 is located away from the proposed LCFA 
binding site on CD36 which includes Lys164 and Lys166 (Kuda et al., 2013b), 
further questioning whether N-linked glycosylation has a role in LCFA utilisation by 
CD36.  
 
6.3. Modified low density lipoprotein binding to CD36 ED 
purified from insect cells 
 
The presence of correctly folded CD36 ED purified from Sf21 insect cells was 
demonstrated by the ability to bind acLDL. Modified LDL bound to the purified 
CD36 ED with the same affinity as full-length CD36 purified from Sf21 insect cells 
and more importantly, with the same affinity as full length CD36 expressed on the 
surface of mammalian cells (Hoosdally et al., 2009). It was suggested by Kar et al., 
that the region of CD36 between amino acids 160-168 (5) contains the binding site 
for oxLDL and furthermore that Lys164 and Lys166 are crucial for this interaction 
(Kar et al., 2008). More recently the apparent importance of these two residues in 
modified LDL binding was shown by mutating both Lys164 and Lys166 to 
glutamates (K164E/K166E), in addition to mutating Leu158 and Leu161 to 
glutamates (L158E, L161E) independently. Introduction of these mutations was 
reported to abolish the ability of CD36 (tagged with an enhanced green fluorescent 
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protein, EGFP) expressed on the surface of CHO cells to bind modified LDL 
(Neculai et al., 2013). Confocal images, however, provided little evidence based on 
EGFP signal to suggest plasma membrane localisation. This is especially true for the 
lysine double mutant (K164E/K166E) and L158E mutant which appear to be 
retained intracellularly. It should be noted that these mutations significantly change 
the character of the side chain, changing positively charged (Lysine) or hydrophobic 
(Leucine) residues to negatively charged (Glutamic acid) residues. This could 
potentially have a significant effect on the protein fold. For example, the introduction 
of a negatively charged side chain close to another negatively charged side chain 
(which would be the case if one or more of the lysines in the native protein is 
involved in a salt bridge) could result in repulsion thus distorting the native fold. The 
chosen mutations may therefore affect ligand binding allosterically, bringing into 
question their direct involvement in binding modified LDL. The localisation of these 
mutants would suggest a folding defect which is either causing the protein to be 
retained within the secretory pathway or it being trafficked for degradation. 
Nevertheless, if it is presumed that amino acids 158-168 are involved directly in 
oxLDL binding then this would implicate α5, the same helix proposed to be 
responsible for homo-oligomerisation, as discussed above. If the modified LDL 
binding site on CD36 is indeed the same site as that involved in homo-
oligomerisation then it would be expected that homo-oligomerisation of purified 
CD36 might prevent modified LDL binding, and this may have consequences for 
ligand binding studies. For example, if oligomeric CD36 ED cannot bind modified 
LDL this would likely reduce the binding maxima, but the affinity and microkinetics 
of binding to the monomeric domain would be unaffected.  
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6.4. Using SPR to measure the microkinetics of ligand 
binding to CD36 
 
As discussed in chapter 5, the rate of association and dissociation of a one molecule 
to another is arguably more relevant than the overall binding affinity at equilibrium, 
especially when considering these binding events within the dynamic environment 
found within the human body. SPR is a powerful label-free tool for measuring these 
binding events in real time (Karlsson, 2004). MAbFA6-152 was shown to bind to 
immobilised purified CD36 ED with an equilibrium binding constant, KD = 5.06nM, 
however analysis of the microkinetics of binding, showed that this antibody bound to 
the immobilised CD36 ED via a two-step process meaning that the binding constant 
is more accurately referred to as a measure of avidity, the strength of multiple 
binding events, rather than affinity. MAbFA6-152 has been used in a number of 
studies to block TSP-1, oxLDL and P. falciparum infected erythrocytes from binding 
to CD36 (Nergiz-Unal et al., 2011, Volf et al., 1999, Baruch et al., 1999). The 
assumption that this antibody can therefore recognise the binding site of all these 
ligands is questionable as these ligands have been reported to have completely 
separate binding sites. Daviet et al., proposed having used homologue-replacement 
mutagenesis, that the likely binding site for mAbFA6-152 was within the region 
containing amino acids 155-183, with Asn162 being a key residue for binding 
(Daviet et al., 1995). This would suggest that mAbFA6-152 recognises the region on 
CD36 proposed as the binding site for modified LDL and P. falciparum infected 
erythrocytes (Neculai et al., 2013, Kar et al., 2008, Baruch et al., 1999). The ability 
of this antibody to block binding of TSP-1 may therefore be due to steric hindrance 
220 
 
or allostery by inducing a conformational change in CD36 that masks the relevant 
binding sites.  
The SPR analysis of mAbFA6-152 binding to immobilised CD36 ED was best fitted 
by a two-step binding model to generate two sets of rate constants. MAbFA6-152 is 
an IgG molecule (~150kDa) and, as with all IgG antibodies, it is bivalent with two 
identical antigen binding sites. At the end of chapter 5 it was proposed that 
mAbFA6-152 bound to two separate sites from two different CD36 molecules. 
Furthermore, combined with the observation in chapter 3 that CD36 ED can form 
homo-oligomers, it is possible that mAbFA6-152 binds to two CD36 ED molecules 
that were in association. If this theory is correct then it once again brings into 
question whether the proposed homo-oligomerisation site on LIMP-2 is the same for 
CD36. If mAbFA6-152 binds to the region containing amino acids 155-183 with 
Asn162 being critical (Daviet et al., 1995), and if homo-oligomerisation occurred via 
the same region, then mAbFA6-152 would be unable to bind to oligomeric CD36 
ED. It seems likely therefore that homo-oligomerisation of CD36 ED is not mediated 
by the alpha-helical bundle identified in the LIMP-2 crystal structure as a putative 
homo-dimerisation interface. To further explore whether mAbFA6-152 is indeed 
binding through a two-step process to CD36, a monovalent antigen-binding fragment 
(fab) of this IgG antibody could be generated which should give a 1:1 binding 
kinetics profile. 
The data presented in chapter 5 and other studies indicates the potential of SPR to 
measure the affinity and microkinetics of physiological ligand binding to CD36. It is 
also a useful technique to screen pharmacological agents which might be used 
against CD36 in the treatment of a range of disease states. Bao et al., showed by SPR 
that equilibrium binding affinities could be measured for SAB and hexarelin binding 
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to immobilised CD36 ED (Bao et al., 2012). Both have been shown to have an anti-
atherosclerotic effect in mice by blocking binding of oxLDL to Cd36 (Bao et al., 
2012, Demers et al., 2004). Both hexarelin and SAB are likely to be good candidates 
for further SPR analysis to determine the microkinetics of binding, i.e. the rate of 
association and dissociation to CD36. In contrast to mAbFA6-152 which is a large 
bivalent IgG molecule, hexarelin is a six-amino acid peptide (Massoud et al., 1996) 
and SAB is a  water-soluble 718.6Da phenolic acid derived from plants (Ho and 
Hong, 2011). Other examples of molecules that could be studied by SPR include the 
CD36 inhibitors AP5055, AP5258 and ursolic acid which, like SAB, are also small 
and unlikely to be bivalent (Geloen et al., 2012, Wilkinson et al., 2011). To predict 
how these compounds may actually perform in the context of a living organism such 
as a rodent or humans, the ability to determine the microkinetics of binding is 
crucial. It is clear that CD36 is important for normal physiology as well as 
pathological conditions. By understanding the rate at which a potential therapeutic 
agent associates and then dissociates from CD36 is fundamental to improving 
efficacy and also for reducing the risk of possible toxic side-effects.   
  
6.5. Summary and Future Perspectives 
 
CD36 is a scavenger receptor present on the surface of a variety of cell and tissue 
types implicated in normal physiological processes as well as a number of 
pathological states. This can be attributed to the poly-specific nature of the receptor 
being able to bind a wide range of ligands. One of the most studied diseases 
associated with CD36 is atherosclerosis which is characterised by the thickening and 
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hardening of the arterial wall in the form of a plaque. The development and 
progression of plaque formation is closely related to the uptake of oxLDL via CD36 
into white blood cells ultimately leading to the formation fat-laden foam cells (a key 
component of the fatty plaque). Irrespective of studies predicting the sites of ligand 
binding such as oxLDL on CD36, proposed binding sites are questionable as the 
precise structure of CD36 remains unknown. In order to aid the development of 
effective therapeutics for conditions such as atherosclerosis that can specifically 
inhibit ligand binding to CD36, it is imperative to improve the current knowledge of 
multi-ligand binding to CD36 with the use of a structure of CD36 to which binding 
sites can be mapped.  
This study describes a method of expressing and purifying sufficient quantities of 
pure CD36 ED in its native fold that can be used for two important future directions. 
The first involves using purified CD36 ED in crystallisation trials with the aim of 
generating protein crystals. Using pure uniform CD36 ED crystals X-ray 
crystallography would describe the three-dimensional shape of the receptor and 
allow modelling of ligand binding sites. The recently solved crystal structure of 
LIMP-2 ED using similar expression and purification processes suggests that it is 
highly likely that purified CD36 ED can also be crystallised. Furthermore, the 
crystallisation process may be improved by reducing the complexity and asymmetry 
of purified CD36 ED (e.g. removal of sugar groups) without losing overall protein 
shape and without reducing the ability to bind ligand (e.g. acLDL in this study). This 
might serve to increase the resolution of the calculated structure and provide a more 
accurate scaffold to map ligand binding sites. Ideally, to clearly define CD36 ligand 
binding sites, purified CD36 ED would be co-crystallised with ligand bound, 
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however further optimisation of crystallisation conditions would need to be 
determined empirically. 
The second avenue of investigation involves measuring the microkinetics of ligand 
and putative inhibitor interactions with purified CD36 ED. Although CD36 is not an 
essential protein (with natural deficiencies occurring in healthy human populations) 
it is critical to the pathophysiology of diseases such as atherosclerosis. Subsequently, 
this makes it a good target for therapeutic intervention as inhibiting CD36 activity is 
less likely to be detrimental providing that the inhibitor is specific and potent (i.e. 
producing only the desired biological response). The microkinetics of binding are a 
set of parameters which are more physiologically-relevant than the overall strength 
of interaction, describing the rates at which an inhibitor binds (on-rate) and 
dissociates (off-rate) from a receptor. These rate constants report physiological 
binding events in more detail and produce a more accurate predictor of the potency 
of putative inhibitors, i.e. the amount of inhibitor required to block ligand binding. 
To be specific and potent, inhibitors would need to display fast on-rates and slow 
off-rates, binding to the specific target receptor readily and remaining bound, 
blocking ligand binding. In drug discovery and development it is thus critical to 
measure the microkinetics of inhibitor interactions to aid the therapeutic selection 
process, meaning that only the inhibitors with the best characteristics are tested in 
animal models, resulting in a reduced demand for animal testing prior to human 
studies. 
A method for measuring the microkinetics of an antibody binding to purified CD36 
ED using SPR was described in this study. Using SPR it was possible to observe the 
interaction between antibody and purified CD36 ED in real-time. In addition to 
measuring the strength of antibody binding to purified CD36 ED, SPR also revealed 
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that this antibody bound to CD36 ED with a fast on-rate and slow-off rate, making it 
an ideal candidate for further testing as an inhibitor of ligand binding to CD36. 
Using similar methods to the one described in this study it would be possible to not 
only measure the microkinetics of physiologically-relevant ligands such as oxLDL 
binding to CD36, but also to assess the ability of candidate therapeutics to inhibit 
ligand binding. A number of compounds such as SAB from the red sage Salvia 
miltiorrhzia have been identified which were previously reported to have 
cardioprotective properties. Furthermore, recent studies have demonstrated the 
ability of SAB to bind CD36 and block uptake of oxLDL into white blood cells. This 
study highlights the potential of SPR to be able to rapidly screen such putative 
therapeutics for the treatment of diseases such as atherosclerosis. By understanding 
the microkinetics of the interaction between SAB and CD36, a more informed 
decision can be made about how to administer SAB as well as aiding in the design 
and development of new drugs with similar properties. To complement microkinetic 
data generated for inhibitors shown to block oxLDL binding to CD36, cell-based 
studies would need to be undertaken prior to testing in animals to ensure that an 
inhibitor would bind specifically to CD36 and also that the inhibitor itself would not 
cause progression and development of plaque formation or any other unwanted side-
effects.  
The data presented and methods described in this study pave the way to generating a 
greater understanding of the polyspecificity of CD36 as well as aiding the design and 
development of therapeutics to block ligand binding. Together this will provide a 
greater insight into the involvement of CD36 in a range of pathological states 
including atherosclerosis, type 2 diabetes and Alzheimer’s disease.  
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Appendices 
Appendix 1 
 
pBacPAK9-HMSS-CD36ED-12His 
 
                                 >EcoRV 
                                    | 
      1130      1140      1150      1160      1170      1180      1190      1200 
ACAAACTGGAAATGTCTATCAATATATAGTTGCTGATATCATGGAGATAATTAAAATGATAACCATCTCGCAAATAAATA 
 
 
      1210      1220      1230      1240      1250      1260      1270      1280 
AGTATTTTACTGTTTTCGTAACAGTTTTGTAATAAAAAAACCTATAAATATGAAATTCTTAGTCAACGTTGCCCTTGTTT 
                                                  M  K  F  L  V  N  V  A  L  V> 
                                                 _______________________________> 
 
 
                                       >SacI 
                                         | 
      1290      1300      1310      1320 |    1330      1340      1350      1360 
TTATGGTCGTATACATTTCTTACATCTATGCGGATCCGAGCTCGAAGACAATTAAAAAGCAAGTTGTCCTCGAAGAAGGT 
F  M  V  V  Y  I  S  Y  I  Y  A  D  P  S  S  K  T  I  K  K  Q  V  V  L  E  E  G> 
________________________________________________________________________________> 
 
 
      1370      1380      1390      1400      1410      1420      1430      1440        
ACAATTGCTTTTAAAAATTGGGTTAAAACAGGCACAGAAGTTTACAGACAGTTTTGGATCTTTGATGTGCAAAATCCACA 
 T  I  A  F  K  N  W  V  K  T  G  T  E  V  Y  R  Q  F  W  I  F  D  V  Q  N  P  Q> 
________________________________________________________________________________> 
 
 
      1450      1460      1470      1480      1490      1500      1510      1520 
GGAAGTGATGATGAACAGCAGCAACATTCAAGTTAAGCAAAGAGGTCCTTATACGTACAGAGTTCGTTTTCTAGCCAAGG 
  E  V  M  M  N  S  S  N  I  Q  V  K  Q  R  G  P  Y  T  Y  R  V  R  F  L  A  K> 
________________________________________________________________________________> 
 
 
     1530      1540      1550      1560      1570      1580      1590      1600 
AAAATGTAACCCAGGACGCTGAGGACAACACAGTCTCTTTCCTGCAGCCCAATGGTGCCATCTTCGAACCTTCACTATCA 
E  N  V  T  Q  D  A  E  D  N  T  V  S  F  L  Q  P  N  G  A  I  F  E  P  S  L  S> 
________________________________________________________________________________> 
 
 
      1610      1620      1630      1640      1650      1660      1670      1680 
GTTGGAACAGAGGCTGACAACTTCACAGTTCTCAATCTGGCTGTGGCAGCTGCATCCCATATCTATCAAAATCAATTTGT 
 V  G  T  E  A  D  N  F  T  V  L  N  L  A  V  A  A  A  S  H  I  Y  Q  N  Q  F  V> 
________________________________________________________________________________> 
 
 
      1690      1700      1710      1720      1730      1740      1750      1760 
TCAAATGATCCTCAATTCACTTATTAACAAGTCAAAATCTTCTATGTTCCAAGTCAGAACTTTGAGAGAACTGTTATGGG 
  Q  M  I  L  N  S  L  I  N  K  S  K  S  S  M  F  Q  V  R  T  L  R  E  L  L  W> 
________________________________________________________________________________> 
 
 
      1770      1780      1790      1800      1810      1820      1830      1840 
GCTATAGGGATCCATTTTTGAGTTTGGTTCCATACCCTGTTACTACCACAGTTGGTCTGTTTTATCCTTACAACAATACT 
G  Y  R  D  P  F  L  S  L  V  P  Y  P  V  T  T  T  V  G  L  F  Y  P  Y  N  N  T> 
________________________________________________________________________________> 
 
 
      1850      1860      1870      1880      1890      1900      1910      1920 
GCAGATGGAGTTTATAAAGTTTTCAATGGAAAAGATAACATAAGTAAAGTTGCCATAATCGACACATATAAAGGTAAAAG 
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 A  D  G  V  Y  K  V  F  N  G  K  D  N  I  S  K  V  A  I  I  D  T  Y  K  G  K  R> 
________________________________________________________________________________> 
 
 
      1930      1940      1950      1960      1970      1980      1990      2000 
GAATCTGTCCTATTGGGAAAGTCACTGCGACATGATTAATGGTACAGATGCAGCCTCATTTCCACCTTTTGTTGAGAAAA 
  N  L  S  Y  W  E  S  H  C  D  M  I  N  G  T  D  A  A  S  F  P  P  F  V  E  K> 
________________________________________________________________________________> 
 
 
     2010      2020      2030      2040      2050      2060      2070      2080 
GCCAGGTATTGCAGTTCTTTTCTTCTGATATTTGCAGGTCAATCTATGCTGTATTTGAATCCGACGTTAATCTGAAAGGA 
S  Q  V  L  Q  F  F  S  S  D  I  C  R  S  I  Y  A  V  F  E  S  D  V  N  L  K  G> 
________________________________________________________________________________> 
 
 
      2090      2100      2110      2120      2130      2140      2150      2160 
ATCCCTGTGTATAGATTTGTTCTTCCATCCAAGGCCTTTGCCTCTCCAGTTGAAAACCCAGACAACTATTGTTTCTGCAC 
 I  P  V  Y  R  F  V  L  P  S  K  A  F  A  S  P  V  E  N  P  D  N  Y  C  F  C  T>           
________________________________________________________________________________> 
 
 
      2170      2180      2190      2200      2210      2220      2230      2240     
AGAAAAAATTATCTCAAAAAATTGTACATCATATGGTGTGCTAGACATCAGCAAATGCAAAGAAGGGAGACCTGTGTACA 
  E  K  I  I  S  K  N  C  T  S  Y  G  V  L  D  I  S  K  C  K  E  G  R  P  V  Y> 
________________________________________________________________________________> 
 
 
      2250      2260      2270      2280      2290      2300      2310      2320 
TTTCACTTCCTCATTTTCTGTATGCAAGTCCTGATGTTTCAGAACCTATTGATGGATTAAACCCAAATGAAGAAGAACAT 
I  S  L  P  H  F  L  Y  A  S  P  D  V  S  E  P  I  D  G  L  N  P  N  E  E  E  H> 
________________________________________________________________________________> 
 
 
      2330      2340      2350      2360      2370      2380      2390      2400 
AGGACATACTTGGATATTGAACCTATAACTGGATTCACTTTACAATTTGCAAAACGGCTGCAGGTCAACCTATTGGTCAA 
 R  T  Y  L  D  I  E  P  I  T  G  F  T  L  Q  F  A  K  R  L  Q  V  N  L  L  V  K> 
________________________________________________________________________________> 
 
 
      2410      2420      2430      2440      2450      2460      2470      2480   
GCCATCAGAAAAAATTCAAGTATTAAAGAATCTGAAGAGGAACTATATTGTGCCTATTCTTTGGCTTAATGAGACTGGGA 
  P  S  E  K  I  Q  V  L  K  N  L  K  R  N  Y  I  V  P  I  L  W  L  N  E  T  G>          
________________________________________________________________________________> 
 
                                         >BstEII 
                                            | 
      2490      2500      2510      2520    | 2530      2540      2550      2560 
CCATTGGTGATGAGAAGGCAAACATGTTCAGAAGTCAAGTAACTGGTCACCATCACCATCACCACACCGGTCATCATCAC 
 T  I  G  D  E  K  A  N  M  F  R  S  Q  V  T  G  H  H  H  H  H  H  T  G  H  H  H> 
________________________________________________________________________________> 
 
                                                                      >XbaI 
                                                                         | 
      2570      2580      2590      2600      2610      2620      2630   |  2640            
CATCACCATTGAGTTTATCTGACTAAATCTTAGTTTGTATTGTCATGTTTTAATACAATATGTTATGTTTGGGTCTAGAT 
 H  H  H  *> 
____________> 
